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ABSTRACT OF DISSERTATION

NEONATAL IMMUNE MODULATION TO IMPROVE PNEUMOCYSTIS
CLEARANCE

Pneumocystis carinii is an opportunistic fungal pathogen that causes lifethreatening pneumonia in immunocompromised individuals. Infants appear to be
particularly susceptible to Pneumocystis (PC) pulmonary infections. The higher
incidence of PC as well as other pulmonary infections among infants is likely due
to an immature immune system. The neonatal lung environment is deficient
immunologically in preterm as well as term infants (1, 2). Decreased phagocytic
capacity of macrophages in newborns may increase the risk of infection from
inhaled pathogens (1, 2).

We have previously demonstrated that there is

approximately a 3-week delay in the clearance of PC organisms from pup mouse
lungs compared to adults. Herein, we demonstrate that there is also a 1-week
delay in the infiltration of AMs in pup compared to adult PC-infected mice. We go
on to show that there is a delay in pup versus adult lung macrophage phenotypic
expression and cytokine production in response to PC organisms. We
demonstrated that pup AMs are competent to produce cytokine in response to
LPS and that stimulation with zymosan generates cytokine production in pup
AMs that is comparable to adult cytokine production. These data indicate that
pup lung macrophages are specifically poorly responsive to PC organisms and
likely require exogenous stimulation to mount a significant immune response and
expedite clearance of the organism. We go on to show that heat-killed Escheriae

coli improves cytokine response, cellular infiltration and reduces organism
burden in PC-infected pup mice. The clinically relevant cytokine, GM-CSF, has
been used to improve the clearance of several pulmonary infections, including
PC in adult animal models. We show that monotherapy with GM-CSF is
insufficient to improve PC clearance in pup mice; however, when combined with
TMP/SMX it improves PC clearance and maintains a reduced PC burden
following discontinuation of therapy. Furthermore, we have shown that GM-CSF
improves the ability of human infant lung macrophages to phagocytose PC
organsms without generating an increased inflammatory response. These data
suggest that combination therapy with TMP/SMX and GM-CSF may be a viable
treatment option for infants failing or intolerant to standard therapy.
KEYWORDS: Pneumocystis, alveolar macrophage, granulocyte macrophagecolony stimulating factor, neonate/infant, immunomodulation
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CHAPTER 1. Introduction
A. Overview
Pneumocystis carinii f. sp. hominis is an opportunistic fungal pathogen
known to cause life-threatening pneumonia in immunocompromised individuals.
Infants, predominantly those that are immunocompromised, appear to be
particularly susceptible to primary PC infection. Among HIV-infected children
who develop pneumonia, Pneumocystis carinii f. sp. hominis is one of the most
common causative pathogens (1). Furthermore, HIV-infected children less than 1
year of age have a higher incidence and a more fulminate course of
Pneumocystis pneumonia (PCP) than older children with AIDS (2). More recently
Pneumocystis (PC) colonization and infections have been identified in
immunocompetent individuals, particularly in young children (3-6).
The higher incidence of PC as well as other pulmonary infections among
infants is likely due to an immature immune system. The neonatal lung
environment is deficient immunologically in preterm as well as term infants (7, 8).
Decreased phagocytic capacity of polymorphonuclear (PMN) cells, monocytes,
and macrophages, low immunoglobulin levels, decreased expression of
complement receptors and possible defects in T lymphocyte immunoregulation in
newborns may increase the risk of infection from inhaled pathogens (7, 8).
It is well known that T lymphocytes are crucial in host defense against PC
as made evident by the Human Immunodeficiency virus (HIV) epidemic; a
disease which kills CD4 T cells. We have previously demonstrated that there is
approximately a 3-week delay in the clearance of Pneumocystis organisms from
pup mouse lungs compared to adults which corresponds with a delay in T cell
infiltration into the neonatal versus adult lungs (9). However, when T lymphocytes
from pup mice were adoptively transferred into adult mice, they were shown to
clear PC as efficiently as adult T cells (10) suggesting that the delayed PC
clearance in pups can not be attributed to T cells alone. We have further shown
that there is approximately a 1-week delay in alveolar macrophage (AM)
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activation in pup versus adult mice (11). Macrophages are resident in the lungs
and thus make up the first line of defense against inhaled pathogens. They
appear to be the primary effector cells responsible for killing and clearance of PC
(12) and are therefore important cells to consider when studying the failure of
pup lungs to clear the organism. It is therefore, the goal of this project to
determine the possible delays or defects present in pup lung macrophages (LMs)
compared to adult LMs and to further identify a clinically relevant treatment
option that would help stimulate LMs and expedite the clearance of PC
organisms from infant lungs. Throughout this dissertation, lung macrophages
(LMs) will be used to refer to both alveolar and lung tissue macrophages;
alveolar macrophages (AMs) will be used when specifically refering to
macrophages residing in the alveolar spaces.
According to the Center for Disease Control (CDC) guidelines,
Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the drug of choice in
both adults and children for treatment and prophylaxis of PCP (13). Some of the
adverse reactions that occur in children secondary to TMP/SMX include, but are
not limited to, rash, hematological abnormalities, and interstitial nephritis (13-15).
Furthermore, infants less than 4 weeks of age are at increased risk of jaundice
when exposed to TMP/SMX due to its bilirubin displacing properties (1995
MMWR Revised guidelines for prophylaxis against PCP), (Brito 2006, Science
Direct). If intolerance to TMP/SMX occurs, adults have several other treatment
options,

including

pentamidine,

atovaquone,

clindamycin/primaquine,

dapsone/trimethoprim, or trimotrexate glucuronate/leucovorin (13).

Treatment

options for the 15% of children who develop substantial adverse reactions to
TMP/SMX (16), however, are severely limited with pentamidine being the only
alternative agent with available data for use in children (13). Pentamidine is not a
benign drug with 17% of children experiencing a substantial adverse drug
reaction (17). Severely limited options, significant adverse reactions, and
increasing resistance to TMP/SMX (18) (19) (20) (21), obviate and accentuate
the need for further treatment options in infants suffering from PCP.
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Granulocyte-macrophage

colony-stimulating

factor

(GM-CSF)

is

a

glycoprotein produced by several pulmonary cells including macrophages,
activated T cells, and epithelial cells (22). It is a hematopietic growth factor that
regulates the proliferation and release of progenitor cells and modulates the
function of mature monocytes and macrophages. Among the functions of GMCSF are its ability to influence the number of macrophages at a site of infection
and activate macrophages for enhanced activity against invading pathogens (23)
(24). GM-CSF is a commercially available agent indicated for use in leukemia
following cancer chemotherapy, myeloid reconstitution following bone marrow
transplants and mobilization for peripheral blood stem harvesting (Immunex Co.).
Unlike G-CSF, GM-CSF is a potent inhibitor of neutrophil migration which may be
beneficial during pulmonary infections known to mount a large, damaging
inflammatory response, such as PC infection. GM-CSF has also been shown to
enhance the clearance and improve outcomes of several different pulmonary
infections, including but not limited to group B streptococcus infection (24),
Pseudomonas

aeruginosa

(25),

Histoplasma

capsulatum

(26,

27),

Mycobacterium tuberculosis (28), and Pneumocystis carinii (29). However, there
is little data on the effects of GM-CSF on pulmonary infections in infants and no
data regarding the addition of GM-CSF for the treatment of PCP in the infant
population. These aforementioned attributes and the ability of GM-CSF to
improve outcomes in pulmonary infections in adult animal models suggest that
this clinically relevant agent may be of therapeutic benefit for infants with
pulmonary infections failing to respond to antimicrobial therapy alone. HIVinfected infants with PCP are a particularly fragile population requiring more
treatment options to improve outcomes. However, the potential role of GM-CSF
in the lung for host defense against PC has not been investigated in the neonatal
population and will therefore be addressed within the scope of this project.
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B. Neonatal Lung Environment
1. Immature neonatal immune function
Neonates are highly susceptible to infectious diseases during the early
postnatal period, particularly at the mucosal surface of the respiratory tract (30,
31). Maturational deficiencies in both the innate (32) and adaptive (31) immune
functions are thought to contribute to this increased vulnerability (33) (34).
Studies in both humans and mice have demonstrated that neonatal immune cells
are qualitatively distinct from adult cells. Among neonates and adults, subsets of
cells exist in different proportions; furthermore cells of the same subtypes exhibit
different phenotypes. Many studies throughout the literature have demonstrated
deficiencies or alterations in neonatal T cells, B cells, and antigen-presenting
cells (APCs) compared to adult cells. (30, 31, 33-35). These aforementioned
immune deficiencies occur in the lung as well as throughout the neonatal
immune system and likely contribute to the increased risk of respiratory infections
observed in newborns. LMs, in particular, constitute an important first line of
defense against inhaled pathogens (36) (30), therefore underdeveloped or
functionally inefficient LMs must be considered when studying increased
susceptibility to pulmonary infections in the neonatal population.
2. Alveolar macrophages
Phagocytosis
Tissue-fixed macrophages in the lung are instantly available to respond to
inhaled pathogenic organisms. They do so through phagocytosis followed by
death of the organisms intracellularly. Some organisms, such as Mycobacterium
tuberculosis and Listeria monocytogenes, are able to escape death and live
within a cell following phagocytosis by evading the killing capacity of the
phagolysosome (37). Most organisms, such as Pneumocystis carinii, however,
are extracellular and succumb readily to the acidic environment composed of
oxygen radicals generated within the phagosome upon ingestion.

Some

phagocytosis assays performed on neonatal and adult macrophages have
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demonstrated that neonatal macrophages are as competent as adult
macrophages at phagocytosing both bacterial (38) and fungal pathogens (39).
However, other studies done specifically on alveolar macrophages have shown
that there is a strong correlation between impaired phagocytosis and infancy
(40). One possibility for this stark discrepancy is the difference in the local
environment. The phagocytosis assays performed by Karlsson et al. and Marodi
et al. were done on cord blood derived monocytes, whereas those done by
Martin et al. were performed on alveolar macrophages. The neonatal lung
environment is thought to be immunosuppressant during its vulnerable post-natal
development period which may, therefore, contribute to the lower phagocytic
function demonstrated by Martin et al. Similar to phagocytic function; research
done on the generation of oxygen radicals within activated macrophage
phagosomes differs according to where the cells were derived. Neonatal and
adult monocyte-derived macrophages from either cord or peripheral blood have
been shown to produce similar levels of oxygen radicals in response to various
stimuli (41, 42). Delacourt and colleagues, however, demonstrated that oxygen
radical production is significantly reduced in neonatal rat LMs compared to adult
LMs upon stimulation (43).
In addition to phagocytosis, upon interaction with foreign particles normally
functioning LMs perform several duties which have been shown to be less
efficient in neonates compared to adults, including recognition and binding
through pattern recognition receptors (PRRs) (44), secretion of cytokines and
chemokines (45) (44, 46, 47), up-regulation of complement receptors or integrins
(45), and up regulation of co-stimulatory molecules (48) and antigen presenting
molecules (49).
Pattern recognition receptors
Macrophages express several PRRs that recognize many different
microbial components and which can discriminate between the surface
molecules displayed by a pathogen versus one displayed by the host. Some
important PRRs found on macrophages include the macrophage mannose
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receptor (MMR), beta-glucan receptors (BGRs) (Dectin-1, CD11b, etc.),
scavenger receptor (SR), LPS receptor (CD14), toll-like receptors (TLR), and
CD11b/CD18 (complement receptor 3; CR3) (50). The up regulation of these
receptors can often tell us if the macrophage has become activated or stimulated
by a pathogenic organism. For example, CD14 recognizes and binds to the
lipopolysaccharide component of the Escherichia coli (E. coli) cell wall.
Additionally, macrophages are thought to identify PC through recognition of its
cell wall components, MMRs (51) (52) and BGRs (53) (54) (55).
Of particular importance in regards to identifying the presence of PC are
MMR and the beta-glucan receptor, dectin-1. These 2 receptors are known as Ctype lectin receptors (CLR), which are defined as carbohydrate binding
molecules that bind ligands in a calcium-dependent manner (56). The MMR
binds both endogenous and exogenous ligands bearing mannose, fucose, Naceytlglucosamine, and sulphated sugars via its cysteine-rich domain (56). It is
most commonly known for its ability to bind pathogen-associated mannose
structures found on bacteria, yeast, and fungi (56). Many studies have suggested
that the MMR is important in the recognition and clearance of PC (51, 52).
Interestingly, however, other studies performed found that MR-/- mice were no
more susceptible to fungal pathogens, including PC, than their wild-type
counterparts as measured by mortality and dissemination of infection (57) (58).
Like the MMR, dectin-1 is also a CLR involved in the clearance of
glycosylated antigens present in fungal cell walls such as PC, particularly β-1,3and β-1,6-linked glucans (56, 59). Unlike MMR, however, dectin-1 elicits proinflammatory mediators such as TNFα in response to fungal pathogens (60). It
does this in collaboration with TLR2 (60) (61) which interacts with dectin-1’s
immunotyrosine activation motif (ITAM). Furthermore, dectin-1 has recently been
shown to stimulate both CD4 and CD8 T lymphocytes, thereby inducing costimulatory molecule expression and IFNγ production (62). The MMR (51, 63)and
BGRs (64) (54, 65) are both thought to play important roles in the recognition of
PC and the subsequent stimulation of alveolar macrophages in the adult lung.
Currently, however, there is no available data demonstrating whether or not
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differences exist in the expression levels of MMR or dectin-1 on lung
macrophages following bacterial or fungal stimuli in neonates versus adults.
The family of PRRs known as TLRs is unique from other PRRs in that they
appear not to recognize and bind pathogens directly like MMR and dectin-1 (50).
Instead, they associate with other receptors that directly recognize and bind
pathogens. Once associated, the TLRs initiate an intracellular signaling cascade
resulting in translocation of the transcription factor, NFkB, to the nucleus. This
results in the subsequent production of several important mediators of innate
immunity such as cytokines and chemokines. Additionally, TLR signaling is
responsible for generating CD80 and CD86, two important molecules in adaptive
immunity. The presence of these co-stimulatory molecules along with pathogenic
antigens presented on the surface of antigen presenting cells (APC), including
macrophages, is an important method by which CD4 T lymphoctyes are activated
and thus tie TLRs to the initiation of the adaptive immune response (50). Specific
agonists for nine of the ten human TLR members have been described thus far
(66). Among these are the previously mentioned TLR2 which is known to
associate with the BGR following recognition of the fungal pathogen PC. One of
the first TLRs to be described was TLR4, which is known to associate with the
LPS receptor CD14 following recognition of the E. coli cell wall component, LPS.
Previous research has suggested that the deficiency of the innate immune
response in neonates is due, in part, to impaired responses of neonatal
macrophages to TLR ligands (67) (68).
The final PRR that will be discussed in regards to lung macrophages is
CR3. Like many mediators of the immune system, CR3 is a multifunctional
receptor performing roles in pathogen recognition as well as leukocyte adhesion
and extravasation. CR3 is one of 4 complement receptors found on phagocytes.
It is responsible for binding pathogens opsonized with complement components
and stimulating phagocytosis (50). CR3 also belongs to a family of cell-adhesion
molecules called integrins which are responsible for binding to cell-adhesion
molecules and promoting the extravasation, whereby phagocytic cells expressing
CR3 or other integrins are transported through endothelial membranes to the site
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of infections (50). The third function of CR3 is as a PRR which recognizes and
ligates β-1,3-glucans leading to cell priming for ingestion of the fungal pathogen
(69-71). The ability of CR3 to recognize the β-1,3-glucan component of fungal
cell walls as well as its constitutive expression on LMs makes it a useful tool in
assessing LMs activation status following PC infection. There is no data in the
literature describing whether or not differences exist in the expression level of
CR3 in neonates versus adults. Thus information on the expression level of this
receptor in the presence of PC infection in pup versus adult LMs is also lacking.
Evidence from data collected in our lab demonstrates that clear differences exist
between the expression level of the CD11b component of CR3 between pup and
adult mice (11). Following intranasal PC inoculation of both pup (24-48hrs old)
and adult mice (≥ 8 weeks old), CD11b expression was significantly lower on pup
LMs compared to adult LMs by 6 days post-infection (11).
While other PRR exist, such as the scavenger receptor, for the purposes
of this introduction, I have chosen to focus on the ones that are pertinent for my
work with PC infection in the neonatal lung. One final PRR that I will briefly
mention is CD11c/CD18 (CR4). CR4 is another complement receptor in the
same family as CR3 which also plays a dual role as an integrin. Unlike CR3, CR4
has demonstrated no ability to recognize any pathogenic organisms outside the
realm of the complement pathway. Throughout this research, however, we use
antibodies specific for both the CD11b and CD11c components of CR3 and CR4,
respectively, as a means of identifying LMs.
Cytokines and chemokines
Once a tissue macrophage recognizes and binds a pathogenic organism
it is activated to release cytokines and chemokines, which in turn increase the
state of inflammation by recruiting more immune cells and eventually initiating the
cellular immune response (50). Cytokines are small proteins released by many
different immune cells, including macrophages. The release of cytokines from
their respective cells is generally initiated through the ligation of specific
receptors as described above. Once these soluble proteins are released they can
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act in an autocrine, paracrine, or endocrine manner thereby affecting the
behavior of the host cell, adjacent cells, or distant cells, respectively (50).
Chemokines are a distinct subset of cytokines with chemoattractant properties.
These proteins are responsible for recruiting mainly monocytes, neutrophils, and
other blood-derived cells with the appropriate receptors to sites of infection where
the chemokine was initially released (50).

The cytokines secreted by

macrophages in response to pathogenic stimuli include interleukin-1 (IL-1),
interleukin-6 (IL-6), interleukin-12 (IL-12), TNFα, and the chemokine interleukin-8
(IL-8) (50). IL-1 functions include activation of the vascular endothelium and
local tissue destruction thereby mediating an increase in access of additional
effector cells. Additionally, IL-1 is involved in lymphocyte activation and therefore
is yet another link between the innate and adaptive immunity. IL-6 is also
involved in B lymphocyte activation leading to increased antibody production. IL12 induces the differentiation of CD4 T lymphocytes into TH1 cells, thereby
driving a more cellular response. IL-8, MIP-1, and MCP-1 are all chemokines
responsible for recruiting other leukocytes to the site of infection; MCP-1 also
acts to activate macrophages in an autocrine fashion. TNFα is an extremely
potent cytokine involved in vascular endothelium activation and increased
permeability, allowing an increased flux of immune cells and molecules to the site
of infection and an increase in fluid drainage to regional lymph nodes (50). IFNγ
is a cytokine that is produced and secreted by T lymphocytes and natural killer
(NK) cells. While it is not produced by macrophages in significant amounts, it is
important in that it activates macrophages to further boost the immune response
by increasing phagocytosis, increasing the expression of PRRs and costimulatory molecules, and increasing the production of cytokines and
chemokines.
The two cytokines TNFα and IFNγ have been shown to be very important
in the clearance of PC (72) (73) (74, 75). Additionally, upon infection with PC,
neonatal mice demonstrated a much weaker TNFα and IFNγ mRNA response
compared to adult mice (10). As previous research in our lab has demonstrated,
the exogenous administration of TNFα
9

is capable of stimulating a T cell

response in neonatal mice and thus may expedite the clearance of PC in
neonatal mice (73). In my research, I have demonstrated that the administration
of inhaled IFNγ alone does not improve clearance in PC infected neonatal mice.
However, the administration of heat-killed E. coli (HKEC), a known stimulator of
TNFα production, demonstrated a significantly increased clearance in PCinfected neonatal mice compared to their untreated counterparts. As will be made
evident in the results section of my research, TNFα is an important cytokine in
the pathogenesis of PC in a neonate. Furthermore, I will show that the production
of TNFα in a neonate differs from that of an adult and may be due in part to the
vulnerable state of the underdeveloped lung environment of a neonate.
Table 1.1 Cytokines/Chemokines
Effect on Macrophages and
Affect on PC infection
other cells
Activates Macrophages;
PC is not cleared from reconstituted SCID
Activates vascular
TNFα
mice in the absence of TNFα; must be
endothelium and increases
present early in disease (74)
vascular permeability
Activates vascular
In the absence of IL-1, clearance of PC is
IL-1
endothelium and
almost completely inhibited (76)
lymphocytes
Activates lymphocytes
PC clearance is not dependent on IL-6;
IL-6
leading to increased antibody
during infection IL-6 regulates
production
inflammation and antibody response (77)
Improves proliferation of immune cells
Promotes differentiation of
IL-12p70
during PC infection but does not improve
CD4 T cells to TH1 cells
clearance (78)
IL-8 promotes lung pathogenesis
Recruits T cells and
secondary to PC leading to a poorer
IL-8
neutrophils
prognosis; PC-mediated IL-8 release from
AMs requires MRs and TLR2 (79)
Recruits monocytes, T cells,
MIP-1
Not specifically studied in PCP infection
and DCs
Contributes to the pathologic T cell
Recruits monocytes, T cells,
MCP-1
response leading to progression of PCP;
and DCs
may increase epithelial cell repair (80)
IFNγ does not play a significant role in PC
Activates macrophages
IFNγ
clearance when given exogenously (74)
Increases differentiation and Critical role in inflammatory response to
GM-CSF proliferation of granulocytes; PC through granulocyte proliferation and
activates macrophages
macrophage activation (81)

Cytokine

10

Co-stimulatory molecules
The co-stimulatory molecules and signals that are required for lymphocyte
activation provide an extremely important function in maintaining a form of
checks and balances in the initiation of the immune response. Activation of T
lymphocytes by APCs are controlled by specialized ligands and receptors found
on the APCs and the T lymphocytes. The co-stimulatory molecules I will focus on
for the purposes of this research are the two structurally related glycoproteins
CD80 and CD86 (also known as B7.1 and B7.2 respectively) found on APCs and
CD40 ligand (CD40L) found on T lymphocytes. Once an APC, such as an LM,
recognizes a pathogen (often by a PRR), it phagocytoses it, internally processes
it and then presents an antigenic component of that pathogen on its surface in
the context of a major histocompatibility class II (MHC II) molecule. This peptide:
MHC II complex on the APC can now be recognized by naïve T lymphocytes.
The peptide: MHC II complex on the APC binds to the T-cell receptor (TCR) and
its co-receptor (ex. CD4) thereby delivering the first required signal in T
lymphocyte activation. This one signal is not enough, however; a second
stimulatory signal is required for full T lymphocyte activation. The second signal
is delivered through binding of the co-stimulatory molecules CD80 and CD86 on
the APC to the CD28 receptor found on the T lymphocyte. Only now will clonal
expansion and the subsequent differentiation into a TH1 or TH2 T lymphocyte
occur. The requirement of this second signal ensures that naïve T lymphocytes
won’t react to self antigen that is sometimes presented in an MHC II molecule
(50). This description of the APC and T lymphocyte interaction is a basic one;
there are several caveats that bear mentioning.

Before a macrophage

phagocytoses a pathogenic organism, it expresses little to no MHC II, CD80, or
CD86 on its surface. The PRR that initially recognizes the pathogen is what
provides the necessary signals for the expression of MHC II and the costimulatory molecules on its surface. At this point, macrophages are still in a
relatively unstimulated state and may still function as APCs, but lack the capacity
to be highly effective phagocytic cells which are often needed to clear many
extracellular organisms such as PC. Like naïve T lymphocytes, macrophages
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also require two signals in order to become activated. The first signal is provided
by IFNγ, which can come from a number of sources, but the primary source is
from armed effector T lymphocytes (CD4 or CD8 T lymphocytes). In the absence
of T lymphocytes, IFNγ may also be provided by NK cells. The second signal,
which can be provided by a variety of means, is required to sensitize the
macrophage to respond to IFNγ (50). Perhaps the most common source of this
second signal is the CD40L found on the surface of TH1 cells as previously
described, thereby allowing TH1 cells to be the primary source of both signals
required for macrophage activation. Without these two signals and the
subsequent activation of macrophages, one can see how organism such as PC,
which requires macrophage activation, can cause fulminate infections. This
scenario is best exemplified by HIV, in which CD4 T lymphocytes are destroyed,
subjecting the infected host to a wide range of opportunistic infections (OI) such
as PC. Although TH1 cells provide the most convenient source of both
macrophage activating signals, there are other sources. As already described,
IFNγ can be provided by CD8 T lymphocytes or NK cells. In addition to CD40L,
the secondary signal may also come from TNFα, LPS, or other bacterial or fungal
antigenic components. Once activated, macrophages undergo several changes
that greatly increase their antimicrobial effectiveness leading to an enhanced
immune response. For example, activated macrophages increase their
expression of CD40 receptor, MHC II, CD80 and CD86, as well as inducing the
production of oxygen radicals (50). In my research, I will be discussing the
differences of some of these markers of macrophage activation as it pertains to
neonates versus adults that have been infected with PC organisms. Additionally,
I will discuss my findings regarding the up regulation the PRRs (CR3, TLR2,
MMR, and BGRs) and cytokines (IFNγ, TNFα, IL-6, and MCP-1) thought to be
important in PC infection.
The role of lung macrophagess in Pneumocystis clearance
LMs are known to play a significant role in host defense against PC. Using
a rat model depleted of LMs, Limper and colleagues demonstrated that PC
12

infection could not be controlled in adult rats in the absence of LMs (82). There
are many organisms that come into contact with LMs that are cleared without the
need for LM activation. PC organisms however, have been shown to require T
lymphocytes for adequate clearance, suggesting that LM activation, and
therefore, T lymphocyte: LM interaction, is important for clearance (83). While
LMs are believed to be the effector cells that are directly involved with killing the
PC organisms, LMs are not capable, on their own, to adequately control the
infection. This has been clearly demonstrated in experiments in which T
lymphocyte-deficient mice, with fully functional LMs, are susceptible to PC
infection (83).

Using an adoptive transfer model, our lab has previously

demonstrated that neonatal T lymphocytes are fully functional and work as
efficiently as adult T lymphoctyes in clearing PC organisms (10). Thus, while it is
understood that T lymphocytes continue to play a crucial role, the goal of my
research is to define the differences between neonatal and adult LMs that lend to
the inefficient clearance of PC from neonatal lungs. Furthermore, my research
will focus on evaluating clinically relevant means by which to improve neonatal
LM function to help fight PC infection as well as other pulmonary infections in the
neonatal host.
3. Neutrophils
Following macrophages, neutrophils (polymorphonuclear cells; PMNs)
comprise the second major group of phagocytes. There are many similarities and
differences

between

these

two

phagocytic

families;

Table

1.

Unlike

macrophages, neutrophils are not tissue-fixed. They have a short life cycle which
is spent primarily in the blood until called upon to help fight off an invading
pathogen. While macrophages are the first to respond to an infectious process in
the tissues, they are soon reinforced with large numbers of neutrophils to help
with phagocytosis. Like macrophages, neutrophils recognize foreign pathogens
through their large repertoire of PRRs. Neutrophils, however, differ from
macrophages in that once they phagocytose a foreign particle they die soon
thereafter, whereas a macrophage proceeds to present antigenic material on its
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surface and thus acts as an intermediary between innate and adaptive immunity.
The most import difference between these two phagocytic cells, for the purposes
of my research, is that neutrophils do not appear to play a major role in the
clearance of PC organisms compared to macrophages which are a key effector
cell in clearing this organism (84). There are many differences between these
two phagocytic cells that may contribute to the apparent lack of neutrophil
involvement in PC clearance; Table 1.1. While a specific reason for this
difference has not been fully elucidated, one could speculate that because
neutrophils do not reside in the tissues, unlike macrophages (LMs in this case)
they are less involved in the response to PC.
Table 1.2 Macrophages Versus Neutrophils
Function

Macrophages

Neutrophils

Life span

Long-lived

Short-lived

Phagocytic capacity

Continual

Once

MMR

Present

Absent

BGR

Present

Present

CD14 (LPS receptor)

Predominant

Little to no expression

Location

Tissues

Blood

CD4 T cell activation

Yes

No

Complement receptors

Yes

Yes

4. Dendritic cells
The function of a dendritic cell (DC) resembles that of a tissue
macrophage, with some distinct exceptions. DCs are considered the primary
professional APC. Like tissue-fixed macrophages, DCs take up antigenic material
within infected tissue via PRRs, such as those previously described. Once this
has occurred, intracellular signals trigger the DCs to lose their phagocytic abilities
and become potent APCs. Like LMs, once a DC has become activated, they
increase their expression of the co-stimulatory molecules, CD80 and CD86 as
well as MHC II molecules on their surface. Unlike LMs, the activated DCs are no
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longer phagocytic; instead they are signaled to migrate to the spleen or regional
lymph nodes where they exhibit highly efficient T lymphocyte activation.
DCs exist as two major subsets in the human system. Myeloid DCs (MDC)
are postulated to originate from circulating monocytes. Depending on the
surrounding signals, monocytes can be stimulated to develop into either
macrophages or MDCs (85). Monocytes, in the presence of granulocyte
macrophage – colony stimulating factor (GM-CSF), develop into macrophages;
however, in the presence of both GM-CSF and interleukin-4 (IL-4), monocytes
differentiate into MDCs (86). The role of GM-CSF will be discussed in great detail
later in the introduction. The other major subset of DCs are the plasmacytoid
DCs (PDC), which look more like plasma cells, but retain some MDC
characteristics (87). Structurally, when we think of DCs, we often picture follicular
DCs (FDC) with their characteristic finger-like protrusions called dendrites. When
we look at these cells under a standard light microscope, however, they are
difficult if not impossible, to differentiate from macrophages. Additionally, both of
these cells express the same surface markers, albeit at different expression
levels, making these two cells even more difficult to discriminate; DCs and LMs
are notoriously difficult to decipher from one another (88). For my in vitro
experiments that I will discuss later in this dissertation, I rely on the fact that
macrophages differ from DCs in their level of adherence. When cells are lavaged
from an uninfected mouse lung, the majority of the cells are macrophages, with a
small percentage of them being DCs. When incubated in a tissue culture plate,
macrophages stick readily. DCs, on the other hand, are washed off, leaving a
relatively pure population of macrophages to work with. Our in vivo work, which
involves in vivo stimulation followed by flow cytometric analysis, discriminates
between LMs and DCs based on the level of CD11c expression. Cells that
express a high level of CD11c are considered LMs, whereas cells that express
low levels of CD11c are considered DCs (89, 90).
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5. T lymphocytes
T lymphocytes play a crucial role in the clearance of PC, as made evident
by the HIV epidemic. HIV is a virus that targets CD4 T cells leaving its host
vulnerable to opportunistic pathogens such as Cytomegalovirus (CMV),
Toxoplasmosis, Candida albicans, and PC (13). T cells can be distinguished
based on their distinct functions and expression of cell-surface proteins. T cells
that express the co-receptor CD4 recognize antigens presented within MHC
class II molecules, while T cells that express CD8 recognize antigens presented
within MHC class I molecules (50). As discussed in the macrophage portion of
the introduction, APCs associate with T cells via a peptide:MHC complex and
receive 2 signals in order to become activated. Once an APC has engulfed a
pathogenic organism, processed it internally and presented an antigenic
component of it on its surface via an MHC molecule, it is ready to interact with a
naïve T cell. During antigen recognition, CD4 or CD8 co-receptors associate on
the T cell surface along with the T-cell receptor (TCR) and bind to the
peptide:MHC II or I complex respectively, on the APC. As previously described, a
second signal is required in order for the T cells to become activated. This
second signal is provided by the co-stimulatory molecules, CD80 and CD86,
expressed on the surface of APCs, which in turn bind to the CD28 receptor found
on the surface of T cells. Once activated, T cells proliferate and differentiate to
perform their respective effector functions (50).
CD8 T cells are known for their direct interactions with APCs bearing
recognizable antigens. Antigens derived from replicating virus or other pathogens
are displayed, in the context of MHC class I molecules, on the surface of an
infected cell, where they are recognized by cytotoxic T cells (CD8 T cells). The
CD8 T cells kill the infected cell by releasing perforin (which punches holes in the
target cell membrane) and granzymes (proteases that trigger apoptosis
intracellularly). CD8 T cells, also termed cytotoxic T cells, are important in the
clearance of viral pathogens (50). CD4 T cells, however, appear to be the most
crucial component of cell-mediated immunity in terms of PC infection. As
previously stated, CD4 cells are the primary target in HIV disease, which leave
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the host vulnerable to opportunistic infections (OI) such as PC. Also as
previously pointed out however, in the absence of CD4 T cells, CD8 T cells are
capable of providing LMs with IFNγ, 1 of the 2 signals required for macrophage
activation. Furthermore, it has been demonstrated that while CD8 T cells alone
are insufficient to clear PC organisms, they are associated with increased
pathology in the lungs of PC-infected mice (91). When mice are depleted of both
CD4 and CD8 T cells, they developed a less fulminate infection compared to
mice depleted of CD4 T cells alone (92).
Upon activation, CD4 T cells can differentiate into either TH1 or TH2 cells,
which differ in their cytokine production and thus in the functions they perform.
Although the precise factors that determine whether a CD4 T cell will differentiate
into a TH1 or TH2 cell are not fully understood, it is thought that the environment
under which they differentiate may guide them, including the cytokines elicited by
pathogenic organisms, the co-stimulatory molecules used to drive the activation,
and the nature of the peptide: MHC molecule. Upon interacting with their specific
peptide:MHC molecule complex, naïve CD4 T cells first respond by making IL-2
and proliferating. Subsequently, these cells will then differentiate into a TH1 or
TH2 cell. This differentiation is extremely important in the type of immune
response that will be elicited as each type of cell performs distinctly different
functions. TH1 cells function to activate macrophages, enabling them to destroy
organisms, such as PC, more efficiently. Additionally TH1 cells can activate B
cells to produce opsonizing antibodies which aid in the recognition and uptake of
certain microorganism by phagocytic cells. TH2 cells, alternatively, drive a
primarily humoral response characterized by the differentiation of B cells and
their production of immunoglobulins. Additionally, TH2 cells are responsible for
activating naïve B cells to proliferate and secrete IgM. In our lab we have
demonstrated that opsonization of PC by PC-specific antibody results in
increased clearance of the organism from neonatal lung (11). Thus, B cell
activation, in addition to CD4 T cell activation also plays an important role in the
clearance of PC from neonatal lungs.
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6. B lymphocytes
It is widely accepted that both T lymphocytes and LMs play a critical role
in the host defense against PC, however, the role of B lymphocytes has been
somewhat overlooked. In fact, B lymphocytes appear to play a significant role in
PC infection as demonstrated by B cell deficient mice which were shown to be
susceptible to PC (93). Furthermore, it is known that over 90% of people have
PC-specific antibody by two years of age, suggesting that B lymphocytes have
responded to PC organisms by at least the age of two (94). B lymphocytes play
several roles in host defense in general, including antibody production, antigen
presentation, and regulating the expansion of antigen-specific CD4 T cells (95).
In regards to PC, it has been previously reported that B lymphocytes are capable
of enhancing clearance through the production of PC-specific antibodies by
promoting macrophage phagocytosis (96-98). The importance of PC-specific
antibody production by B lymphocytes is reiterated when we look at children
afflicted with X-linked hyper-IgM syndrome that are susceptible to PC infection.
This disease is characterized by a mutation in the CD40L gene, which results in
deficient T lymphocyte – dependent antibody responses (99). Additionally, further
research has demonstrated that B lymphocytes can aid in PC clearance through
an antibody-independent mechanism (96, 98). Although, the precise role(s) that
B lymphocytes play in PC clearance has not been fully elucidated, it appears to
be multifactorial. Lund and colleagues looked at the role that B lymphocytes play
in CD4 T cell-mediated immunity against PC. Using a chimeric mouse model in
which MHC class II molecules were expressed on all APCs except B
lymphocytes, these researches demonstrated the importance of antigen
presentation by B lymphocytes as the mice lacking MHC class II molecules on
their B cells failed to clear PC compared to wild-type mice. To further assess the
role of B cells on CD4 T cell-mediated immunity, this same group used an
adoptive transfer mouse model in which they transferred CD4 T cells from either
B-cell-deficient or wild-type mice into severe combined immunodeficient mice
(SCID) mice. The mice that received CD4 T cells primed in B-cell-deficient mice
were unable to affect PC clearance due to their inability develop into effector T
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cells and migrate into the lung (96). Based on this evidence it is obvious that B
cells play multiple roles in the clearance of PC. Although my research does not
directly look specifically at the role of B cells in PC clearance, it is necessary to
consider the whole host immune response to PC organisms when studying a
particular aspect of it such as LMs.
C. Pneumocystis carinii
1. History
The history of Pneumocystis began in the early 1900’s when it was
erroneously characterized as stages in the life cycle of Trypanosoma cruzi (TC).
In 1909 Carlos Chagas, a young Brazilian scientist studying at the Oswald Cruz
Institute in Brazil published a 60-page article describing these newly identified
cyst-like structures (100). This discovery was thought to be of such great
importance that the article included color drawings of the 109 stages of TC’s life
cycle, an extremely rare occurrence at that time. Stages 41 through 44 of
Chagas’ proposed TC life cycle are believed to actually be the cyst forms of PC
in which one can see eight spores (also called intracystic bodies), which Chagas
described as “daughter cells” (100). Antonio Carini, an Italian scientist also
studying in Brazil, became interested in Chagas’ findings and began to search for
these new life cycle stages of TC. Like Chagas, he used a rat model which he
infected with TC. Following removal of the lungs and mounting tissue slices onto
glass slides, Carini also observed the same cystic forms described by Chagas.
This brought about the second article, published 1910, which mistakenly
characterized PC as belonging life cycle stages of TC (101). Fortunately, Carini
began to doubt whether the cysts he and Chargas were observing truly belonged
to the life cycle of TC when he noticed the cysts were absent in some rats
despite extensive infection with TC. Subsequently, he sent data and specimens
to the Pasteur Institute in Paris where careful studies by Pierre and Mme
Delanoe demonstrated that the cysts described by Chagas and Carinii could be
found in TC-naïve rats, thereby proving it to be a separate species. They named
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this new organism Pneumocystis carinii; Pneumocystis, because the organisms
were lung-specific and carinii, in honor of the scientist who provided them with
the specimens (102). Thus, in 1912 the first accurate description of this newly
identified organism was published in a French article by Pierre and Mme
Delanoe, in which they described the morphology of PC as can be observed
upon Giemsa staining to this day (103). The Delanoes proceeded to publish one
more paper describing PC in guinea pigs, a rabbit, a frog, and eels in 1914, after
which time neither the Delanoes, Carini, nor Chagas pursued further research of
the organism assuming it to be a trivial parasite found in rodents (104). Aside
from the articles published by the three key players in the discovery of PC, only
four other descriptions of PC in various species were published from 1913-1917
after which time almost three full decades passed without a single scientific
publication regarding the organism we now know as PC (105-108).
In 1942, around the time of World War II, PC made its second debut in the
history books appearing as a mysterious new type of pneumonitis in human
infants in Europe (109). The disease was primarily afflicting infants between the
ages of 2 to 8 months, born prematurely or suffering from malnourishment in
infant nursing wards. Clinically, the infants would present with a subtle decrease
in feeding, increased restlessness, poor weight gain, and sometimes diarrhea.
Subsequently,

the

infants

developed

labored

breathing

which

became

increasingly worse. Eventually their skin turned a characteristic grey-blue color
along with blue lips and eyes. Over the course of 1-2 weeks the condition would
worsen until they either died from exhaustion or eventually recovered after a
couple more weeks. The caregivers of the time, while they suspected an
infectious etiology, could only provide comfort measures as none of the
antimicrobial agents they tried improved the infants’ outcomes (109) (102). The
first article to report this mysterious infant-specific disease was published in
Berlin in 1938 and described it as an interstitial plasma cell pneumonitis (110).
Subsequently, over 700 cases of this illness were reported in Switzerland alone
between 1941 and 1949 (111). It was also commonly reported throughout
Europe, including Czechoslovakia, Italy, Hungary, Germany, Yugoslavia, Austria,

20

Denmark, Sweden, France, and Finland in the early 1950s (109). Two physicians
from the Netherlands, van der Meer and Brug, had published an article in the
very beginning of this pneumonitis epidemic in 1942 implicating PC as the
etiological organism responsible for the much feared illness. Included in the
article were photomicrographs showing the characteristic PC cysts and
trophozoites retrieved from the autopsy of 3 infants that had succumbed to the
disease (112). Sadly, it was published in a Dutch medical journal during World
War II and went unnoticed for many years.

It wasn’t until 1951 when a

Czechoslovakian doctor by the name of Joseph Vanek discovered PC in the
lungs of 16 infants who had died of the mysterious disease. Upon microscopic
examination the alveoli of these infants were found to be full of PC organisms
(113). Although van der Meer and Brug had made this same discovery a decade
earlier, it was Vanek and his colleagues who, by publishing their work in Czech
and German medical journals, disseminated this important information to the
medical community (114).

Their hypothesis naming PC as the culprit of the

interstitial plasma cell pneumonitis epidemic was soon well accepted by
physicians throughout Europe (114).
The first case of PC was reported in the United States in Connecticut in
1956 by Dauzier and colleagues (115). Four months later, two infants with
pneumonitis in Oklahoma City were described (116). Following this, several
cases of PC were reported in Canada (117, 118) and Chile (119). In 1959, some
important contributions were made in our quest to learn more about PC by Dr.
Walter Sheldon, a pathologist at Emory University in Atlanta, Georgia. Sheldon
demonstrated PC to be the cause of two fatal cases of pneumonitis. The first was
in an otherwise healthy 3-month-old infant found dead in her crib, the second
was in a 10-year-old girl being treated with corticosteroid for glomerulonephritis.
These were the first cases to which PC was associated with both sudden infant
death syndrome (SIDS) and immunosuppressive therapy, respectively (102).
Subsequently, Sheldon began to use experimental animals to try to reproduce
the disease, which added to our understanding of PC and the eventual use of
animal models in order to research PC organisms (120, 121). Sheldon and a
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German scientist named Weller were the first to generate cortisone-treated
animal models to study PC organisms (120, 122, 123). Unfortunately, no culture
system has ever been developed that has been able to sustain PC organisms,
thus the work done by Sheldon and Weller, built the foundation by which PC is
still studied today.
Eventually the PC pneumonitis epidemic in European infants subsided
along with World War II. Perhaps it had something to do with the improved
economics and living conditions leading to less malnourishment among infants.
Once again, PC was forgotten until it emerged again in the 1960s with the
introduction of cancer-related chemotherapy and radiation. This time the
organism was not targeting infants in European nursing wards, but rather
children and adults in major medical centers with cancer or congenitive
immunodeficiencies. Although no epidemiological reporting system for PC was in
place during this time in history, a resourceful researcher by the name of Peter
Walzer took advantage of the fact that Pentamidine was the only drug available
for the treatment of PC and it was only available upon special request from the
Centers for Disease Control (CDC) (102). Walzer determined that 579 requests
for pentamidine were made from 1967 to 1970; of these, the diagnosis of PC was
confirmed histologically in 194 patients. The underlying diseases in these cases
included leukemia, Hodgkin’s disease and lymphomas, solid tumors, congenitive
immunodeficiency disorders, and organ transplant recipients (124). As the use of
immunosuppressive cancer chemotherapy became more common, the incidence
of PC pneumonitis increased leading to epidemic proportions at cancer centers
throughout the United States. The problem had become so alarming that in 1973,
the first international symposium on PC pneumonitis was held at the NIH leading
to the publication of important events in the evolution of the disease (125). Two
more important articles were published during this decade which demonstrated
the association of PC with immunosuppressive therapy and immunodeficiency
disorders. In both articles, severe combined immune deficiency disease (SCID)
was the most common underlying illness associated with the presence of PC
pneumonitis (126, 127). While PC pneumonitis was routinely discovered in
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immune deficient syndromes and malnourished infants, reports of the organism
in normal, healthy people were not reported until the late 1960s (128). In 1977
and 1978, important serological studies performed on normal populations in the
Netherlands (129) and the United States (130) provided evidence to suggest that
PC organisms were common in the human host. Results from these serologic
studies indicated that most people become infected with PC organisms by 6
months of age and that by the age of 2 years basically all children have
detectable antibody titers (129). From the 1960s up to the 1980s many
histological and morphological studies were undertaken in both animals and
humans to help further elucidate the organism that was still thought to be a
protozoan at that time (131-134). In 1972 the first article to demonstrate speciesspecificity between PC organisms was published comparing PC isolated from
rats versus those isolated from humans (135). It was the following year, in 1973
that the name P. jiroveci was suggested and came to be used to designate the
human form of the organism (102).
The history of PC now becomes more familiar after 1980 and the global
AIDS epidemic. It was in 1981 when young men in both New York and California
were found to have PC pneumonitis without any known risk factors, which led
some shrewd physicians to search for some kind of underlying immune
deficiency to help explain the appearance of PC. Among the 11 men in New York
(136) and the 4 men in California (137) reported to have PC pneumonitis; they
had in common a homosexual lifestyle and/or intravenous drug abuse along with
abnormally low T cell numbers. These reports aroused suspicion at the CDC and
within the year, AIDS was defined and PC was to become known as an
“opportunistic infection” and an “AIDS defining illness”. In 1983 a review by
Jaffee and colleagues revealed that 50% of the first 1000 cases of AIDS also had
PC pneumonitis (138). In addition to reports of PC in the context of AIDS, there
have been some reports of PC occurring in immunocompetent individuals.
Specifically, in 1999 Vargas and colleagues published an article demonstrating a
correlation between SIDS and PC organisms. The study, performed in Santiago,
Chile and Oxford, United Kingdom, looked at autopsies from SIDS cases and
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identified PC in 35.1% and 14.8% of the cases respectively, suggesting a link
between PC infection and SIDS (6).
Within the United States, PC infection remains primarily a disease of the
immunocompromised host, whether the immune deficiency is chemotherapyinduced, AIDS-induced, or congenitally acquired, PC is common among all. In
underdeveloped countries such as South Africa, where the HIV is poorly
controlled, PC pneumonitis is still a major cause of morbidity and mortality,
particularly in young children. Among HIV-infected children who develop
pneumonia, PC is one of the most common causative pathogens (1). Infants
appear to be particularly susceptible to primary PC infection, likely due to an
immature immune system and a lung environment that protects against
damaging inflammation early after birth (5). PC pneumonia (PCP) has been
identified in 10-49% of children in Africa (139, 140). An autopsy study of Zambian
children with HIV infection that died due to respiratory illness showed that PCP
was present in 27% of cases. Furthermore, in the same study, PCP was found
more commonly in infants aged 0-5 months (51%) than in those aged 6-11
months (26%) (141). The history of PC began as a case of mistaken identity; it
was thought of as a miniscule, harmless organisms found in rodents. Today we
know it to be one of the deadliest and most prominent infections among the
immune deficient population. Research which furthers our understanding of this
organism and new drugs designed to target the infection this organism causes
remains an extremely important task.
2. Taxonomy
The history of PC would not be complete without some discussion about
PC’s taxonomy. Up through the 1960s, PC was considered to be a protozoon
based on the fact that visually, they did not look like typical fungi (142), they
failed to grow in culture, and antifungal therapy, while it reduced the organisms’
viability somewhat, did not eradicate PC infections (143). The three
morphological forms that PC undergoes throughout its life-cycle also led people
to believe that it was a protozoan: Cysts, which are round or crescent shaped;
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sporozoites, which are found within the cysts, and trophozoites, which are the
free-floating forms of the organisms. A mature cyst can contain up to 8
sporozoites or intracystic bodies. The trophic form of PC tends to be pleomorphic
and found in clusters. Furthermore, drugs that were used against protozoal
infections, such as pentamidine and trimethoprim/sulfamethoxazole, were also
effective against PC. The protozoan theory remained until the late 1980s when
the sequence of the 18S ribosomal RNA (rRNA) gene of PC from rats was found
to more closely resemble those of fungi, such as Saccharomyces cerevisiae and
Candida albicans, than the 18S rRNA genes found in protozoa (144, 145). Since
this time more than 1400 PC genes have been partially sequenced, with most of
these genes closely resembling fungal gene orthologues (143).

Despite the

genetic resemblance of PC to other fungal organisms, other characteristics of PC
are known to be very different from typical fungal characteristics. For instance,
we know that fungal organisms such as S. cerevisiae and C. albicans grow
rampantly in growth media, whereas PC cannot be sustained in culture.
Additionally, ergosterol, the characteristic fungal cell membrane component
which is the target of many antifungal drugs, is lacking in PC; instead, PC
contains cholesterol in its membrane (146).
3. Pathogenesis
The damaging effects of PCP within the lung can be divided into two
different categories; PC-mediated and immune-mediated lung injury. Direct PCmediated damage to the host lung is caused by virulence factors associated with
PC organisms. The first detectable event in PCP disease progression is the
attachment of the trophic forms of PC to type I pneumocytes (TIP) within the lung
(147) (148). Following attachment, there is an increase in permeability of the
alveolar-capillary membrane, degeneration and necrosis of the TIP, and finally
erosion of the basement membrane (147). Two factors were noted during this
process of TIP damage. The first was an increase in the proliferation of Type II
pneumocytes (TIIP), seemingly in an effort to replace the TIPs and repair the
damaged alveoli (149) (150). The second important factor noted in these studies
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of early PC infection was the lack of an inflammatory response despite ongoing
alveolar damage (147) (150). Animal studies suggest that the interaction of PC
organisms with TIPs and the subsequent capillary leak may serve as a
mechanism by which the organisms acquire nutrients needed for continued
growth and survival (151, 152). Although less common, other studies have
shown the adherence of PC organisms to TIIPs and their subsequent
degradation, are likely due to the increased proliferation of TIIPs seen following
TIP loss (149). Furthermore, experts in the area suspect, based on animals
studies (149), that the interaction of PC with TIIPs may contribute to the
pathology caused by PC organisms by preventing the proliferation and migration
of TIIPs to repair the damaged alveoli (152). In addition to directly adhering to
and destroying pneumocytes, PC organisms have other virulence factors that
may contribute to PCP’s pathology, including the production of proteolytic and
glycolytic enzymes. While the primary function of PC-derived enzymes likely
involves the acquisition of nutrients or the evasion of host defense mechanisms,
they may also be causing collateral lung damage (152). A number of different
potentially PC-derived enzymes capable of causing alveolar damage have been
reported in the literature, including chymase (153), collagenase (151), protease
(154), elastase (154),

cysteine protease (155) (156), and enolase (157). In

addition to these enzymes, a fungal kexin-like molecule has been identified in
mouse-, rat-, and human-derived PC (158) (159, 160). Although not thought to be
a virulence factor in human-derived PC, mouse- and rat-derived PC kexin is
localized to the surface of the organism and has been suggested to play a role in
attachment to the host, nutrient acquisition, or host defense evasion and thus
possibly also lung injury. Within mouse- and human-derived PC, the kexin protein
is encoded by single-copy genes; this unique characteristic has enabled its use
in quantifying PC organisms via real-time PCR (159) (3). Lastly, PC is known to
disrupt surfactant homeostasis within the lung leading to respiratory impairment
during PC infection (152). Specifically, PC is thought to inhibit the secretion of
surfactant components from TIIPs or by binding to certain surfactant components
and sequestering them in inactive forms (161, 162).
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In the clinical setting, the presentation of PCP is highly dependent on the
immune status of the patient, suggesting that the host immune response to PCP
is contributing to its pathogenesis by initiating immune-mediated lung injury in
addition to the direct effects of PCP on TIPs and TIIPs. The initial observation of
PCP in cancer patients often occurs once immunosuppressive steroid therapy is
being tapered (163) (164); in bone marrow transplant recipients it typically occurs
after engraftment and immune function restoration (165) (166); and in AIDS
patients it generally occurs following rapid recovery of CD4 T lymphocytes
secondary to initiating highly active antiretroviral therapy (HAART) (167, 168).
Additionally, it has been well documented that lung injury during moderate to
severe PCP is minimized with the administration of adjunctive steroid therapy,
reiterating the detrimental effects of the host immune response to PC in the
infected lung (169) (170).

More specifically, it has been suggested that the

adaptive immune response causes the majority of lung injury compared to the
innate response following PC infection. This theory is generated from the fact
that it is difficult to prove involvement of the innate immune response, whereas
data obtained from studying PC-infected SCID mice point to a significant role of
the adaptive immune response in causing lung injury (152). The accumulation of
PMNs in the lungs of PC-infected patients has been associated with decreased
oxygenation and a poor prognosis (171) (172). Additionally, in vitro experiments
have suggested that PC organisms are capable of directly stimulating
macrophages (173) (47). The dilemma with these experiments, however is that
its impossible to determine if PMNs are directly causing lung injury or are
recruited in response to lung injury. Likewise, it is indeterminate whether PCstimulated macrophages contribute to lung injury or are merely a conduit to the
adaptive immune response, which has been undeniably shown to cause lung
damage in PC-infected lungs (174, 175). Both CD4 and CD8 T lymphocytes have
been implicated in immune-mediated lung damage, the best example of which
can be observed among the AIDS patients infected with PC. The role of CD4 T
cells is obviated following HAART and the rapid recovery of CD4 T cells. While
an AIDS patient with low CD4 T cell counts will often have a high PC burden,
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they also tend to have a subacute onset of PCP. Upon CD4 T cell restitution
following HAART, however, these patients develop a rapid decline in pulmonary
function, suggesting a significant role for CD4 T cells in PC pathogenesis (167,
168). As I describe my research throughout the remainder of this document, I will
discuss both the activation of neonatal versus adult LMs as well as the infiltration
of CD4 and CD8 T lymphocytes following PC infection and the role that each
plays in clearing the infection.
4. Identifying and quantifying Pneumocystis organisms
For the purpose of identifying and studying PC organisms, it is important
to discuss the stages PC’s life-cycle and the different morphological methods
available for studying each of these stages. What is known about the life-cycle of
PC has been derived primarily through the use of transmission electron
microscopy (TEM). Based on this data, the transition from a trophozoite to a
mature, eight-spore-containing cyst is thought to occur through 3 consecutive
stages of the sporocyte (176). The cycle begins with a pleomorphic, thin-walled
mononuclear trophic form of the organism. This form is thought to attach to type I
epithelial cells in the alveoli. These trophic forms are then thought to evolve into
a thick-walled sporocytic and cystic stage. At this point, multiple nuclear divisions
are thought to generate eight spores within the cyst (176). It is hypothesized that
PC growth results primarily from cyst development rather than from trophic binary
division based on the growth retardation imparted by antifungal echinocandins
which function to inhibit beta-1,3 glucan synthesis (a component of the cyst wall).
In a PC-infected rat model, treatment with therapeutic doses of an echinocandin
(L0671,329) resulted in the selective elimination of PC cysts. Subsequently, the
administration of lower, prophylactic doses of L-671,329 prevented the
appearance of the trophic forms of the organism (177). Understanding the
morphology and life-cycle stages of PC are important for both quantification and
targeting drug therapy for this organism, both of which will be discussed herein.
Human-derived PC organisms are retrieved from either BALF or induced
sputum samples. Most commonly, they are then stained with methenamine silver
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nitrate and can then be observed under a light microscope. While this method is
sensitive for identifying the presence of PC, it only stains the cyst cell walls,
leaving the PC trophozoites unstained (176) (178), and thus is not ideal for PC
quantification. PC can also be stained with polychrome methylene blue; however
this method stains only the intracystic bodies and not the cell well (178). For the
purpose of PC quantification it is important to use a method that will identify PC
throughout its different life-cycle stages. Diff-Quik® is one such stain (179). This
staining method is able to discriminate between nuclei (stains pinkish purple) and
cytoplasm (stains blue). In this manner one can not only count PC nuclei for
quantitative purposes, but can also quantify the number of cysts, intracystic
bodies, and trophozoites. More recently, polymerase chain reaction (PCR) (180)
and real-time PCR (181) (182) have been introduced as effective methods for the
diagnosis and quantification of PC organisms. This method has been shown to
be highly sensitive and will likely become more widely used in the study of PC
organisms. In my research, I used real time PCR to identify and quantify PC
organisms when detection by light microscopy was determined to be inefficient
and minimally sensitive. The methods used for PC quantification during my
research will be discussed further in the methods section of this document.
D. Drug Therapy
1. History
When PC first started killing infants in Europe in the early 1940s, little
could be done in the way of treatment. At that time, it wasn’t even known that PC
was the culprit of this mysterious pneumonitis, thus caregivers could only provide
supportive care, while they watched infant after infant succumb to the disease. It
wasn’t until the early 1950s that PC was identified as the source of the infectious
pneumonitis, which by this time, was causing disease in chemotherapy-related
and other immunodeficiency disorders. Because little was known about PC
organisms, the identification of targeted drug therapy was difficult.
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The first drug to show effectiveness against PC was pentamidine
isethionate, manufactured in England by May and Baker, Ltd. Because PC was
thought to be a protozoon, drugs that were effective against other protozoa, such
as pentamidine, were studied for the treatment of PC. One of the first studies to
look at changes in mortality with this drug was published in 1958 by Ivady and
Paldy (183). Subsequent studies looking at outcomes in PC-infected children
receiving pentamidine demonstrated a decrease in mortality from 50% to
approximately 20% (184) (185). While pentamidine was the only drug known to
decrease mortality from PC, it was certainly not an ideal drug. It required parental
administration, it couldn’t be used for prophylaxis, and it had many adverse
effects, including cardiovascular, hematologic, dermatologic, and endocrine
reactions, most notably, severe hypoglycemia (186) (187) (188). Furthermore, in
the 1960s through the early 1980s, pentamidine had not been approved by the
U.S. Food and Drug Administration (FDA), and thus was not available for general
use. If a case of PC was diagnosed, physicians had to contact the Parasitic
Disease Drug Branch of the CDC, provide data confirming their diagnosis of PC
pneumonitis, and wait for CDC approval. If approved, the drug was sent by
commercial airline to the city where it had been requested. Physicians and
patients could only hope that the drug made it there before it was too late (102).
While other antimicrobial agents have shown effectiveness against PC
organisms, it was the discovery of the combination of trimethoprim and
sulfamethoxazole in 1974 that dramatically changed how we treat and prophylax
against PC. Hughes and colleagues demonstrated that this combination drug
therapy was highly effective for both the prevention and treatment of PC
pneumonitis in a corticosteroid-treated rat model (189). Subsequently, their
research was extrapolated to clinical trials where they demonstrated therapeutic
safety and efficacy in PC-infected cancer patients (190, 191). After this
discovery, several studies followed suit which confirmed both the safety and
efficacy of TMP/SMX for the treatment of PC pneumonitis in both adults and
children (192) (193, 194).
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2. Current Recommendations
Guidelines for both the treatment and prevention of opportunistic
infections were devised for both adults and children following the increase in
opportunistic infections (OIs) associated with HIV infections. Being that PCP is
the most common OI associated with HIV, it is included within these
recommendations. While the occurrence of PCP is not limited to HIV-infected
individuals, the guidelines for treatment of PCP associated with HIV can be
extrapolated to all cases of PC infection. Outlined below are the most recent
therapeutic recommendations put forth by the CDC for both adults and children
infected with PC.
Trimethoprim/sulfamethoxazole
As previously described, the CDC recommends TMP/SMX as the first line
treatment and prophylaxis for PCP in both adults and children (13, 195).
TMP/SMX is a combination of two antimicrobial agents, each of which act on two
different enzymes to synergistically inhibit folate metabolism; TMP blocks
dihydrofolate reductase (DHFR) and SMX blocks dihydropteroate synthase
(DHPS) (196). Ultimately, the inhibition of these enzymes leads to the inhibition
of thymidine synthesis and subsequently DNA synthesis within the target
organism.

Since the discovery of its effectiveness against PCP in the early

1970s (190, 197), TMP/SMX has been shown to be as efficacious as IV
pentamidine as well as other alternative agents (191) (189). Its ease of
administration, relatively fewer side effects, and reasonable cost have kept it the
drug of choice for PCP since it was first officially endorsed as first-line treatment
by the CDC in 1989 (198).
Two major factors obviate the need for newer alternative agents for the
treatment of PCP; the first is the high rate of adverse reactions associate with
TMP/SMX. Some of the adverse reactions that occur in children secondary to
TMP/SMX include, but are not limited to, rash, hematological abnormalities, and
interstitial nephritis (13-15). Furthermore, infants less than 4 weeks of age are at
increased risk of jaundice when exposed to TMP/SMX due to its bilirubin
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displacing properties (1995 MMWR Revised guidelines for prophylaxis against
PCP), (Brito 2006, Science Direct) (199-201). If intolerance to TMP/SMX occurs,
adults have several other treatment options, including pentamidine, atovaquone,
clindamycin/primaquine,

dapsone/trimethoprim,

or

trimotrexate

glucuronate/leucovorin (13).

Treatment options for the 15% of children who

develop substantial adverse reactions to TMP/SMX (16), however, are severely
limited with pentamidine being the only alternative agent with available data for
use in children (13). The rate of toxicity is higher among HIV-infected patients
though the reason for this is not understood (202). Over 80% of HIV-infected
individuals experience an adverse reaction to TMP/SMX; in more than 50% of
these patients, the adverse reaction may be dose-limiting. The most common
toxicities include gastrointestinal symptoms, rash, fever, cytopenia, hepatitis,
nephritis, hyperkalemia, and pancreatitis (203) (204).
The second major factor necessitating newer treatments for PCP is the
increase in Pneumocystis jiroveci resistance to SMX (the primary agent in the
combination product) (205), undoubtedly brought about by the wide exposure of
PC organisms to SMX following the start of the AIDS epidemic. While sulfa
resistance has been well documented among a variety of different organisms
such as S. pneumoniae (206), N. meningitides (207), and E. coli (208), drug
resistance to PC cannot be determined by typical methods because patient
isolates cannot be cultured in order to determine drug sensitivities. Thus,
resistance detection relies on the identification of mutations within the DHPS
gene. The PC DHPS gene was sequenced in 1997 from six patient isolates in
which specific genetic polymorphism were identified. Each of the polymorphisms
resulted in changes in the respective encoded amino acids suggesting that an
evolutionary selective pressure, perhaps imparted by exposure to SMX, occurred
in PC isolated from these patients (209). Additional studies have been done
looking at the existence of DHPS mutations in patients receiving TMP/SMX
prophylaxis compared to those not receiving prophylaxis. In every study except
one, the groups receiving TMP/SMX prophylaxis had significantly more DHPS
mutations compared to their respective controls (18, 210-215). The one study
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that did not show a difference had a very small sample size which may have
contributed to the results (216). In addition to these studies, 4 other studies have
been published which take a closer look at the correlation between the DHPS
mutation and clinical treatment failure. The first study, published in 1999 showed
an increased 3-month mortality rate in patients with mutant DHPS compared to
patients with wild-type PC infections. The other three studies looked at
associations between mutant DHPS and treatment failure rates; of these, 2 of the
studies found a correlation between the mutant DHPS and treatment failure (212)
(217) while the third study found no correlation (218). While the conflicting results
of these studies leave us questioning their clinical applications, it is clear that with
continued selective pressure by the wide-spread use of TMP/SMX treatment and
prophylaxis, we will begin to see clinically significant PC mutations leading to
resistance.
Alternative agents available for use in children
IV pentamidine is the only alternative agent recommended in children
infected with PC. While aerosolized pentamidine has been assessed for AIDSrelated PC pneumonia, it was not as effective as IV pentamidine or TMP/SMX
and is therefore not recommended for treatment (219, 220). It is generally only
administered to children who cannot tolerate TMP/SMX or who demonstrate
clinical failure after 5-7 days of TMP/SMX therapy. Approximately 17% of
children who receive pentamidine experience a severe adverse reaction,
including renal toxicity, severe hypotension, severe endocrine abnormalities, and
pancreatitis (17) (195). No evidence exists for any synergistic or additive benefits
with the use of pentamidine together with TMP/SMX; in fact, the use of these two
agents together should be avoided due to the additive adverse effects (195).
Pentamidine is considered only as an alternative treatment to TMP/SMX due to
its greater number of severe adverse effects, IV administration and lack of
availability (191).
While other alternative agents are available for the treatment of PCP in
adults and may actually be used in children, their use in children is not endorsed
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due to the limited data available for their use in children. Although pentamidine is
known to cause many serious adverse reactions, it has long history for treating
PCP in children since it was the first known treatment for the disease. Due to the
limited treatment options available for children intolerant to or failing TMP/SMX
therapy, pentamidine remains one of the few available options left for children
infected with PC.
Alternative agents available for use in adults
Dapsone plus TMP is a recommended alternative in adults for the
treatment of mild-to-moderate PCP for those who are allergic or otherwise cannot
tolerate TMP/SMX. Those who are allergic to TMP/SMX are generally allergic to
the sulfa component (SMX) and thus are still able to take TMP. While dapsone
contains a sulfa moiety, it is a sulfone drug compared to a sulfonamide drug;
therefore patients allergic to sulfonamides such as SMX will generally tolerate
dapsone (221). This regimen may have similar efficacy and fewer side effects
than TMP/SMX, but is less convenient due to the large number of pills required
(13).
Primaquine plus clindamycin is considered to be an effective alternative
regimen for the treatment of mild-to-moderate PCP. Studies have shown this
regimen to be as effective with equal or less side effects that TMP/SMX (222)
(223). While clindamycin is readily available in both IV and PO formulations,
primaquin is only available orally and thus is inappropriate for severe cases of
PCP in which the patient is unable to take oral medications.
IV pentamidine is an alternative agent for treating severe disease in adults
unable to take oral medications. As discussed previously in regards to treating
PC-infected children, this drug has several serious adverse reactions associated
with it, making it a second line treatment option to TMP/SMX (224) (191).
Atovaquone suspension has been shown to be less effective than
TMP/SMX for the treatment of PCP. However, it was also shown to have fewer
side effects than TMP/SMX and is therefore recommended as an alternative
agent for mild-to-moderate disease in adults (225) (226).
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Trimetrexate and

leucovorin is an alternative regimen similar to atovaquone, except that it is
available IV (227).
Corticosteroids
Studies in adults have demonstrated a reduction in mortality and a faster
recovery

time

in

patients

with

moderate-to-severe

PCP

who

receive

corticosteroids within 72 hours of starting PCP treatment (228) (229) (230).
Studies in children have shown similar results with those receiving corticosteroid
treatment having a reduction in acute respiratory failure, decreased need for
mechanical ventilation, and a decrease in overall mortality (231) (232) (233).
Indications for the use of corticosteroids include room air pO2 <70 mm/Hg or
arterial-alveolar O2 gradient >35 mm/Hg (195) (13). The observation that steroid
therapy improves the outcomes of PC infection further demonstrates the role that
the host’s immune system plays in the pathogenesis of PCP and underscores the
need for therapeutic agents involved in immunomodulation.
Granulocyte macrophage colony-stimulating factor
Granulocyte-macrophage

colony-stimulating

factor

(GM-CSF)

is

a

glycoprotein produced by several pulmonary cells including macrophages,
activated T cells, and epithelial cells (22). Among the functions of GM-CSF are its
ability to influence the number of macrophages at a site of infection and activate
macrophages for enhanced activity against invading pathogens (23) (24). GMCSF is a commercially available hematopoietic agent indicated for use in
leukemia following cancer chemotherapy, myeloid reconstitution following bone
marrow transplants and mobilization for peripheral blood stem harvesting
(Immunex Co.). GM-CSF has also been shown to enhance the clearance and
improve outcomes of several different pulmonary infections, including but not
limited to group B streptococcus infection (24), Pseudomonas aeruginosa (25),
Histoplasma capsulatum (26, 27), Mycobacterium tuberculosis (28), and
Pneumocysistis carinii (29). However, there is little data on the effects of GMCSF on pulmonary infections in infants and no data regarding the addition of GM-
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CSF for the treatment of PCP in the infant population. These aforementioned
attributes and the ability of GM-CSF to improve outcomes in pulmonary infections
in adult animal models suggest that this clinically relevant agent may be of
therapeutic benefit for infants with pulmonary infections failing to respond to
antimicrobial therapy alone. HIV-infected infants with PCP are a particularly
fragile population requiring more treatment options to improve outcomes.
However, the potential role of GM-CSF in the lung for host defense against PC
has not been investigated in the neonatal population and will therefore be
addressed within the scope of this project.
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E. Project Overview
Our lab has previously demonstrated that there is approximately a 3-week
delay in the clearance of Pneumocystis organisms from pup mouse lungs
compared to adults which corresponds with a delay in T cell infiltration into the
pup versus adult lungs (9, 234). However, when T lymphocytes from pup mice
were adoptively transferred into adult mice, they were shown to clear PC as
efficiently as adult T cells (10) suggesting that the delayed PC clearance in
neonates can not be attributed to T cells alone. We have further shown that there
is approximately a 1-week delay in LM activation in pup versus adult mice (11).
Resident macrophages in the lungs make up the first line of defense against
inhaled pathogens such as PC and appear to be the primary effector cells
responsible for killing and clearance of PC (12). Furthermore, the role of
activated T lymphocytes during PC infections has been shown to be crucial in the
clearance of this organism (97, 234), thus the activation role of LMs toward T
lymphocytes is likewise crucial to PC clearance. It was therefore, the goal of this
project to elucidate the role that lung macrophages play in delayed T lymphocyte
infiltration and delayed PC clearance, to determine any deficiencies in pup LMs
compared to adult lung macrophages and to further identify a clinically relevant
treatment option that would help stimulate lung macrophages and expedite the
clearance of PC organisms from pup lungs.
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Figure 1.1 Delayed PC clearance in pup mice. Mice were infected with PC as
neonates (24-72 hours after birth) or as adults (>8 weeks). Whole lungs were
collected and processed into obtain single-cell suspensions. Aliquots were spun
onto glass slides, stained with Diff-Quick®, and PC nuclei were enumerated
microscopically. Results represent the mean ± SD of 4-5 mice per group and 4
separate experiments.
I have developed three hypotheses designed to evaluate the role of lung
macrophages in the delayed clearance of PC and potential mechanisms for
improving outcomes in PC-infected pup mice and human infants through the
immunomodulation of LMs. These hypotheses and their respective aims are
outlined below.
Hypothesis I: Lung macrophage activation is delayed in Pneumocystis–infected
pup compared adult mice.
Aim 1: Flow cytometry was used to compare the expression levels of activation
markers on the surface of PC-infected pup and adult LMs. Additionally, the
infiltration of T lymphocytes was assessed using flow cytometry. These markers
of activation and T cell markers were evaluated over the time course of PC
infection in both pup and adult lavage and lung tissue.
Aim 2: CBA and ELISA kits were used to assess cytokine production in pup
versus adult alveolar macrophages. The production of cytokines secondary to
PC, were also determined and compared for both pups and adults over time.

38

Hypothesis II: Exogenous immunomodulation with IFNγ, Heat-killled E. coli
(HKEC), GM-CSF alone, or GM-CSF plus TMP/SMX will stimulate the activation
of LMs and reduce the intensity of PC infection by augmentation of host defense
in pup mice.
Aim 1: CBA and ELISA kits were used to assess cytokine production in pup
versus adult alveolar macrophages in vitro and in vivo following stimulation with
PC ± IFNγ, HKEC (LPS in vitro), or GM-CSF. To determine if differences in NFkB
p65 nuclear translocation could be increased in pup mice following exogenous
stimulation, a cheminluminescent plate-based assay was used.
Aim 2: To determine if pup macrophage infiltration into PC-infected lungs could
be increased and their activation expedited through exogenous stimulation, LM
activation markers were evaluated and compared via flow cytometry following
different immunomodulatory treatment regimens. These treatment regimens were
also evaluated for their ability increase T lymphocyte infiltration and activation in
PC-infected pup lungs via flow cytometry to determine if exogenous LM
activation played a role.
Aim 3: To determine if exogenous immunomodulatory treatment regimens could
expedite the clearance of PC organisms from PC-infected pup lungs, lung tissue
from both pup treatment and control groups were collected, digested, spun onto
glass slides, stained, and analyzed microscopically. PC nuclei were manually
counted and compared between groups.
Aim 4:

To determine if T lymphocytes play a role in LM activation and PC

clearance in HKEC-treated pups, HKEC-treated SCID and WT pups were
compared in their ability to phagocytose DiO-labeled PC organisms.
Hypothesis III: Human infant LMs have a delayed activation profile compared to
adult LMs following exposure to antigenic particles and can be stimulated
exogenously to expedite their activation.
Aim 1: CBA and ELISA kits were used to assess cytokine production in infant
versus adult AMs in vitro. The production of cytokines secondary to PC along
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with immunomodulatory agents, were determined and compared for both infants
and adults over time.
Aim 2: Phagocytosis assays were performed on LMs isolated from uninfected
infants and adults. An in vitro model was used in which cells were isolated from
human subjects and stimulated with PC ± rhGM-CSF. This method enabled me
to determine the utility of rhGM-CSF as a clinically relevant immunomodulator to
improve infant LM phagocytosis of PC organisms.

Copyright © Kerry McGarr Empey 2007
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CHAPTER 2. Materials and Methods
A. Materials
1. Equipment
FACSCalibur cytofluorimeter (BD Biosciences, San Jose, CA), Sorvall
RT7 centrifuge, Sorvall Biofuge, Fresco (Kendro Labs, Newton, CT), Nikon
Eclipse E400 with spot camera, E600 (Tokyo, Japan), µQuant Universal
Microplate Spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT),
Shandon Cytospin 3, cytocentrifuge, (IMEB, inc. San Marcos, CA), Nalgene® Mr.
Frosty freezing container (Sigma-Aldrich, St. Louis, MO).
2. Animals
Five-6 wk-old BALB/c mice (National Cancer Institute, NCI); 8-wk-old
B6xDBA2FI mice (Jackson Laboratory, Bar Harbor, ME); BALB/c and
B6xDBA2F1 (F1) were bred and maintained at the Veterinary Medical Unit
(VMU) of the Veterans Administration Medical Center (VAMC) under specific
pathogen-free conditions. For the purposes of this research, neonatal mice are
considered to be ≤ 7 days old and pups are considered to be ≤ 1month old. C.B17 severe combined immune deficient (SCID) mice were used to maintain a
source of PC and were also bred at the VAMC VMU in microisolator cages
containing sterilized food and water. Protocols for the usage of mice were
approved by the VMU Institutional Animal Care and Use Committee.
3. Cell Line
Murine macrophage cell line, J744A.1 was generously provided by Dr.
Susan Straley, Department of Microbiology, Immunology, and Molecular
Genetics, University of Kentucky, Lexington, KY.
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4. Chemicals
Chemicals/kits
Hank’s Balanced Salt Solution (HBSS) and Roswell Park Memorial
Institute (RPMI) 1640, Gentamicin, and Penicillin-Streptomycin were purchased
from Gibco in Carlsbad, CA. Collagenase A, DNase, Ethylenediaminetetraacetic
acid (EDTA), Phosphate Buffered Saline (PBS), Bovine Serum Albumin (BSA),
Dimethyl sulfoxide (DMSO), glutathione and sodium azide were purchased from
Sigma, in St. Louis, MO. Fetal Bovine Serum (FBS) was purchased from Atlanta
Biologicals in Lawrenceville, GA. Diff-Quik Solution I/II was purchased from Dade
Behring in Newark, DE. Ficoll-Paque Plus was purchased from GE Healthcare
Bio-Sciences in Piscataway, NJ. RosetteSep Human Monocyte Enrichment
Cocktail was purchased from StemCell Technologies, Inc. in Vancouver, B.C.
Vybrant DiO Solution and Carboxyflouroscein succinimidyl ester (CFSE) were
purchased from Molecular Probes in Carlsbad, CA. Murine GM-CSF, human GMCSF, and murine IFNγ were purchased from PeproTech in Rocky Hill, NJ.
TMP/SMX was purchased from Alpharma in Fort Lee, NJ. Halothane was
purchased from Halocarbon Labs in River Edge, NJ. Trypan Blue was purchased
from Fisher Scientific, Houston, TX. Mouse and Human Inflammation and
TH1/TH2 Cytometric Bead Arrays (CBA) were purchased from BD Biosciences,
San Diego, CA. Mouse rmGM-CSF ELISA kit was purchased from eBiosciences,
San Diego, CA. Nuclear Extraction Assay and NFkB p65 Transcription Factor
Assay (Human/Mouse/Rat) kits were purchased from Chemicon, Inc., Temecula,
CA. Nuclear Extraction and TransBinding NFkB Assay Kits (Human) were
purchased from Panomics, Inc., Redwood City, CA. DC Protein Assay was
purchased from Bio-Rad, Hercules, CA. PE-conjugated Human Mannose
Receptor was purchased from Immunotech, Marseille, France. Anti-human
Dectin-1/CLECSF12 was purchased from R&D, Minneapolis, MN.
Prepared media and solutions
Lavage fluid (HBSS + 0.02% EDTA), Lung/spleen collection media (RPMI
1640 + 5% FBS), ACK (8.29 g NH4Cl + 1 g KHCO3 + 37.2 mg Na2EDTA in 1 L
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water, pH 7.2-7.4), PBA (PBS+ 0.1% BSA+ 0.002% sodium azide), Mouse AM
culture media (MACM) [RPMI 1640 + 5% heat-inactivated FBS (HIFBS) + 1%
penicillin and streptomycin (P/S) + 55mM of 2-mercaptoethanol (2-ME) at 1:2000
+ 0.5% gentamicin)], J744A.1 culture media (JCM) (DMEM + 1% p/s + 10%
FBS), Dulbecco’s Modified Eagle’s Medium (DMEM) (ATCC), Human Culture
Media (HCM) (RPMI + 10mcg/ml gentamicin + 12.5% human serum), J744A.1
freezing media (JFM) (40% RPMI 1640 + 50% FBS + 10% DMSO).
Antibodies
Hypothesis I:Aim1: Biotinylated CD11c, PE-Cy5-conjugated streptavidin
(SA), FITC-conjugated Iad, PE-conjugated Iab, PE-conjugated CD40, and PETLR-4 (BD Pharmingen, San Diego, CA); APC-conjugated CD11b, FITCconjugated F4/80, APC-TLR-2, FITC-conjuaged CD68, and PE-Cy5-CD4, APCCD8, PE-CD44, FITC-CD62, FITC-CD4, PE-Cy7-CD44 (eBiosciences, San
Diego, CA), FITC-CD68, FITC-Dectin-1, PE-CD206 (Serotec, Oxford, UK).
Hypothesis II:Aim 1: Biotinylated CD11c, PE-Cy5-SA, FITC-Iad, PE-Iab,
PE-CD40, APC-CD11b, FITC-F4/80, FITC-CD68, FITC-Dectin-1, PE-CD206
(Serotec, Oxford, UK), APC-TLR-2 (eBiosciences), PE-TLR-4 (BD Pharmingen).
Hypothesis II:Aim 2: PE-Cy5-CD4, APC-CD8, PE-CD44, FITC-CD62,
FITC-CD4, PE-Cy7-CD44 (eBiosciences).
Biologicals
Pneumocystis murina (PC) was maintained in C.B-17 SCID mice that
were bred and maintained at the VMU, HKEC was made from lyophilized cells of
strain W(9637; ATCC) Escherichia coli (Sigma), LPS 100ng/ml (Sigma),
Zymosan A 200µg/ml (Sigma).
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B. Methods
1. Preparation of Pneumocystis for inoculations
PC-infected C.B-17 SCID mice were killed via CO2 narcosis, their lungs
were excised, collected in sterile HBSS + P/S (1:100) + gentamicin (1:1000)
(5ml/mouse), and pushed through stainless steel mesh using a glass plunger in a
sterile hood. The tissue was spun at low speed (300RPM) for 3 minutes to
remove heavy debris. The supernatant was collected, the volume noted, and the
sample was placed on ice after taking a small aliquot. The aliquoted sample was
spun onto a glass slide (a 1:20 or 1:50 dilution is usually required), fixed in
methanol, and stained with Diff-Quick®. PC nuclei were enumerated by
microscopy and the final concentration was adjusted to 1x107 PC nuclei/100µl by
spinning down the original sample at 1300 x g for 15 minutes and resuspending
in the appropriate volume of HBSS + P/S + gentamicin. BALB/c or C57BL/6 x
DBA/2J (B6D2F1/J) mice were lightly anesthetized with halothane and inoculated
intranasally at 8-wks-old with 1x107 PC organisms in 50µl and at 48- to 72-hrs-old
with 1x106 PC organisms 10µl. In some experiments, mice were infected with
DiO-labeled PC. Live purified PC was incubated with DiO at a ratio of 5x106
PC:5µl DiO in 1ml PBS for 30 minutes at 37ºC prior to inoculating the mice.
2. Collection and preparation of tissue/BALF for flow cytometry
All mice were killed immediately prior to tissue/BALF collection with either
Halothane or Isofluorane by placing the animals in a bell jar with Halothane- or
Isofluorane-soaked paper towels. Protocols for the usage of mice were approved
by the VMU Institutional Animal Care and Use Committee.
Serum
Whole blood was obtained by severing the abdominal aorta and collecting
it using a disposable glass pipette. The whole blood was spun at 2000RPM for
10 minutes to separate the serum, which was then decanted, placed in fresh
Eppendorf tubes and stored at -80ºC.
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BALF
A flexible syringe-tip needle was inserted into the trachea of both pups
and adults. Two-5ml of
aliquots. Each aliquot of

avaged fluid was instilled into the lungs in 3-5 divided
avaged fluid was massaged in the lung and pulled

back out into a fresh syringe via a 3-way stop-cock mechanism. The first aliquot
was collected separate from the rest of the BALF, spun at 1200RPM for 10
minutes and the supernatant collected and frozen at -80ºC. The cell pellet was
resuspended and combined with the remainder of the BALF. An aliquot of the
BALF was reserved for cytospins and cell counts; the remainder was spun down
at 1200RPM for 7 minutes, the supernatant was removed and approximately 1ml
of ACK was added to lyse any remaining RBCs. Once the ACK was added, the
cells were vortexed briefly; the ACK was left on the cells for 30-60 seconds
before diluting it with twice the volume of HBSS. The cells were then spun at
1200RPM for 7 minutes, washed one more time with HBSS and resuspended in
0.5-1ml of HBSS for flow cytometric analysis. Ten micro liters of the reserved
aliquot of BALF (dilutions were made based on concentration) was mounted on a
hemocytometer and counted under a 40x objective. These cell counts were used
to determine the volume required for each flow cytometry polystyrene tube (1x106
cells/tube) and for later analysis. When enough cells were available, 100µl of the
reserved aliquots were spun onto glass slides, fixed in methanol, and stained
with Diff-Quik® for cell differential counts.
Lung tissue/spleen
Right lung lobes were excised and collected in 2ml of lung collection
media. The lungs were then prepared for flow cytometry by processing them to
achieve a single-cell suspension. They were minced and enzyme treated at 37◦C
for 1hr in lung collection media, 50U/ml Dnase, and 1 mg/ml collagenase A.
Digested lung tissues were pushed through 70µm cell strainers with 3ml syringe
plungers to obtain a single cell suspension. At this point, an aliquot was reserved
to be spun onto glass slides and stained as previously described for BALF. For
pup experiments in which the mice were ≤ 13 days post-infection, the lung digest
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was diluted 1:10; for experiments in which the mice were > 13 days postinfection, the dilution was 1:20. The glass slides were then fixed in methanol and
Diff-Quik® stained. For the remaining lung digest, RBCs were lysed with ACK,
resuspended in 0.5-1ml HBSS and counted on a hemocytometer as previously
described for BALF. Once the appropriate volume per tube was determined, the
cells were filtered into polypropylene tubes through 80µm mesh prior to
processing for flow cytometry.
Tracheobronchial lymph nodes
The TBLNs were collected in 1ml of HBSS. To obtain a single-cell
suspension they were pushed through 70µm cell strainers with 3ml syringe
plungers. As previously described for BALF, the cells were treated with ACK,
resuspended in 0.5-1ml HBSS and aliquoted into polypropylene tubes for flow
cytometry. The spleen, often used as a one-color control for T lymphocyte
antibodies, was processed in the same manner as the TBLN.
Staining
Once all the cells were aliquoted into the appropriate tubes, PBA was
added to achieve approximately the same volume for all tubes. They were then
spun down at 1200RPM for 10 minutes and the supernatants dumped.
Fluorochrome-conjugated antibodies, previously titrated for optimal staining of
1x106 cells, were diluted in PBA; added to the pelleted cells and incubated for 20
minutes on ice (the antibodies used are outlined in the Materials section). At this
time, 1 ml PBA was added to all the cells and spun at 1200RPM for 10 minutes.
The supernatant was dumped and the cells were resuspended in 200µl of HBSS
to be run on the FACSCalibur or CSRII cytofluorimeter. Cells being stained with a
biotinylated Ab were incubated a second time with streptavidin before being
resuspended in HBSS. 50,000 events were routinely required.
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3. Pneumocystis enumeration and differential cell counts
As previously described, BALF and lung digest were spun onto glass
slides and stained for later microscopic evaluation. Both BALF and lung digest
samples were spun onto the glass slides via cytospin at 900 RPM for 5 minutes.
Each slide was allowed to air dry before fixing in methanol for 1 minute. Once
again the slides were air dried and then Diff-Quik® stained by submerging them
for 1 minute in Diff-Quik® Solution I, followed immediately by 5 minutes in DiffQuik® Solution II. The slides were then washed 3 times by submerging them in
water. They were air dried and cover slipped and allowed to dry overnight. The
slides were analyzed microscopically under a 60x oil emersion lense. For each
BALF sample slide, the number of macrophages, monocytes, neutrophils, and
lymphocytes were determined. For each lung digest sample slide, PC nuclei
were enumerated and reported as Log10 PC per lung.
4. Cell culture
Murine macrophage cell line, J744A.1
Cells were stored in vapor-phase liquid nitrogen until ready for use. To
freeze, cells were pelleted at 1200RPM for 10 minutes and resuspended in JFM
to a concentration of 1x106 cells/ml in cryotubes. The 1ml aliquots were then
submerged in an isopropyl alcohol-filled freezing container (Mr. Frosty®) and
placed in the -80ºC freezer for two days before transferring them to the liquid
nitrogen tank. To thaw, cells were removed from liquid nitrogen and placed in a
37ºC water bath just long enough for the media to begin to change back to a
liquid phase. At this time 37ºC media was added directly onto the cells, they were
transferred to a fresh Eppendorf® tube and then immediately spun at 1200RPM
for 10 minutes. The pelleted cells were resuspended in 1ml of JCM and
transferred to a 75cm2 tissue culture flask. An additional 19ml of JCM was added
to bring the total volume to 20ml. The cells were then placed in a 37ºC, 5% CO2
incubator and were allowed to grow to confluence. Once the cells became
confluent they were either used for an experiment or they were scraped with a
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rubber spatula and split at no more than 1:6 and replated for future experiments.
All J744A.1 cell manipulations were performed under sterile conditions.
Culture of murine alveolar macrophages
The BALF from uninfected pup and adult mice was collected as previously
described in section 2.2 of Methods, except that the collection process was
performed under sterile conditions. All BALF cells collected from pups were
pooled together as was the BALF cells from adults. Aliquots of both pup and
adult BALF cells were reserved to be spun onto glass slides, stained, and
evaluated microscopically for AM purity. The remainder of the BALF was spun at
1200RPM for 10 minutes. To lyse any contaminating RBCs, ACK was added at
one tenth the original BALF volume, vortexed, and allowed to sit for 60 seconds.
HBSS was added at 6 times the volume of ACK and the cells were spun again at
1200RPM for 10 minutes. The cells were washed a second time and
resuspended in 1/10 the original BALF volume with MACM warmed to 37ºC. Both
pup and adult cells were counted using a hemacytometer, as previously
described, and their volumes were adjusted to achieve concentrations of 1x106
cells/ml. On average, the BALF yielded approximately 2 x105 Ams per pup and 6
x105 Ams per adult. Cells were then plated in either 96-well tissue culture plates
in aliquots of 200µl (2x105 cells/well), or in 6-well tissue culture plates in aliquots
of 2ml (2x106cells/well) depending on the experiment being performed. The cells
were rested overnight before being used experimentally.
Human airway macrophages
Human neonatal suctioned sputum samples were obtained in accordance
with the University of Kentucky, Institutional Review Board (IRB) approved
research protocol entitled “Immunomodulation to Improve Neonatal Clearance of
Pneumocystis” (Protocol # 04-0086-P1B); informed consent was waived. Human
adult BALF samples were obtained in accordance with the IRB approved
research protocol entitled “Control, Immunoregulation, and expression of Innate
Host Defenses” (Protocol # 05-0796-P2G). Subjects were excluded if they had
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HIV or tuberculosis. All other demographic information was excluded and
informed consent was waived as no patient identifiers were used. Each human
sample was collected in hospital issued specimen cups and maintained on ice till
they could be picked up; no samples were left on ice for more than 1 hour before
being retrieved and sample processing begun. All human samples were handled
with biosafety level (BSL) 2 precautions under sterile conditions. Each sample
was immediately washed with equal volumes of HBSS and spun at 1200RPM for
10 minutes. The supernatants were dumped, resuspended in HCM (warmed to
37ºC), and counted on a hemacytometer under a 40x objective. The samples
were adjusted with HCM to a final concentration of 1x106 cells/ml and added in
200µl (2x105 cells) aliquots to 96-well tissue culture plates. The cells were rested
overnight before being used experimentally.
Throught this text the term “neonate” will be used to refer to infants less
than or equal to 4 weeks of age and “adults” include persons who are 18 years or
older.
Human peripheral blood monocyte-derived macrophages
Human peripheral blood was obtained in accordance with the University of
Kentucky, IRB approved research protocol entitled “Immunomodulation to
Improve Neonatal Clearance of Pneumocystis” (Protocol # 04-0086-P1B).
Peripheral blood was obtained from enrolled healthy volunteers with whom
informed consent was obtained. Between 5 and 15ml of blood per session was
collected into sterile Buffered Sodium Citrate Plus Blood Collection Vacutainer
tubes (BD) using 23G3/4 x12” Vacutainer Brand Safety-Lok Blood Collection
Sets (Becton Dickinson, Franklin Lakes, NJ). Monocytes were isolated using the
RosetteSep

Human

Monocyte

Enrichment

Cocktail

according

to

the

manufacturer’s instructions. Per the manufacturer’s protocol, 10µl of room
temperature (RT) 100mM EDTA per 1ml of whole blood was mixed gently with
the blood sample in a 50ml conical vial. Next, 50µl of RosetteSep Cocktail per ml
of whole blood was added, mixed, and incubated for 20 minutes at RT. The
sample mixtures were then diluted with equal volumes of PBS + 2% FBS + 1mM
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EDTA (wash buffer) and gently mixed. Separately, Ficoll-Paque (volume
specified in protocol based on volume of whole blood retrieved) was placed in a
new, sterile 50ml conical vial. Subsequently, the blood solution layered on top of
the Ficoll-Paque very carefully so as not to disrupt the Ficoll-Paque layer. The
layered 50ml conical vial was then spun at 1200xg at RT for 20 minutes with the
brake turned off. The RosetteSep cocktail crosslinked all unwanted cells (leaving
the monocytes free) to multiple RBCs, forming immunorosettes. This caused the
density of the unwanted or rosetted cells to increase so that they were pelleted
along with the RBCs when they were centrifuged through the Ficoll-Paque.
Following the 20 minute spin, 4 layers were formed, including (starting from the
bottom): RBCs/unwanted cells (red), Ficoll-Paque (clear), enriched monocytes
(white), and the top plasma layer (yellow). The top plasma layer was removed
and discarded to allow better access to the white monocyte layer. A bulk pipette
was used to remove the monocyte layer, which was then placed in a fresh 50ml
conical vial. To this, 20ml of PBS + 2% FBS + 1mM EDTA was added and the
cells spun at 1200RPM for 7 minutes. The supernatant was removed and the
cells were resuspended in 2ml of wash buffer to be counted on the
hemocytometer. On average, 3x105 monocytes per 1ml of whole blood are
retrieved via this method. The wash step is repeated one more time before
resuspending the cells in a volume of HCM to achieve a final concentration of
1x106 cells/ml. The cells were then placed in sterile, autoclavable, 6-well Teflon
liners at 0.5-1ml per well (5x105 – 1x106 cells/well, respectively) and cultured for
5-7 days to allow them to differentiate into macrophages. Upon differentiation,
the peripheral blood, monocyte-derived macrophages are ready for stimulation
experiments to be described later in the Experimental Design section.
Cell Viability
An equal volume of 0.4% Trypan Blue was added to a cell suspension of
approximately 1x106 cells/ml in PBS or serum-free media. The suspension was
incubated for 3 minutes at RT before being mounted on a hemocytometer and
observed under a 40x objective. Non-viable, deep-blue cells and clear, viable
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cells were both enumerated. The percent viability was calculated as follows:
Percent viable = (number of viable cells/number of total cells) x 100.
Cell Stimulation
If cytokine analysis was the goal of the experiment, once the Ams were
isolated or thawed (as described above) they were plated in sterile 96-well tissue
culture plates. If the Ams were to be used to compare NFkB levels or
phagocytosis, the cells were cultured in sterile 6-well tissue culture plates. All
cultured Ams were allowed to rest over night following initial plating before any
experimental stimulation or manipulations were performed and fresh media
added the following day. In all culture experiments, cells were suspended in a
final concentration of 1x106 cells/ml and plated at 200µl (2x105 cells) per well; if
6-well plates were being used, cells were plated at 1ml (1x106 cells) per well.
Table 2.1 describes the agents used to stimulate or block AM activity in culture.
Table 2.1 Cell Stimulation
Stimulant/Block

Dose

PC

50 PC per 1 macrophage

IFNγ

165ng/ml

LPS

100ng/ml

rmGM-CSF

100ng/ml

rhGM-CSF

100ng/ml

Opsonized Zymosan

250µg/ml

Unopsonized Zymosan

250µg/ml

Dectin-1 Receptor Antibody

25µg/ml

Mannose Receptor Antibody

40µl/ml

5. Pneumocystis purification
PC-infected C.B-17 SCID mice were killed via CO2, their lungs were
excised, collected in sterile-filtered HBSS + 0.5% glutathione (pH 7.3)
(5ml/mouse), and pushed through stainless steel mesh using a glass plunger in a
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sterile hood. The Tissue was then aspirated through a 22G needle 2 times, a
26G needle once and transferred to a 50ml conical vial. The lungs were then
spun at 300RPM for 3 minutes to remove the heavy sediment and the
supernatant was transferred to a fresh 50ml conical vial and spun at 2600RPM
for 15 minutes. The supernatant was removed and discarded, the pellet
dissociated and resuspended/washed in 2ml of sterile deionized water for 30
seconds, followed by 2ml of 2x PBS, 6ml of HBSS + 0.5% glutathione (pH 7.3),
and 200U Dnase (in 500µl HBSS). The lungs were incubated in this solution for
30minutes at 37ºC and then aspirated once again through a 26G needle 2 times.
The tissue was spun at 300RPM for 3 minutes and the supernatant was
transferred to a new 50ml conical vial before being spun once again at 1300g for
15 minutes. The supernatant was removed and the pellet was resuspended in
1ml HBSS. A 1:100 dilution is usually made before spinning an aliquot of the
purified PC onto a glass slide, fixed in methanol, stained with Diff Quik and
enumerated microscopically. The resultant purified PC can then be adjusted to
the desired concentration with HBSS.
6. Phagocytosis Assay
Human and mouse macrophages were acquired as described in sections
4.2 and 4.3 respectively. Each sample was washed by adding 2x the volume of
HBSS and spinning at 1200RPM for 10 minutes. When necessary, a RBC lysing
buffer was added to the pelleted cells and washed twice with HBSS. The final
pellets were resuspended in HBSS to a final concentration of 1x106 cells/ml. One
10 x 75-mm snap-top tube was prepared for each condition being studied. To
each tube, 100µl of macrophage suspension (1 x105 cells), 100µl (1 x106) freshly
thawed, purified, murine PC (as described above), and 2µl of freshly thawed icecold human serum was added.

For each sample, tubes were prepared as

describe above with and without the addition of GM-CSF (100ng/ml); duplicate or
triplicate tubes were set up for each sample and condition. The tubes were
capped tightly, parafilmed, and rotated end over end in a 37ºC water bath for 25
minutes.
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Following this incubation, the tubes were spun at 1200RPM for 10
minutes, the supernatant was dumped, and 1ml of ice-cold HBSS was added and
the pellet was resuspended by pipetting up and down with a Pastuer Pipette.
This wash step was repeated 2 more times for a total of 3 washes. The pellet
from the last wash was resuspended in 1ml of ice-cold HBSS to a final
concentration of 1 x105 cells/ml. A 100µl aliquot (1 x104cells) of each sample was
removed and cytocentrifuged onto a microscope slide by spinning 5 minutes at
900 rpm in a Cytopsin 3. The slides were stained with Diff-Quik® as described in
section 3. Phagocytosis was quantified using oil-immersion microscopy (1000x)
by examining at least 200 cells and counting the number of internalized PC
organisms in each one. The amount of phagocytosis was calculated according to
the following formula: phagocytic index (PI) = (percent macrophages containing
at least 1 organism) x (mean number of PC per positive cell)(235-237).
7. In Vivo Treatment Protocols
IFNγ
Recombinant murine IFNγ was purchased as a lyophilized protein and
reconstituted in sterile deionized water to a stock concentration of 100µg/ml. This
stock was further diluted into working aliquots with sterile PBS + 0.5% mouse
serum and stored at -20ºC. Prior to administering IFNγ, the mice were lightly
anaesthetized with a mixture of 5% halothane in O2. A frozen aliquot of IFNγ was
brought to RT and then administered intranasally to the anaesthetized mice.
Experiments using IFNγ treatment were designed in one of two ways. The first
experimental design included 4 groups of mice in which 2 groups were infected
with PC and two groups were uninfected. One subset from the infected and one
subset from the uninfected group received 16ng/g of i.n. IFNγ daily every 72hrs
starting on day 1 post-infection and through the completion of the experiment.
The second experimental design involved a dose escalation study to determine if
differences in outcomes could be altered by increasing dose. Doses included
16ng/g, 80ng/g, and 160ng/g of body weight; control mice received vehicle only
(sterile PBS + 0.5% mouse serum).
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Heat-killed E. coli
In order to heat-kill the E. coli, 1 gm of the lyophilized cells were
suspended in 100ml of sterile, deionized water and divided into two separate
50ml conical vials. They were then boiled for 45 minutes in a double boiler (in a
chemical hood) to remove the capsular antigens and expose the “O” antigens.
The cells were allowed to cool, centrifuged at 3500g for 15 minutes, and the
supernatant was removed and placed in a beaker of bleach. The pelleted cells
were resuspended in 80ml (40ml per conical vial) of sterile deionized water and
spun once again at 3500g for 15minutes. This wash step was repeated 2 more
times for a total of 3 washes. The pelleted cells from the last wash were
resuspended in 20ml (10ml per conical vial) of sterile, deionized water and the
two vials were then combined for a total volume of 20ml (238). The resultant
HKEC solution was then transferred into cryotubes in 1ml aliquots and stored at 80ºC.
When dosing mice with HKEC, 1 vial would be thawed to RT and brought
up to 5ml with sterile, deionized water. Mice were placed in a 20 x 20 x 40cm
Plexiglas chamber attached to a T Updraft Nebulizer as depicted in Figure (2.1).
The 5ml E. coli solution was placed in the nebulizer and aerosolized into the
chamber till all of the solution had been aerosolized (~ 30-45min). The nebulizer
and chamber were contained in a chemical hood during the aerosolization
process. For all HKEC experiments, mice were dosed once daily beginning 48hrs
post-PC-infection and continuing through day 20 post-infection. Control mice
were aerosolized with sterile, deionized water on the same schedule as the
treatment mice.
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Figure 2.1 HKEC aerosolization chamber.
Granulocyte Macrophage-Colony Stimulating Factor
Recombinant murine GM-CSF (rmGM-CSF) was purchased as a
lyophilized powder; it was reconstituted with sterile, deionized water to a stock
concentration of 1µg/µl and was stored at -20ºC. Further dilutions were made by
adding sterile normal saline (NS) + 1% mouse albumin to the desired
concentration. If the rmGM-CSF was to be used within 1 week’s time, it was
stored at 4ºC in order to avoid frequent freeze-thaw cycles. If the route of
administration was intraperitoneal (i.p.) injection into the abdomen, no
anaesthetization was required. The dose used for i.p. experiments was 0.5mcg/g
daily in two divided doses beginning day 7 post-PC-infection and continuing for a
total of 5 days (239). If the rmGM-CSF was to be administered intranasally, the
mice were first lightly anaesthetized in 5% halothane in O2. The i.n. dose of
rmGM-CSF ranged between 5-50ng/g in 10µl of diluent daily (to minimize
halothane exposure) beginning on day 7 post-PC-infection and continuing for a
total of 5-7 days. All control mice received diluent only on the same schedule and
by the same route of administration as the treatment mice in the same
experiment.
Trimethoprim/Sulfamethoxazole
TMP/SMX was purchased as a cherry-flavored, oral suspension. Each
milliliter contained 8mg of TMP and 40mg of SMX. For mice receiving TMP/SMX,
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it was administered orally using a pipette at a dose of 40mg/kg TMP/200mg/kg
SMX body weight twice daily (240); no anaesthetization was required. For all
experiments involving treatment with TMP/SMX, dosing began 7 days post-PC
infection and continued for 14 days (21 days post-infection).
8. Cytokine analysis
Cytokine production in pup versus adult mouse BALF and cultured AM
supernatants was determined using a Mouse Inflammation CBA® kit as outlined
in the manufacturer’s instructions. Briefly, CBA® kits are bead-based assays that
utilize flow cytometry to measure soluble analytes. The standards, provided in
each kit, are used to make a standard curve, which then allows the measured
proteins to be quantified. Each bead in a CBA® kit provides a capture surface for
a specific protein; the capture bead mixture provided in each CBA® kit is in a
suspension to allow for the detection of multiple analytes in a small volume
sample, which is crucial when working with the small volumes collected from
pups. The Mouse Inflammation CBA® kit includes the following analytes: IL12p70, TNFα, IFNγ, MCP-1, IL-10, and IL-6. Data analysis was performed using
the BD CBA® Software according to the manufacturer’s instructions. An ELISA kit
was used to determine the level of GM-CSF in pup and adult BALF and cultured
AM supernatants according to the manufacturer’s instructions.
Cytokine production in human neonate versus adult LM supernatants was
determined using either a Human Inflammation or TH1/TH2 CBA® kit as outlined
in the manufacturer’s instructions and as described above. The Human
Inflammation kit includes the following analytes: IL-8, IL-1β, IL-6, IL-10, TNFα,
and IL12p70; the Human TH1/TH2 kit includes the following analytes: IL-2, IL-4,
IL-5, IL-10, TNFα, and IFNγ.
In all cell culture experiments, supernatants were collected from treated or
control cells and frozen at -80ºC until ready for cytokine analysis. Depending on
the experiment, supernatants were collected at 6, 12, 18, 24, 48, or 72 hours
post-stimulation.
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9. NFkB analysis
NFkB p65 transcription factor levels within the nucleus of Ams were
compared between pups and adults using Chemicon’s Nuclear Extraction Assay
and NFkB p65 Transcription Factor Colorimetric Assay according to the
manufacturer’s instructions. Briefly, cells were lysed using a detergent-based
lysis buffer and a 27 gauge needle. They were subsequently centrifuged at high
speed to create a pellet which contained the nuclear portion of the lysed cells.
The pellet was resuspended in Nuclear Extraction Buffer, 0.5mM dithiothreitol
(DTT), and 1/1000 protease inhibitor (PI) provided with the kit. The DTT was
added as a reducing agent to stabilize enzymes with free sulfhydril groups and
the PI was added to inhibit protease enzyme activity. I used a 27 gauge needle to
pull up each sample and a 30 gauge needle to expel them to further disrupt the
nuclei. The samples were gently agitated in the Extraction Buffer on an orbital
shaker and centrifuged at high speed once again; the supernatant contained the
nuclear extracts. The protein from each nuclear extract sample was quantified
using Bio-Rad’s DC Protein Assay kit according the manufacturer’s instructions.
The samples were then snap-frozen in liquid nitrogen and stored at -80ºC.
The samples were later thawed to be used in the NFkB Transcription
Factor, plate-based, colorimetric assay. Briefly, a Streptavidin-coated 96-well
strip plate was incubated with the following reagents and samples in the order
listed: Blocking Reagent dissolved in Transcription Factor Assay (TFA) buffer
containing sonicated salmon sperm DNA to block non-specific DNA binding
activity was added first, followed by the NFkB Capture Probe (5’-GGGACTTTCC3’) or TFA Negative Control Probe (non-specific oligonucleotide), and lastly the
nuclear extract samples or HeLa Whole Cell Extract provided with the kit as a
positive control were added. Following a two-hour incubation at RT, the wells
were washed 3 times, then incubated with the primary anti-NFkB p65 antibody
(incubated for 1hr) and the secondary anti-HRP antibody (incubated for 30
minutes. At this time, TMB substrate was added to each well and incubated for 510 minutes while monitoring for color change. Once the color change was
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adequate, the provided Stop Solution was added and the absorbances read on a
spectrophotometer.
10. Medical Institutional Review Board
Two Expedited Review Applications were submitted to the IRB requesting
approval to collect both adult and neonatal human samples. Both protocols were
approved and samples were subsequently collected in accordance with each
protocol as described in the methods section. The protocol entitled:
Immunomodulation to Improve Neonatal Clearance of Pneumocystis (Protocol
number 04-0086-P1B) was approved to collect neonatal BALF and adult
peripheral blood. The second protocol, entitled “Control, Immunoregulation, and
expression of Innate Host Defenses” (Protocol # 05-0796-P2G) was approved to
collect adult BALF samples.
11. Statistical analysis
Data are expressed as the means ± standard deviations (SD) for three to
six mice per group. Differences between experimental groups with treatment as
the only variable were determined using the Student’s t tests (comparing 2
groups) or 1-way analysis of variance (1-way ANOVA) (comparing more than 2
groups) followed by Student Neuman Kuels post-hoc test where appropriate.
Differences between experimental groups with two variables (treatment and time)
were analyzed using a 2-way ANOVA. If data was not normally distributed it was
analyzed using the Holm-Sidak test. Differences were considered statistically
significant when p was < 0.05. SigmaStat statistical software (SPSS, Inc.,
Chicago, Ill) was used for all statistical analysis.
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CHAPTER 3: Alveolar macrophage activation markers and T cell infiltration
are delayed in PC-infected pups
It has been previously demonstrated that there is a 3 week delay in the
clearance of PC from mice infected as neonates compared to mice infected as
adults (Figure 1.1) (9), (234), (10). To determine whether AM infiltration and
activation is also delayed in pups in response to PC we used flow cytometry to
examine macrophage markers at various times post-infection.

Mice were

infected with PC within 72 hrs of birth or as adults and their lungs lavaged at four
different time points. Alveolar macrophage activation was examined using
antibodies specific for CD11b, MHC class II, CD40, and CD80. There was a
significant 2 week delay in the infiltration of macrophages into PC-infected pup
lungs compared to adults (Figure 3.1). Adult mice infected with PC demonstrated
an increase in the expression level (Figure 3.2) and the total number of cells
expressing (Figure 3.3) CD11b, MHC class II, CD40 and CD80 compared to PCinfected pups (Data not shown for CD40 and CD80). These data demonstrate
that adult mice respond to PC infection more efficiently than pups.
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Figure 3.1 Delayed macrophage infiltration into pup lungs. Mice were infected
with PC as neonates (24-72 hours after birth) or as adults (>8 weeks). Four to six
mice per group were lavaged at each indicated time post-infection. The cells
were stained with antibodies specific for CD11c and CD11b and then analyzed
by flow cytometry. Results represent the mean ± SD of 4-6 mice per group and 2
separate experiments. **Total number of CD11c+/CD11b+ cells are significantly
greater than their control groups and PC-infected pup groups (p<0.05). # Total
number of CD11c+/CD11b+ cells are significantly greater than PC-infected pup
group and uninfected adult group (p<0.05). *Total number of CD11c+/CD11b+
cells is significantly greater than pup and adult control groups (p<0.05).
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Figure 3.2 Delayed expression of CD11b and MHC class II molecules on pup
AMs. Mice were infected with PC as neonates (24-72 hours after birth) or adults.
Lungs were lavaged at day 10 post-infection to examine macrophage levels.
Cells were stained with antibodies specific for CD11c and CD11b or MHC class
II; phenotypes were examined by flow cytometry. Representative histograms of
CD11b+ cells (gated on CD11c+ cells) and MHC class II+ cells (gated on large
nonlymphocytes) are shown. Cells were gated for large nonlymphoid cells by
using forward and side light scatter. Controls include BALF cells from uninfected
neonates or adults. Data are representative of results for 3-5 mice per group.
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Figure 3.3 Pup AM activation is delayed following PC infection. Numbers of
nonlymphoid cells expressing CD11b and MHC class II in the alveolar spaces of
PC-infected neonates were significantly lower than those in adult lungs through 2
weeks post-infection. Mice were infected with PC as neonates (24-72 h after
birth) or adults. Control mice received HBSS vehicle. Lungs were lavaged at the
indicated time points, cells were stained with antibodies specific for CD11b and
MHC class II, and cells were examined by using flow cytometry. Cells were gated
on large nonlymphocytes and the number of cells expressing (A) CD11b and (B)
MHC class II were determined. Data represent the means ± SD for three to five
mice per group. *p < 0.05 compared to all other groups at the same time point.
To further demonstrate an age-specific difference, separate phenotypic
studies were performed in which pup mice were infected with PC as neonates
and followed through day 50 post-infection. Expression of the macrophage
markers CD11c, CD11b, FcγR, MHC class II, and CD40 following infection were
compared to those of PC-infected adult mice at similar time points. As expected,
the expression of CD11c did not change based on infection status (Figure 3.4ab). The total number of cells expressing CD11b, MHC class II, CD40, and FcγR
was increased among all infected animals compared to controls; however, this
expression was delayed up to 2 weeks in pups compared to adults (Figure 3.4cj). This data describes the kinetics of AMs expressing activation markers
following PC infection in pups versus adults and demonstrates the delayed
expression in PC-infected pups compared to adults.
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Figure 3.4 Delayed activation markers on pup AMs. The number of cells
expressing activation markers following PC infection was delayed on pup AMs
compare to adults. Mice were infected with PC as neonates (24-72 h after birth)
or adults. Control mice received HBSS vehicle. Lungs were lavaged at the
indicated time points. Cells were stained with antibodies specific for CD11c,
CD11b, MHC class II, CD40, and FcγR and were examined by flow cytometry.
Cells were gated on large nonlymphocytes and CD11c and the number of cells
expressing (A-B) CD11c, (C-D) CD11b, (E-F) MHC class II, (G-H) CD40, and (IJ) FcγR were determined for mice infected with PC as neonates and as adults.
Data represent the means ± SD for four to five mice per group. *p<0.05
compared to the respective pup groups at the same time point.
The expression of two important chemokine receptors, chemokine
receptors 2 and 5 (CCR2 and CCR5) on LMs were compared over time between
PC-infected and PC–uninfected pups and adults. CCR2 and CCR5 are receptors
for the ligands macrophage chemoattractant protein-1 (MCP-1) and macrophage
inflammatory protein-1 (MIP-1) respectively and function to increase the number
of inflammatory cells, primarily macrophages, at the site of infection.

The

number of adult macrophages that are CCR2 positive are greater than pup
macrophages regardless of infection status up to day 28 post-infection (Figure
3.5a). At this time, the number of CCR2-expressing macrophages increases in
the PC-infected pups. A similar trend occurs in the CCR5-expressing
macrophages except that the rise in pup cells occurs about 1 week earlier than
CCR2-expressing cells (Figure 3.5b). The dual expression of CCR2 and CCR5
peaks by day 14 on macrophages from PC-infected adults but not till day 28 on
pup macrophages infected with PC (Figure 3.5c). These data demonstrate a
delay in the up-regulation of CCR2 and CCR5 on LMs from pups compared to
adults infected with PC. Overall, the delayed expression of these key activation
markers on PC-infected pups compared to adults may contribute to their
inefficient clearance of the organism.
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Figure 3.5 PC-infected pup AMs expressing CCR2 and CCR5 are delayed. The
number of cells expressing CCR2 and CCR5 following PC infection was delayed
on pup AMs compare to adults. Mice were infected with PC as neonates (24-72 h
after birth) or adults. Control mice received HBSS vehicle. Lungs were lavaged at
the indicated time points. Cells were stained with antibodies specific for CD11c,
CCR2, and CCR5 and examined by flow cytometry. Cells were gated on large
nonlymphocytes and CD11c and the number of cells expressing (A) CCR2, (B)
CCR5, and (C) CCR2/5 were determined for mice infected with PC as neonates
and as adults. Data represent the means ± SD for four to five mice per group.
*p<0.05 compared to the indicated groups.
The delay in PC clearance observed in pups compared to adults
correlates with a delay in CD4 T cell infiltration into the alveolar spaces of pups
versus adults (3.6). It is well known that T cells are important for controlling PC
infections (241), (242). As previously discussed in the introduction, it is known
that T cells require activation in order to efficiently respond to PC organisms at
the site of infection in the lung. This occurs through cell-to-cell signaling and
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antigen presentation, both of which are important functions of LMs during PC
infection. Likewise, LMs work more efficiently when they are in turn, stimulated
by activated T cells. Thus, when discussing the role of LMs in the clearance of
PC, it is important to assess part of the LM function based on T cell infiltration
into the lungs. As shown in figures 3.6 a and b, the infiltration of both CD4 and
CD8 T cells occurs much more rapidly in PC-infected adults versus PC-infected
pups. At days 7 and 14 post-infection there are significantly more T cells in the
infected adult group compared to the infected pup groups. The infiltration of T
cells into infected pup lungs does not occur until day 21 post-infection. By looking
at the time frame of T cell infiltration compared to PC clearance, one can see a
correlation in which T cells enter the lungs of the infected mice approximately 1
week prior to the initiation of PC clearance (Figure 3.6). This data further
demonstrates the importance of T cells in the clearance of PC organisms.
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Figure 3.6 T cell infiltration is delayed in PC-infected pup mice. An increase in T
cell infiltration occurs approximately one week prior to a reduction in PC burden
and is delayed in PC-infected pup compared to adult mice. Mice were infected
with PC as neonates (24-72 h after birth) or adults. For A-B, lungs were lavaged
at the indicated time points. Cells were stained with antibodies specific for (A)
CD4 and (B) CD8 and examined by flow cytometry. Cells were gated on small,
non-granular lymphocytic cells. For panel C, whole lungs were collected at the
indicated time points and processed into single-cell suspensions. Cells were
spun onto glass slides, stained with Diff-Quick®, and enumerated
microscopically. Data represent the means ± SD of four to five mice per group.
*p< 0.05 compared to the indicated groups.
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CHAPTER 4: In vitro cytokine production is delayed in PC-stimulated pup
compared to adult alveolar macrophages.
The initial experiments done to assess cytokine production in pup versus
adult LMs were performed on cultured cells. As previously described, uninfected
pup and adult mice were lavaged under sterile conditions and AMs were isolated
from the BALF. The cells were allowed to rest overnight and were then
stimulated in culture for various lengths of time depending on the specific
experiment. One of the first experiments performed using this method involved
stimulating the cells with sonicated PC, whole PC, or media for 24 hours.
Following this incubation, the culture supernatants were retrieved and analyzed
for TNFα , IL-6, and MCP-1using a BD CBA kit®. These cytokines are important
pro-inflammatory cytokines responsible for cell recruitment and lymphocyte
activation (50) in PC infection (74, 77, 175). As illustrated in figure 4.1, PC was
unable to stimulate pup AMs to produce TNFα, IL-6, or MCP-1 after 24 hours.
While both PC formulations were able to stimulate some cytokine production
among adult AMs, whole PC provided a much stronger stimulus than sonicated
PC for IL-6 and MCP-1, but not TNFα (Figure 4.1a-c). This observation suggests
that cytokine production may be linked to the simultaneous binding of multiple PC
antigenic components which would be possible with whole PC and much less
likely with sonicated PC. Overall, this data demonstrates that pup AMs do not
respond as well as adult AMs to PC.
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Figure 4.1 Pup AMs are specifically unresponsive to PC. The lavage fluid from 710 day-old pup mice and adult mice were each pooled and the AMs were allowed
to adhere to a 96-well tissue culture plate. Culture media was replaced after 24
hours with fresh media containing media only (Controls), sonicated PC, or whole
PC organisms. After 24 hours of stimulation, the levels of (A) TNFα, (B) MCP-1,
and (C) IL-6 were determined by Cytometric Bead Array (BD Biosciences). Data
represent the means ± SD for 3 wells per group and are representative of 3
experiments. *p<0.05 compared to the respective pup groups. **p<0.05
compared to respective pup group and the adult control group.
To evaluate the effect of time, similar experiments were performed as
described above. Supernatant aliquots were evaluated for cytokine production
following 1, 6, 12, 24, and 48 hours of incubation with PC. No increase in TNFα
or IL-6 occurred after 1 hour of PC stimulation within pup or adult AMs relative to
unstimulated cells. After 24 hours, PC stimulation induced a significantly
increased production of TNFα and IL-6 compared to PC stimulated pup cells and
adult unstimulated cells (Figure 4.2a-b). Alternatively, PC appeared to produce
an early stimulation of MCP-1 production in pup and adult cells which was lost by
24 hours post-stimulation (Figure 4.2c). IL-10 production was relatively elevated
in both pup and adult unstimulated cells suggesting that there is a constitutive
production occurring in the absence of antigenic stimulation (Figure 4.2d). Within
the first hour of PC-stimulation among pup AMs, IL-10 production was reduced to
below detectable limits (Figure 4.2d). Overall, this data suggests that pup AMs
have a poor pro-inflammatory response to PC compared to adult AMs, but they
appropriately reduce production of the inhibitory cytokine IL-10.
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Figure 4.2 Pup and adult AM cytokine production following PC stimulation. The
lavage fluid from 7-10 day-old pup mice and adult mice were each pooled and
the AMs were allowed to adhere to a 96-well tissue culture plate. Culture media
was replaced after 24 hours with fresh media containing media only (PC-) or
sonicated PC (PC+). After 1 or 24 hours of stimulation the levels of (A) TNFα, (B)
IL-6, (C) MCP-1, and (D) IL-10 were determined by Cytometric Bead Array (BD
Biosciences). Data represent the means ± SD for 3 wells per group and are
representative of 3 experiments. *p < 0.05 compared to the indicated groups.
The production of TNFα and IL-6 among PC-stimulated pup AMs did not
increase above their untreated control cells until 48 hours post-stimulation,
compared to 6 and 24 hours respectively in adult cells (Figure 4.3 a-b). MCP-1
production in PC-stimulated pup cells was undetectable at 6 and 12 hours of
incubation. After 24 hours, however, MCP-1 levels were equal to those of the
adult AMs (Figure 4.3 c). No differences were observed in IL-10 production in
pup or adult AMs regardless of PC stimulation (Figure 4.3 d), however overall
levels were greater in these later time points compared to the levels after 1 hour
(Figure 4.2 d). After 48 hours of incubation, there is a small increasing trend in IL10 production in pup and adult cells stimulated with PC. Taken together, these
data suggest that pup AM pro-inflammatory cytokine production is delayed
compared to adult AMs.
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Figure 4.3 Cytokine production is delayed in PC stimulated pup AMs. The lavage
fluid from 7-10 day-old pup mice and adult mice were each pooled and the AMs
were allowed to adhere to a 96-well tissue culture plate. Culture media was
replaced after 24 hours with fresh media containing media only (PC-) or
sonicated PC (PC+). After the indicated times post-stimulation the levels of (A)
TNFα, (B) IL-6, (C) MCP-1, and (D) IL-10 were determined by Cytometric Bead
Array (BD Biosciences). Data represent the means ± SD for 3 wells per group
and are representative of 3 experiments. *p<0.05 compared to the indicated
groups.
NFkB is a transcription factor involved in the synthesis of cytokines,
including TNFα, IL-6, and MCP-1. To elucidate if NFkB could be involved in the
differential cytokine production between PC-stimulated pup and adult AMs, a
nuclear translocation assay was performed on pup and adult AMs stimulated for
1 hour with PC. NFkB p65 nuclear translocation was significantly increased in
adult AMs stimulated with PC compared to their unstimulated control cells
(Figure 4.4). No differences were observed between pup PC-stimulated and
unstimulated cells due to the high baseline level of NFkB p65 in the unstimulated
pup control cells which were similar to the levels measured in adult PCstimulated cells. This data reflects the increased pro-inflammatory cytokine
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production observed in adult LM stimulated with PC compared to unstimulated
control cells. The lack of increased NFkB p65 translocation to the nucleus
observed in pup PC-stimulated cells also reflects the lack of cytokine production
previously demonstrated. The high baseline level of nuclear NFkB p65 without a
concomitantly high baseline cytokine production may indicate that pup mice have
inefficient binding of NFkB p65 to the DNA binding site. This data further reflects
the absent cytokine response from pup LMs following PC stimulation. This data
also suggests that the cytokine response demonstrated by pup LMs following
stimulation with other stimuli, such as LPS and zymosan, that will be described in
future

sections

may

utilize

alternative

signaling

intermediates

and

or

transcriptions factors.

Figure 4.4 NFkB nuclear translocation is unchanged in pup AMs stimulated with
PC. The lavage fluid from 7-10 day-old pup mice and adult mice were each
pooled, stimulated with 50 PC organisms for every 1 AM (50:1) for 1 hour. The
cells were lysed and the nuclear extract was isolated. Chemicon’s NFkB p65
Transcription Factor Colorimetric Assay was used to quantify NFkB p65 in the
nuclear extract. Data represent the means ± SD for 3 samples per group and are
representative of 2 experiments. *p<0.05 compared to adult PC- group.
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CHAPTER 5: Exogenous immunomodulation stimulates the activation of
lung macrophages and reduces intensity of Pneumocystis infection in pup
mice
A. Interferon gamma
We have previously shown that infant mice have a significant delay in
mounting an immune response to PC compared to adult mice (9, 234). Delayed
clearance is accompanied by a delay in the infiltration of T cells and activation of
LMs as well as delayed cytokine up regulation, including IFNγ (9, 10, 234). It has
been shown, moreover, that the delivery of IFNγ to the lungs of PC-infected adult
SCID mice can stimulate clearance of the organism (243, 244). We therefore
hypothesized that infected pup mice would clear their infection faster when
treated with exogenous IFNγ.
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Figure 5.1 Effects of exogenous IFNγ on pup lung defenses against PC. Mice
were infected with PC as neonates (24-72 h after birth) and then treated with
either IFNγ or PBS intranasally every 72 h beginning 24 h post-infection. Lungs
were lavaged and cells collected at the indicated times. Cells from BALF were
stained with antibodies specific for CD4 or CD8 and then analyzed using flow
cytometry. Total CD4 T cell (A) and CD8 T cell (B) numbers were determined.
(C) Whole lungs were digested and aliquots stained with Diff-Quik®; PC nuclei
were enumerated microscopically. Results represent the mean ± SD of four to
five mice per group and are representative of 3 separate experiments. No
statistical differences were found between groups.
Murine IFNγ (16ng/g) or vehicle (PBS) was administered intranasally to
PC-infected pup mice every 48 hours beginning 24 hours post-infection and
continuing throughout the course of the experiment. Mice from each group were
killed at days 8, 19, and 28 post-infection. Whole lung and lung lavage were
collected and flow cytometry was performed to examine the infiltration of
lymphocytes in response to PC infection. Exogenous IFNγ had no effect on the
infiltration of either CD4 T cells (Figure 5.1 a) or CD8 T cells (Figure 5.1 b) into
the lungs of PC-infected neonates. Similarly, no statistically significant
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differences were found in lung burden of PC organisms between the two groups
by day 28 (Figure 5.1 c). However, there appeared to be a shift in the clearance
kinetics between the two groups. The IFNγ-treated group actually had a greater
PC burden than the control group at day 19 but by day 28 the burden among the
two groups diverged in opposite directions with the IFNγ-treated group having
less PC than the control group. Ultimately, no statistically significant difference in
PC clearance was observed between the two groups; furthermore, no mice from
either group were able to clear the PC completely by day 28 post-infection.
To determine if the IFNγ dosing strategy had an impact on initiating the
immune response and PC clearance, this experiment was repeated with a dose
escalation. PC-infected pup mice were divided into 4 groups. Three groups
received 16ng/g, 80ng/g, or 160ng/g of intranasal IFNγ. The fourth group served
as a control and received PBS only. Mice from each group were killed at days 15
and 29 post-infection. Despite increased doses of IFNγ, no differences in either
T-cell or macrophage infiltration into pup PC-infected lungs were observed when
compared to the control group (data not shown).

Additionally, cytokine

production in the BALF of each group was determined by CBA® analysis, and no
statistically significant differences were found between any of the groups
receiving IFNγ compared to the control group, suggesting that the resident LMs
were not stimulated by the presence of PC plus IFNγ (data not shown). Lastly,
PC clearance was assessed microscopically by counting the number of PC
nuclei in each group treated with IFNγ as well as the control group (Figure 5.2).
While the group receiving 16ng/g had more mice clearing the organism than mice
in the control group, the results were highly variable and, as with the previous
IFNγ experiment, no significant differences were detected. Furthermore,
increased doses of IFNγ did not improve PC clearance. These data indicate that
none of the intranasally administered doses of IFNγ tested significantly improved
the clearance of PC in pup mice. Furthermore, no dose of IFNγ tested was able
to stimulate the infiltration or activation of immune cells in the infected lung, nor
did it increase the production of cytokines in PC-infected pup lungs.
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Figure 5.2 Low levels of exogenous IFNγ moderately reduced PC lung burden in
pups. Mice were infected with PC as neonates (24-72 h after birth) and then
treated with 16ng/g, 80ng/g, 160ng/g IFNγ or PBS intranasally every 72 h
beginning 24 h post-infection. Whole lungs were collected and digested at days
15 and 29 post-infection. PC nuclei were enumerated microscopically. Filled
symbols represent the means ± SD for five to six mice per group.
B. Heat-killed E. coli
1. LPS increases cytokine production from pup alveolar macrophages in
vitro
We have shown that LM activation is delayed in pup compared to adult
mice in response to PC infection. To elaborate upon this finding, an in vitro model
was used to determine whether pup AMs are capable of responding to
exogenous stimulation with LPS compared to PC. AMs from uninfected pup and
adult mice were isolated and cultured with PC, LPS, or media. The activation of
AMs was assessed by quantifying their cytokine responses at 6, 12, 24, and 48
hours post-stimulation. At all time points both adult and pup AMs treated with
LPS produced significantly more TNFα, IL-6, and MCP-1 than their
corresponding control groups (Figure 5.3a-c). Moreover, LPS-stimulated adult
AMs produce significantly more TNFα at 6 hours post-stimulation, more IL-6 at all
time points, and more MCP-1 at 6, 12, and 24 hours post-stimulation compared
to pup LPS-treated cells (Figure 5.3a-c). PC stimulation did not induce the same
level of TNFα or IL-6 production as LPS in pup or adult cells. Overall, adult AMs
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still produced more TNFα and IL-6 than pup cells stimulated with PC. These data
demonstrate that pup AMs are capable of pro-inflammatory cytokine production
following exogenous stimulation with LPS but produce less than adults overall
and are specifically unable to respond PC.

Figure 5.3 Pup and adult alveolar macrophages produce significant amounts of
TNFα upon stimulation with LPS. Macrophages from 2-week old and adult mice
were isolated from the BALF, placed in 96-well tissue culture plates and allowed
to rest for 24 h. Subsequently, the cells were treated with either 100ng/ml of LPS,
4x105 PC organisms, or media alone for 6, 12, 24, or 48 h. Supernatant
concentrations of LPS- and PC-stimulated cells were determined by Cytometric
Bead Array.® P = pups, A = adults, con=unstimulated control. Data represent the
means ± SD for three wells per group. * Concentration of cytokine was
significantly greater than the respective control and PC-infected groups per time
point, p<0.05. ** Concentration of cytokine was significantly greater than that
produced by pup cells stimulated with LPS at the same time point, p<0.05. #
Concentration of cytokine was significantly greater than adult control cells at the
same time point, p<0.05. Comparisons are representative of 2 separate
experiments.
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Two other macrophage-produced cytokines, IL-12p70 and IL-10, were
evaluated in their response to LPS and PC stimulation due to the effects their
functions may have on delayed neonatal responses to PC. IL-12p70 induces
CD4 T cell differentiation into TH1 cells and IL-10 is a potent suppressor of
macrophage function (50). Both PC and LPS failed to induce IL-12p70 production
in pup and adult AMs at any time points tested (data not shown). Similarly, IL-10
production was not increased secondary to either stimulus; however, there was a
constitutive elevated production among all groups (data not shown).
To determine whether the kinetics of cytokine production in pup AMs was
delayed, this experiment was repeated looking at 72 hour post-stimulation. The
cytokine response among both pup and adult AMs was similar to the responses
observed at the earlier time points with the exception of IL-10. After 72 hours of
stimulation, IL-10 production had increased among the LPS-treated pup
compared to adult AMs (P<0.05; data not shown). This observation suggests that
with continuous stimulation, pup AMs respond by producing the anti-inflammatory
cytokine, IL-10. The in vitro data described above demonstrates two important
findings; the first being that pup macrophages are less responsive to LPS
compared to adults and the second being that PC appears to be a relatively
weak stimulus to adult AMs and pup AMs are unresponsive. These findings
begged the question of whether or not differences exist in the expression level of
the following three important receptors: dectin-1, a beta-glucan receptor (44, 65),
TLR4 a receptor for LPS (44, 245), and TLR2 a receptor for ligands such as
zymosan, peptidoglycan, lipoprotein, and more recently thought to be a receptor
for the major surface glycoprotein found on PC (44, 246-249). To answer this
question, the expression levels of dectin-1, TLR2, and TLR4 on pup and adult
LMs were determined. As illustrated in figure 5.4, the expression of dectin-1 and
TLR2 was the same on pup and adult LMs isolated from uninfected mice (Figure
5.4). These data suggest that the difference in production of TNFα between PCstimulated pup and adult macrophages is not due to differences in dectin-1 or
TLR2 pattern recognition receptor expression. Conversely, differences were
detected in TLR4 expression between pup and adult LMs (Figure 5.4). It is
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possible then, that the delayed expression of TLR4 on pup LMs may be at least
partially responsible for the significantly reduced cytokine production compared
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Figure 5.4 Adult LMs expressed significantly higher baseline TLR4 than pup LMs
(p< 0.05). LMs were isolated from uninfected 14-day old pup and adult (≥ 8weeks
old) BALF. Cells were stained with antibodies specific for CD11c, dectin-1, TLR2,
and TLR4 and analyzed by flow cytometry. Representative histograms of dectin1, TLR2, and TLR4 positive cells (gated on CD11c+ cells) are shown. Cells were
gated on large nonlymphoid cells by using forward and side light scatter. Data
are representative of five mice per group and 2 separate experiments.
The transcription factor NFkB p65 is responsible for the production of
several cytokines, including TNFα. Considering the differences in TNFα
production following stimulation in pup versus adult AMs, we examined the
possibility that the nuclear translocation of NFkB p65 may be delayed in pups
versus adults stimulated with LPS. AMs were isolated from pooled BALF
collected from uninfected pup and adult mice. These cells were cultured for 1
hour with LPS or media, the cells were collected, and the nuclear extracts were
isolated. The amount of NFkB p65 was determined for both pup and adult AMs.
The level of NFkB p65 was significantly greater in the adult cells compared to the
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pup cells following 1 hour of LPS stimulation (Figure 5.5). This data suggests that
the impaired TNFα production may be at least partially caused by poor NFkB p65
nuclear translocation, which may be related to an upstream impairment such as
low TLR4 expression or the use of a MyD88-independent pathway.

Figure 5.5 NFkB nuclear translocation increases in adult but not pup AMs
stimulated with LPS. The lavage fluid from 7-10 day-old pup mice and adult mice
were each pooled, the cells were lysed, and the nuclear extract was isolated.
Chemicon’s NFkB p65 Transcription Factor Colorimetric Assay was used to
quantify NFkB p65 in the nuclear extract. Data represent the means ± SD for 3
samples per group and are representative of 2 experiments. *p< 0.05 compared
to adult control and pup LPS groups.
We next asked the question of whether pup AMs have a global
unresponsiveness to other fungal ligands. To investigate this question an in vitro
experiment was performed comparing the response of pup versus adult AMs to
the Saccharomyces cerevisiae cell wall polysaccharide, zymosan. This yeast cell
wall preparation is known to express substrates, such as beta-1,3-glucans and
mannan, for several pattern recognition receptors present on LMs, including
Dectin-1 and mannose receptors as well as TLR2 and TLR6 ligands (61, 250).
After 12 and 24 hours of stimulation with zymosan, both pup and adult
AMs produced significantly more TNFα compared to their respective PCstimulated and control wells (Figure 5.6a), suggesting that both pup and adult
LMs have functional beta-glucan receptors and TLR2. Interestingly, pup AMs
stimulated with zymosan also produced significantly more TNFα than their adult
counterparts after 12 hours of stimulation. Consistent with the results shown in
figure 5.3, stimulation of the AMs with PC, an organism known to contain beta-

80

1,3-glucan (47, 249), failed to induce the production of TNFα in pup AMs after
12 and 24 hours of stimulation. At 24 hours post-PC-stimulation, adult AMs
produced slightly elevated levels of TNFα compared to unstimulated control cells
as well as pup PC-stimulated AMs.

Figure 5.6 Zymosan stimulated significantly more AM cytokine production
compared to PC. AMs were isolated from the pooled BALF of adult (A=adult) (≥ 8
wks) and 12-14 day old pup (P=pup) mice and cultured in a 96-well plate with
PC, zymosan (zym), or media alone (con). Supernatants were removed at 12
and 24 hours post-stimulation and (A) TNF, (B) MCP-1, (C) IL-6, (D) and IL-10
were analyzed by Cytometric Bead Array analysis and flow cytometry. Data
represent 3-4 wells per group. * Cytokine concentrations are significantly greater
than their respective control and PC-treated groups, p<0.05. + Cytokine
concentrations are significantly greater than their respective control group only,
p<0.05. ** Cytokine concentrations are significantly greater than their comparator
zymosan-treated groups, p<0.05.
Production of the other pro-inflammatory cytokines tested, IL-6 and MCP1, were significantly increased in both pup and adult AMs secondary to
stimulation with zymosan (Figure 5.6b and c). Furthermore, MCP-1 production
was significantly greater in adult AMs compared to pup AMs stimulated with
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zymosan at both 12 and 24 hours post-stimulation. The levels of IL-6 and MCP-1
following PC stimulation were minimal or undetectable, further suggesting that
AMs are specifically less responsive to PC organisms. Interestingly, IL-10, an
inhibitory cytokine, was significantly increased in pup AMs following 12 and 24
hours of stimulation with zymosan, but not PC (Figure 5.6d). These data indicate
that pup AMs respond differently than adult AMs to fungal antigens. Pup AMs are
capable of producing significant amounts of pro-inflammatory cytokines when
stimulated appropriately. These data suggest that PC is a significantly weaker
stimulus than either zymosan or LPS for both pup and adult LMs.
2. Aerosolized heat-killed E. coli improves Pneumocystis clearance in pup
mice
The resolution of PC in immunocompetent adult mice is associated with
the up-regulation of pro-inflammatory cytokines IFNγ and TNFα (10, 234). Since
our in vitro studies demonstrated that LPS, but not PC, stimulates pup AMs to
produce significant levels of TNFα, we wanted to evaluate whether the TNFα
produced secondary to LPS administration in vivo would improve PC clearance
in pup mice. Reports in the literature further support the hypothesis that
exogenously increasing the level of TNFα can improve PC clearance (251).
Harmsen and Chen have reported that treatment of adult thymectomized and
CD4-depleted mice with aerosolized HKEC also expedites the clearance of PC
(238). They further showed that pretreatment of the animals with anti-TNF IgG
minimizes the benefit imparted by the aerosolized HKEC suggesting that
stimulation of TNFα plays a significant role in the clearance of PC from
immunocompromised mice (238). Based on this information, we proceeded with
experiments to administered aerosolized HKEC to PC-infected pup mice.
Treatment with HKEC began 48 hours post-infection and continued through day
20 post-infection. Control mice received PC and aerosolized sterile water. By day
12 post-infection a divergence in PC burden between HKEC-treated and control
mice could already be identified (Figure 5.7a). By day 21 there was a sharp
decline in the HKEC-treated group and by day 32 post-infection, there was a
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significant difference in PC burden in the HKEC-treated group compared to the
control group. These data suggest that pup mice, as was found with CD4depleted adult mice (238), can clear PC infection more efficiently when treated
with aerosolized HKEC.

Figure 5.7 Mice treated with HKEC demonstrated a faster rate of PC clearance
than control mice. Mice were infected as neonates (24 to 72 h after birth) and
treated with aerosolized HKEC or sterile water 3 times per week. Lungs were
collected at (A) days 12, 21, 32, and 44 post-infection or (B) days 7, 14, 21, and
32 post-infection, digested and spun onto glass slides. Slides were Diff-Quik®
stained and enumerated microscopically. Data are representative of results of
four to five mice per group and 3 separate experiments; *p<0.05.
3. Aerosolized heat-killed E. coli influences the infiltration of immune cells
in pup lungs
We were able to induce a more efficient clearance of PC organisms from
the lungs of infected pup mice with the administration of aerosolized HKEC. In
order to determine if this improved PC clearance was associated with an
increase in cellular lung infiltration, BALFs were collected from mice treated with
aerosolized HKEC and control mice treated with aerosolized sterile water. Cell
differential counts were performed to determine macrophage, lymphocyte and
neutrophil infiltration into the lungs of both the HKEC-treated mice and control
mice. Overall minimal differences were noted, but most importantly, a divergence
between the treated and untreated groups was observed among infiltrating
macrophages into the lung by day 32 post-infection (data not shown). This
correlates with the significant decrease in PC burden observed in the HKEC-
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treated mice by 32 post-infection (Figure 5.7b). Neutrophil numbers appeared to
follow HKEC treatment rather than PC infection as the neutrophil numbers rose
early on and declined upon discontinuation of the HKEC treatment by day 21
(data not shown).
For both the HKEC-treated and untreated PC-infected mice, the infiltration
of lymphocytes into the lung space, as determined by cell differential counts,
sharply increased on day 21 post-infection and rapidly declined by day 32 postinfection (data not shown). The evaluation of lymphocytes, namely CD4+ T cells,
by flow cytometry showed similar results with a rise in CD4+ T cells by day 21
post-infection and a subsequent drop thereafter (Figure 5.8a). By comparing the
timing of CD4+ T cell infiltration into the lungs and PC clearance, one can see
that the increase in CD4+ T cells in the alveolar spaces as well as the lung tissue
immediately precedes the subsequent decline in PC burden in the HKEC-treated
mice (Figures 5.7 and 5.8a-b). The infiltration of CD8+ T cells followed the same
pattern as CD4+ T cells (data not shown). The decline in T cell numbers in the
lungs falls rapidly upon discontinuation of HKEC treatments at day 20 postinfection suggesting that T cell infiltration was stimulated by HKEC.

Figure 5.8 Treatment with HKEC induced CD4+ T cell infiltration into the lungs of
PC-infected pups. Mice were infected with PC as neonates (24 to 72 h after birth)
and then treated with either aerosolized HKEC or sterile water. BALF and whole
lungs were collected on days 12, 21, 32, and 44 post-infection. No statistical
difference in CD4+ T cells in the (A) BALF or (B) lung digest was observed
between the groups treated with HKEC or the control group. Data represent the
means ± SD for five mice per group and are representative of 3 separate
experiments.
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4. Aerosolized heat-killed E. coli influences the activation of pup lung
macrophages
We used flow cytometry to assess the activation status of PC-infected,
pup LMs treated with aerosolized HKEC compared to those treated with
aerosolized vehicle. Several different combinations of surface markers known to
be signs of macrophage activation in adults were used. For all experiments
involving flow cytometry, the cells were gated on non-lymphocytes using forward
and side scatter.
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Figure 5.9 Expression levels of CD11b, MHC class II, and F4/80 on
macrophages from alveolar spaces of PC-infected. HKEC-treated neonatal mice
were increased at days 14 and 21 post-infection. Mice were infected with PC as
neonates (24 to 72 h after birth) and then treated with either aerosolized HKEC
or sterile, deionized water. BALF was collected at days 7, 14, 21, and 32 postinfection. Cells were stained with antibodies specific for CD11c and CD11b, MHC
class II, or F4/80, and phenotypes were examined using flow cytometry.
Representative histograms of CD11b, MHC class II, or F4/80 positive cells and
the MFI for each (gated on CD11c+ cells) are shown. Cells were gated for large
nonlymphoid cells by using forward and side light scatter. Data are
representative of four to five mice per group and 2 separate experiments.
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Figure 5.9 shows expression of the LM activation markers, CD11b, MHC
II, and F4/80 at 4 time points after PC infection in representative pup mice from
each group. The PC-infected group receiving HKEC showed an increase in
activated LMs, as indicated by a right shift in the CD11b cell populations,
compared to the infected group receiving aerosolized water only (Figure 5.9).
This right shift could be seen in the HKEC group as early as day 7 post-infection
and persisted through day 21 post-infection. These data correlated well with the
decreased PC lung burden beginning at day 21 post-infection, suggesting that
the activation of pup LMs by HKEC contributed to the expedited PC clearance
(Figure 5.7b). The group that was PC-infected, but received aerosolized water
only did not start to increase in CD11b expression until day 21 post-infection and
both groups showed a return to baseline expression levels by day 32 postinfection. Similarly, the group receiving HKEC had increased expression of both
MHC Class II and F4/80 molecules compared to untreated mice by day 7 postinfection. The difference in expression was most notable at days 14 and 21 postinfection and preceded PC clearance (Figure 5.7b). Overall, these data suggest
that the treatment of PC-infected mice with HKEC increases the activation of LMs
in pup lungs and contributing to the reduced PC lung burden.
5. Cytokine production was increased secondary to aerosolized heat-killed
E. coli
We have previously reported that cytokines such as TNFα and IFNγ
appear in the lungs of PC-infected pup mice much later than in the lungs of
infected adult mice (234). We next examined cytokine production in vivo following
treatment of PC-infected mice with aerosolized HKEC using Cytometric Bead
Array® analysis. Similar to the results observed in vitro with LPS, neither IL12p70 nor IL-10 levels were elevated in the HKEC group compared to the control
group at any time points following infection with PC (data not shown). While no
statistically significant differences in TNFα, IFNγ, or MCP-1 were found between
groups in the BALFs, the group treated with HKEC tended to have greater levels
of cytokines compared to the untreated group (Figure 5.10 a-c). Additionally, LMs
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from the HKEC-treated group did produce significantly more IL-6 compared to
the uninfected group (Figure 5.10 d). The production of IL-6 throughout this
experiment was interesting in that it appeared to follow the HKEC treatment
rather than the PC (Figure 5.10 d). At day 21 post-infection only those groups
receiving HKEC had increased production of IL-6 regardless of PC infection.
Furthermore, the production of IL-6 was minimal following the day 21 timepoint,
which can likely be explained by the fact that the final HKEC treatment occurred
on day 20 post-infection. Overall, this cytokine data reiterates the findings that
LM-produced cytokines, particularly TNFα, are involved in the expedited
clearance of PC observed in the HKEC-treated groups. Although IFNγ is not
produced by LMs in significant quantities, LMs are known to stimulate IFNγproducing cells such as T lymphocytes, which would explain the increase seen
herein (Figure 5.10 b).
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Figure 5.10 PC-infected mice treated with HKEC had elevated cytokine levels by
day 21 post-infection. Mice were infected as neonates (24 to 72 h after birth) and
then treated with either aerosolized HKEC or sterile, deionized water. BALF was
collected on days 12, 21, 32, and 44 post-infection. Production of (A) TNFα, (B)
IFNγ, (C) MCP-1, and (D) IL-6 was determined by Cytometric Bead Array® BD
Biosciences, San Diego, CA. There were no significant differences between the
group receiving HKEC and the group receiving only sterile water. Data represent
the means ± SD of five mice per group; *p<0.05.
6. Lung macrophage phagocytosis is less efficient in the absence of T
lymphocytes
To determine if T lymphocytes are playing a role in the increased LM
activation and PC clearance observed in HKEC-treated pups, HKEC-treated
SCID and WT pups were compared in their ability to phagocytose DiO-labeled
PC organisms. Six-7 day-old Balb/c or SCID mice were treated with aerosolized
HKEC (as previously described) on days 4 and 2 prior to and once more on the
day of PC infection (DiO-labeled). On day 1 post-infection the mice were
lavaged. Some cells were reserved for differential counts and the rest were
processed for analysis via flow cytometry. The total number of LMs
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phagocytosing PC organisms was the same between SCID and WT pups (data
not shown). However, treatment with HKEC drove more efficient phagotyosis of
PC in LMs from treated compared to untreated WT pups as shown by the
increased mean fluorescence intensity of DiO (Figure 5.11b). LMs from WT pups
were significantly more efficient at phagocytosing PC compared to SCID pups,
despite HKEC treatment in both groups (Figure 5.11a-b). The overall MHC class
II expression was similar between the WT and SCID pups suggesting that the
difference in phagocytosis was not likely due to lower activation in the SCID pups
(data not shown). Although neutrophils are not thought to be important in PC
clearance (84), we show that neutrophil infiltration in SCID pups was equal to WT
pups but they were less capable of phagocytosing PC organisms compared to
WT pups despite treatment with HKEC (Figure 5.11c-d). These data suggest that
in the absence of T lymphocytes, HKEC-treated pup LMs are still capable of
phagocytosing PC but are less efficient.

90

10 1

% of Total

120
100
80
60
40

10 2

CD11c+/PC+ MFI
10 3

10 4

FL1 DiO (FITC)

C

WT/PC+/HKEC+
WT/PC+/HKECSCID/PC+/HKEC+

1600
1400
1200
1000
800
600
400
200
0

% CD11c+/CD11b+/PC+

Number

Control

0

20 40 60 80 100 120 140

A

100

**

20

0
Macs LymphsMonos PMNs

B

*

D

* *

80
60
40
20
0

Figure 5.11 SCID pups treated with HKEC do not phagocytose DiO-labeled PC
as efficiently as WT pups. SCID and WT pups were treated with aerosolized
HKEC on days 4 and 2 previous to and on the day of DiO-labeled PC infection.
BALF was collected on day 1 post-infection. Cells were stained with antibodies
specific for CD11c, CD11b, and MHC class II and examined for co-expression
with DiO-labeled PC. (A) Representative histogram showing DiO
fluorescent/CD11c+ cells from HKEC-treated, WT pups (thick black line), HKECtreated, SCID pups (medium line), untreated, WT pups (grey fill); (B) Mean
fluorescence intensity of DiO in CD11c+ cells, *p<0.05 compared to untreated
WT and HKEC-treated SCID pups; (C) Differential counts of BALF cells, *p<0.05
compared to untreated WT pups; (D) Mean fluorescence intensity of DiO in
CD11c-, CD11b+ cells, *p<0.05 compared to HKEC-treated SCID pups. Data
represent the means ± SD of four mice per group.
C. Granulocyte macrophage-colony stimulating factor
GM-CSF has been shown to enhance clearance and improve outcomes of
several different pulmonary infections, including but not limited to group B
streptococcus infection (24), Pseudomonas aeruginosa (25), Histoplasma
capsulatum (26, 27), Mycobacterium tuberculosis (28), and Pneumocystis carinii
(29). However, there is little data on the effects of GM-CSF on pulmonary
infections in infants and no data regarding the addition of GM-CSF for the
treatment of PCP in the infant population. The ability of GM-CSF to improve
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outcomes in pulmonary infections in adult animal models suggests that this
clinically relevant agent may be of therapeutic benefit for infants with pulmonary
infections failing to respond to antimicrobial therapy alone. Thus, we
hypothesized that treatment of PC-infected pup mice with rmGM-CSF
(recombinant mouse GM-CSF); either alone or in combination with TMP/SMX,
would improve PC clearance secondary to increased LM numbers and activation.
1. rmGM-CSF increases cytokine production in pup alveolar macrophages
Initial rmGM-CSF experiments were done in vitro to minimize cost while
testing the potential benefit of this agent and its ability to stimulate LMs to
produce cytokines. The first of such experiments was done by collecting the
BALF of both adult and pup mice, isolating the AMs and culturing them with
rmGM-CSF for 6, 24, 30, and 48 hours. Stimulation of both adult and pup cells
with rmGM-CSF alone increased the production of TNFα, MCP-1, and IL-6 at 24
hours post-stimulation above that which was produced by the control cells; for
MCP-1 this increase was significantly greater than that produced by the control
cells for both pups and adults (Figure 5.12 a,b,d). For TNFα and IL-6, while the
increased cytokine production stimulated by rmGM-CSF alone was not
statistically significant, stimulation of both pup and adult cells with rmGM-CSF
plus PC did generate a statistically significant increased cytokine production at
24 hours post-stimulation (Figure 5.12 a and d). After 30 and 48 hours poststimulation, the production of TNFα in the pup cells secondary to rmGM-CSF
alone was significantly greater than their control cells; while the adult cells also
had an increase in TNFα after 30 and 48 hours, it did not reach statistical
significance. However, for both pup and adult cells stimulated with rmGM-CSF
plus PC, TNFα was still significantly greater than the control cells after 30 and 48
hours post-stimulation (Figure 5.12a).

MCP-1 production was significantly

greater in both pup and adult cells stimulated with rmGM-CSF alone at 48 hours
post-stimulation, but only the adult cells stimulated with both rmGM-CSF and PC
had significantly more MCP-1 production after 48 hours of stimulation; the pup
cells had a large intra-group variability causing it to fail reaching statistical
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significance (Figure 5.12b). IL-6 production was significantly increased in both
pup and adult cells stimulated with both rmGM-CSF and PC together; IL-6
production was not significantly increased in those cells stimulated with rmGMCSF alone (Figure 5.12d). The production of IL-10 was not affected by the
addition of rmGM-CSF either alone or in combination with PC (Figure 5.12c).
Overall these data suggest that the addition of rmGM-CSF to PC-infected pup
cells increases the production of TNFα, MCP-1, and IL-6, but not IL-10.
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Figure 5.12 rmGM-CSF increases cytokine production in pup AMs. AMs were
isolated from the pooled BALF of adult (≥ 8 wks) and 7-10 day old pup (P) mice
and cultured in a 96-well plate with media alone (Con), PC, rmGM-CSF (GM), or
PC plus rmGM-CSF (GM/PC). Supernatants were removed at 6, 24, 30, and 48
hours post-stimulation and (A) TNF, (B) MCP-1, (C) IL-10, (D) and IL-6 were
analyzed by Cytometric Bead Array analysis and flow cytometry. Data represent
the mean ± SD of 3-4 wells per group. #p<0.05, compared to all other pup groups
and A-GM/PC; +p<0.05, compared to the respective pup or adult control and PC
groups; *p<0.05, compared to the respective pup or adult control groups.
2. NFkB p65 nuclear translocation is stimulated by rmGM-CSF in adult but
not pup alveolar macrophages
Similar to the assay performed following LPS stimulation, an NFkB p65
assay was performed to determine the level of translocation into the nucleus
following 1 hour of stimulation with PC alone, rmGM-CSF alone, or PC and
rmGM-CSF in combination. After one hour there was significantly more NFkB
p65 nuclear translocation in the adult AMs stimulate with rmGM-CSF compared
to the pup AMs (Figure 5.13). Both adult and pup AMs stimulated with PC
antigen and rmGM-CSF had less NFkB p65 translocation than that which
occurred with rmGM-CSF alone, suggesting that this combination may play some
what of an inhibitory role on NFkB p65 nuclear translocation in both adult and
pup AMs early in the AM-PC encounter. Upon prolonged exposure to PC
antigen, however, it would appear that this possible suppression is overcome
based on the cytokine data shown in figure 5.12a in which TNFα is largely
produced secondary to rmGM-CSF alone and in combination with PC infection
by 24 hours post-stimulation.
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Figure 5.13 rmGM-CSF increases adult, but not pup NFkB p65 nuclear
translocation. The lavage fluid from 7-10 day-old pup mice and adult mice were
each pooled and then cultured with media alone (con), rmGM-CSF (GM), PC
(PC), or PC plus rmGM-CSF (PC/GM). The cells were lysed and the nuclear
extract was isolated and NFkB p65 quantified using Chemicon’s NFkB p65
Transcription Factor Colorimetric Assay. Data represent the means ± SD for 3
samples per group and are representative of 2 experiments. +p<0.05 compared
to adult control and pup rmGM-CSF groups. *p<0.05 compared to adult control
group.
3. rmGM-CSF delivered i.p. increases pup lung macrophage activation and
T cell infiltration but not Pneumocystis clearance
Based on the data generated from the in vitro experiments, an rmGM-CSF
pilot experiment was performed using a small number of mice. Pups were
infected with PC, as previously described, at 24-72 hours old. Half the pups were
then dosed with 0.25µg of rmGM-CSF per gram body weight by i.p. injection
twice daily beginning on day 7 post-infection and continuing for a total of 5 days
(ending day 11 post-infection). The mice were lavaged and their lungs collected
at days 10 and 20 post-infection for flow cytometry and PC enumeration. While
no statistically significant differences between the two groups were found during
our data analysis, some interesting trends were observed. First, those mice
receiving the rmGM-CSF treatment had an increase in AM infiltration as indicated
by a rise in CD11c+ cells in the lavage (Figure 5.14a) as well as a rise in their
activation level as indicated by an increase in CD11c+/CD11b+ and
CD11c+/MHC class II+ cells (Figure 5.14b-c). Interestingly, no differences were
observed in macrophages in the lung digest (Figure 5.15a-c). Additionally
activated CD4 and CD8 T cells were elevated in the rmGM-CSF-treatment
groups in the lavage and activated CD8 T cells were elevated in the treatment
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group in the lung digest (Figure 5.16 a,c, and d). No changes were noted in the
lung digest for CD4 T cells (Figure 5.16b). Lastly, no differences were observed
in PC burden between the treated and untreated mice at either timepoint tested
(Figure 5.17). While this data showed no definitive results, some important trends
were observed. Although not statistically significant, the increase in AM and T
cell infiltration and activation in the BALF of mice receiving rmGM-CSF was
promising and encouraged us to proceed with experiments using rmGM-CSF in
larger experiments with more mice. A change in both the dose and route of
administration were applied for subsequent experiments; administration of
rmGM-CSF by i.n. rather than by i.p. administration was instituted based on
published literature demonstrating safety and efficacy in initiating a specific
pulmonary immune response with aerosolized GM-CSF (252, 253).

Figure 5.14 rmGM-CSF administered i.p. did not affect the number of pup AMs
expressing CD11c, CD11b, or MHC class II molecules in the lavage. Mice were
infected with PC as neonates (24 to 72 h after birth) and then treated with
0.25µg/g i.p. rmGM-CSF or sterile, deionized water twice daily for 5 days
beginning day 7 post-infection. BALF was collected on days 10 and 20 postinfection. Cells were stained with antibodies specific for CD11c and CD11b, or
MHC class II and were examined using flow cytometry. Cells were gated for large
nonlymphoid cells by using forward and side light scatter and CD11c+ cells. Data
are representative of the mean ± SD of four to five mice per group and 2
separate experiments.
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Figure 5.15 rmGM-CSF administered i.p. did not affect the number of pup
macrophages expressing CD11c, CD11b, or MHC class II molecules in the lung
digest. Mice were infected with PC as neonates (24 to 72 h after birth) and then
treated with 0.25µg/g i.p. rmGM-CSF or sterile, deionized water twice daily for 5
days beginning day 7 post-infection. Whole lungs were collected on days 10 and
20 post-infection and processed into single cell suspensions. Cells were stained
with antibodies specific for CD11c and CD11b, or MHC class II and were
examined using flow cytometry. Cells were gated for large nonlymphoid cells by
using forward and side light scatter and CD11c+ cells. Data are representative of
the mean ± SD of four to five mice per group and 2 separate experiments.
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Figure 5.16 rmGM-CSF administered i.p. did not increase the infiltration of
activated T cells in PC-infected pup lungs. Mice were infected with PC as
neonates (24 to 72 h after birth) and then treated with 0.25µg/g i.p. rmGM-CSF or
sterile, deionized water twice daily for 7 days beginning day 7 post-infection.
Lavage fluid and whole lungs were collected on days 10 and 20 post-infection
and processed into single cell suspensions. Cells were stained with antibodies
specific for CD4, CD8, CD44, and CD62 and examined using flow cytometry.
Cells were gated for small non-ganular lymphoid cells by using forward and side
light scatter. Data are representative of the mean ± SD of four to five mice per
group and 2 separate experiments.
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Figure 5.17 rmGM-CSF administered i.p. did not reduce PC lung burden in pup
mice. Mice were infected with PC as neonates (24 to 72 h after birth) and then
treated with 0.25µg/g i.p. rmGM-CSF or sterile, deionized water twice daily for 7
days beginning day 7 post-infection. Whole lungs were collected on days 10 and
20 post-infection, processed into single cell suspensions. Aliquots were spun
onto glass slides, stained with Diff-Quick® and enumerated microscopically. Data
are representative of the mean ± SD of four to five mice per group and 2
separate experiments.
4. rmGM-CSF administered i.n. improves Pneumocystis clearance
The next rmGM-CSF experiment included seven C57BL/6 x DBA/2J
(B6D2F1/J) pup mice, which were infected with PC at 72 hours old. On day 7
post-infection 3 of the 7 mice were treated with i.n. rmGM-CSF daily (5ng/g) for 5
days (254-256); the 4 control mice received i.n. PBS on the same dosing
schedule. On day 18 post-infection, BALF and lungs were collected and
processed for flow cytometry and microscopic analysis as previously described.
Mice treated with rmGM-CSF had a reduced PC burden without a concomitant
increase in the number of LMs expressing activation markers (Figure 5.18a). All
cells were first gated on large nonlymphocytes and CD11c. None of the markers
tested were increased in the treatment group compared to the control group,
including CD11b, MHC class II, dectin-1, and mannose receptor. Figure 5.18b
depicts the PC burden in the lungs of both the rmGM-CSF-treated and the
control mice. Although both groups of mice have a relatively large PC burden and
no statistically significant differences were found, the rmGM-CSF-treated group
had fewer overall PC organisms in their lungs compared to the control group
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(Figure 5.18b). This data suggests that rmGM-CSF is capable of reducing PC
burden without increasing the number of LMs expressing an activated
phenotype. Such a pattern would be desirable in an infant whose developing
lungs are vulnerable to damage from excessive inflammatory responses. It is
possible that the reduced PC lung burden observed in the rmGM-CSF-treated
mice resulted in the decreased number of macrophages expressing activation
markers compared to the untreated group.

Figure 5.18 rmGM-CSF administered i.n. reduced PC burden in pup mice. Mice
were infected with PC as neonates (24 to 72 h after birth) and then treated with
5ng/g i.n. rmGM-CSF or PBS daily for 5 days beginning day 7 post-infection.
Lavage fluid and whole lungs were collected on day 18 post-infection and
processed into single cell suspensions. (A) Cells were stained with antibodies
specific for CD11c, CD11b, dectin-1, MHC class II, and mannose receptor and
examined using flow cytometry. Cells were gated for large non-lymphoid cells by
using forward and side light scatter and were gated on CD11c+ cells. Data are
representative of three to four mice per group. (B) Aliquots of lung digest were
spun onto glass slides, stained with Diff-Quick® and enumerated microscopically.
White symbols represent the mean log10PC/Lung.
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Figure 5.19 rmGM-CSF administered i.n. increased the number of LMs
expressing activation markers in PC-infected pup mice. Mice were infected with
PC as neonates (24 to 72 h after birth) and then treated with 5ng/g i.n. rmGMCSF or PBS daily for 7days beginning day 7 post-infection. Lavage fluid and
whole lungs were collected on days 14, 18, 22, and 28 post-infection and
processed into single cell suspensions. Cells were stained with antibodies
specific for CD11c, (A-B) CD11b, and (C-D) MHC class II and examined using
flow cytometry. Cells were gated for large non-lymphoid cells by using forward
and side light scatter and were gated on CD11c+ cells. Data are representative
of the mean ± SD of three to four mice per group. *p<0.05 compared to
respective PC+/GM- groups.
Based on this data, a second rmGM-CSF experiment was designed to
include multiple timepoints. As previously described, mice were infected with PC
at 72 hours old, and treatment with 5ng/g rmGM-CSF i.n. was begun 7 days
post-infection and continued for 7 days. In addition to looking at LMs, flow
cytometry was used to compare differences in T cell infiltration and activation in
both the lungs and lymph nodes in the treatment group compared to the control
group. At day 14 post-infection there was a significant increase in LMs
(CD11c+/CD11b+ non-lymphocytes) in both the BALF and the lung tissue in the
rmGM-CSF-treated mice compared to the untreated mice (Figure 5.19a and b);
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suggesting an increase in LM infiltration and/or activation of macrophages or
granulocytes. In both tissues this difference was lost by day 18 post-infection.
While these cells increased again in both tissues by day 22 post-infection in the
treatment group compared to the untreated group, the difference was not found
to be statistically significant. The number of nonlymphocytes expressing MHC
class II was also assessed in both the BALF and the lung tissues. As can be
seen in figures 5.19c and d, there was a lot of intra-group variability, thus the only
significant difference noted in the number of cells expressing MHC class II was at
day 28 post-infection in the lung tissue (Figure 5.19d). Taken together, this data
suggests that rmGM-CSF may both increase the infiltration of AMs into the
alveolar spaces as well as increase the number of infiltrated and tissue
macrophages expressing activation markers in the lungs of PC-infected pups.
With an increase in the infiltration and activation of LMs in the BALF as
well as the lung tissue, one would expect an increase in the infiltration and
activation of T lymphocytes within the same time frame. Based on this premise,
flow cytometry was used to evaluate the presence of both CD4+ and CD8+ T
cells with a high expression of CD44 and a low expression of CD62L (an
indication of T lymphocyte activation). As expected, the infiltration and activation
of both CD4+ and CD8+ T cells followed a very similar patter to that of the AM
and tissue macrophages (Figure 5.20). Pups treated with rmGM-CSF had an
increase in activated CD4+ and CD8+ T cells in the BALF and the lung tissue.
This increase occurred earlier at day 14 post-infection in the lung tissue
compared to day 22 post-infection in the BALF, likely reflecting the time it takes
for lymphocytes to extravasate across the lung tissues to reach the alveolar
spaces. (Figure 5.20a-d). Overall, no statistically significant differences between
the pups receiving rmGM-CSF and the pups receiving vehicle only were found.
The TBLNs were analyzed for activated T lymphocytes to determine if rmGMCSF treatment improved the time to specific antigen response in the regional
lymph node, presumably through expedited or improved TBLN homing and/or
antigen presentation. Treatment with rmGM-CSF did not improve lymphocyte
activation time in the TBLN compared to the untreated group (Figure 5.21a-b).
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Lastly, figure 5.21c depicts the PC lung burden in each mouse from both the
treatment and control groups at each timepoint tested. While the lung burden of
PC organisms at day 14 post-infection was the same in both groups, a
divergence is obvious at day 18 post-infection whereby the rmGM-CSF-treated
group has a lower burden compared to the control group (NS). This divergence is
lost, however by day 22 post-infection and overall, no statistically significant
differences in PC burden were observed between the two groups (Figure 5.21c).

Figure 5.20 rmGM-CSF administered i.n. did not significantly increase the
number of activated T cells in PC-infected pup lungs. Mice were infected with PC
as neonates (24 to 72 h after birth) and then treated with 5ng/g i.n. rmGM-CSF or
PBS daily for 7days beginning day 7 post-infection. Lavage fluid and whole lungs
were collected on days 14, 18, 22, and 28 post-infection and processed into
single cell suspensions. Cells were stained with antibodies specific for CD4 (AB), CD8 (C-D), CD44, and CD62L and examined using flow cytometry. Cells
were gated for small, non-granular cells by using forward and side light scatter.
Data are representative of the mean ± SD of three to four mice per group.
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Taken together, the data describing this rmGM-CSF in vivo experiment
demonstrates that mice infected with PC as neonates have a more robust LM
response to the organism following treatment with rmGM-CSF compared to
untreated mice. The increase in activated LMs at day 14 post-infection in the
rmGM-CSF group occurred approximately 7 days prior to the reduced PC burden
seen at day 18 in comparison to the control group. Overall, rmGM-CSF increased
the activation of LMs in PC-infected pups. While the reduction in PC burden did
not reach statistical significance, it is clear that rmGM-CSF bolstered the overall
immune response to PC infection in pup mice.

Figure 5.21 rmGM-CSF administered i.n. did not significantly reduce PC burden
in pup mice. Mice were infected with PC as neonates (24 to 72 h after birth) and
then treated with 5ng/g i.n. rmGM-CSF or PBS daily for 7days beginning day 7
post-infection. TBLNs and whole lungs were collected on days 14, 18, 22, and 28
post-infection and processed into single cell suspensions. Cells were stained with
antibodies specific for CD4 (A), CD8 (B), CD44, and CD62L and examined using
flow cytometry. Cells were gated for small, non-granular cells by using forward
and side light scatter. (C) Aliquots of lung digest were spun onto glass slides,
stained with Diff-Quick® and enumerated microscopically. Data are
representative of the mean ± SD of three to four mice per group.
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This data differs from the first i.n rmGM-CSF experiment which
demonstrated a reduction in PC burden without a concomitant increase in LM
expressing activation markers (Figure 5.18). Two explanations can be offered
when comparing the results of these two experiments. First, is that the second
experiment continued rmGM-CSF therapy for 7 days, unlike the first experiment
in which treatment was extended for only 5 days. The extra 2 days of therapy
may have contributed to the increased number of LMs expressing activation
markers. Second, as previously stated, the reduced PC burden seen in the first
i.n. rmGM-CSF experiment was likely driven by the reduced PC burden. The
second experiment also had a reduction in PC burden at day 18 post-infection
which correlated with a lower number of LMs expressing activation markers. This
second experiment, however, looked at days further out from infection and as will
be described in the next two figures, demonstrated somewhat of a rebound in PC
burden with a concomitant increase in activation markers. Overall this data
suggests that rmGM-CSF treatment alone is not sufficient to treat PC infection.
D. Recombinent mouse granulocyte macrophage-colony stimulating factor
plus Trimethoprim/sulfamethoxazole
Although the standard of care treatment for PC pneumonia is TMP/SMX,
the use of combination therapy for infectious diseases is a common, wellaccepted practice depending on the severity of the infection, its location, and the
virulence of the infecting organism (257). Considering the use of combination
therapy together with the rationale of using immunomodulatory agents to fight
infectious diseases, we hypothesized that the use of GM-CSF and TMP/SMX
together could improve PC clearance in pup mice. Experiments were designed
to include four groups of pups; all were infected with PC between 24 and 72
hours old. The infection was allowed to grow for 7 days and become established
before beginning one of the following treatment regimens: 40mg/kg TMP/
200mg/kg SMX orally twice daily for 14 days, 5ng/g rmGM-CSF i.n daily for 7
days, 40mg/kg TMP/ 200mg/kg SMX orally twice daily x 14 days + 5ng/g rmGMCSF i.n daily x 7 days, or vehicle only i.n. once daily x 7 days.
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1. Pneumocystis burden
As demonstrated in Figure 5.22, the groups treated with TMP/SMX alone
and TMP/SMX plus rmGM-CSF had significantly lower PC burdens by day 22
post-infection compared to control mice. By day 29 post-infection the PC burden
in the combination group remained low. However, the burden in the TMP/SMX
group seems to rebound slightly upon discontinuation of the drug. This
observation suggests that in the combination group, the TMP/SMX was
responsible for the brunt of the work in reducing PC, but the addition of rmGMCSF enabled the host’s immune system to maintain that reduction more
efficiently after the TMP/SMX was removed.

Figure 5.22 TMP/SMX and the combo groups significantly reduced PC burden in
pup mice. Mice were infected with PC as neonates (24 to 72 h after birth).
Beginning on day 7 post-infection, mice were treated with either 40 mg/kg
TMP/SMX orally twice daily for 14 days + 10 µl normal saline (NS) daily for 7
days (TMP/SMX), 5ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 40 mg/kg
TMP/SMX orally twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily for 7days
(Combo), or 10 µl NS daily for 7 days (Control). Whole lungs were collected on
days 12, 19, 22, and 29 post-infection, processed into single-cell suspensions.
Aliquots were spun onto glass slides, stained with Diff-Quik®, and enumerated
microscopically. Data represent four to five mice per group and are
representative of 3 separate experiments. *p< 0.05 mean ± SD compared to the
control group at the indicated time point.
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2. rmGM-CSF levels in the lung
To determine if the rmGM-CSF sufficiently made it to the lungs via the i.n.
route of administration, an ELISA was performed on the BALF collected after
each timepoint. Since the rmGM-CSF was exogenously administered for 7 days
beginning 7 days after the pups were infected with PC, the last day of rmGMCSF dosing was day 14 post-infection. Thus, the results observed in the GMCSF ELISA were somewhat predictable in that there was a significantly elevated
level of GM-CSF on day 12 post-infection in the rmGM-CSF-treatment group
which was not observed at the later time points (Figure 5.23). Unexpectedly,
however, there was less GM-CSF in the rmGM-CSF/TMP/SMX (combination)
group than in the untreated controls. By day 19 post-infection, the exogenous
administration of rmGM-CSF had ceased and no groups were producing
significant levels of the cytokine endogenously. On days 22 and 29 post-infection
the TMP/SMX and rmGM-CSF single-treatment groups were producing elevated
levels of GM-CSF compared to the control group, but not enough to reach
statistical significance (Figure 5.23).

Figure 5.23 GM-CSF levels were significantly elevated in GM-CSF-treated pup
lungs. Mice were infected with PC as neonates (24 to 72 h after birth). Beginning
on day 7 post-infection, mice were treated with either 40 mg/kg TMP/SMX orally
twice daily for 14 days + 10 µl NS daily for 7 days (TMP/SMX), 5ng/g i.n. rmGMCSF daily for 7days (GM-CSF), 40 mg/kg TMP/SMX orally twice daily for 14 days
and 5ng/g i.n. rmGM-CSF daily for 7days (Combo), or 10 µl NS daily for 7 days
(Control). Lungs were lavaged on days 12, 19, 22, and 29 post-infection and GMCSF levels were determined by ELISA. *p<0.05 compared to all other groups at
day 12 post-infection. Data represent the mean ± SD of four to five mice per
group and are representative of 3 separate experiments.
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3. Lung macrophage activation markers reflect rmGM-CSF treatment and
Pneumocystis burden
Similar to previous experiments, flow cytometry was used to evaluate the
level of LM and lymphocyte infiltration and activation within the lungs of mice
from each of the groups outlined above. As depicted in figure 5.24, the infiltration
and activation of pup LMs in the BALF were somewhat variable. A look at nonlymphocytes expressing CD11c in figure 5.24a shows us that there is a slight
surge of macrophage infiltration into the alveolar spaces on day 12 post-infection
in the rmGM-CSF-treated group compared to all other groups, although the
differences are not statistically significant. On day 19 post-infection, all groups
demonstrated similar numbers of CD11c+ cells and then interestingly, on day 22
post-infection, there was significantly lower numbers of CD11c-expressing cells
in the TMP/SMX group compared to the untreated group. At day 29 post-infection
the combination group had significantly fewer CD11c+ expressing cells
compared to the untreated group, whereas numbers in the TMP/SMX group had
rebounded back up to the level of the untreated group. It is important to consider
the timeframe of rmGM-CSF and TMP/SMX treatments when analyzing this data.
To relate fluctuations in the surface marker expression to the treatment period of
each drug, a timeline is provided in figure 5.24b. One can see, by comparing the
expression of CD11c+ cells to the timeline that the greatest numbers occurred in
the rmGM-CSF-treated group 5 days into the treatment period; the subsequent
drop in cells expressing CD11c occurring at day 19 post-infection may reflect the
discontinuation of the drug at day 14 post-infection. Overall, this data suggests
that rmGM-CSF may have been driving the infiltration of CD11c+ cells early on
and upon discontinuation of the drug, the number of CD11c+ expressing cells
returned to baseline. Furthermore, in the group receiving TMP/SMX alone, the
number of CD11c+ cells appeared to be driven by PC burden (Figure 5.22),
which was decreased by the activity of TMP/SMX. This decreased number of
CD11c-expressing cells was not seen in the combination group most likely, due
to the promotion of CD11c+ cell infiltration imparted by the rmGM-CSF. Thus the
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overall reduction in CD11c+ cells in the combination group by day 29 postinfection likely represents a reduction in PC burden (compare to figure 5.22)

Figure 5.24 GM-CSF drove an increase in infiltrating AMs in PC-infected pup
mice. Mice were infected with PC as neonates (24 to 72 h after birth). Beginning
on day 7 post-infection, mice were treated with either 40 mg/kg TMP/SMX orally
twice daily for 14 days + 10 µl normal saline (NS) daily for 7 days (TMP/SMX),
5ng/g i.n. rmGM-CSF daily for 7 days (GM-CSF), 40 mg/kg TMP/SMX orally
twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily for 7 days (Combo), or 10
µl NS daily for 7 days (Control). Lungs were lavaged on days 12, 19, 22, and 29
post-infection and cells were stained with antibodies specific for CD11c and
analyzed by flow cytometry. Cells were gated for large non-lymphoid cells by
using forward and side light scatter. (A) Data represent the mean ± SD of four to
five mice per group and are representative of 3 separate experiments. *p<0.05
compared to respective control groups at the indicated time points. (B) Timeline
depicts the start and discontinuation of treatments.
The other markers of macrophage activation tested showed very similar
trends to the number of cells expressing CD11c. The number of cells dually
expressing CD11c and CD11b appeared to correlate with PC burden (Figures
5.25a and 5.22). This is most apparent when looking at day 12 compared to day
22 at which time the number of CD11c/CD11b+ cells are significantly less in the
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groups receiving TMP/SMX compared to the control group. Treatment with
rmGM-CSF alone is not capable of significantly reducing PC burden. However, at
day 12 post-infection the groups receiving rmGM-CSF had more cells expressing
CD11c and CD11b (Figure 5.25a). Cells dually expressing CD11c and dectin-1
or MHC class II had very similar patterns. While still driven by PC burden, at day
22 post-infection the combination group had more dual positive cells compared to
the TMP/SMX group despite the drop in PC burden (Figures 5.22 and 5.25b and
d). Unlike the other markers described here, the cells co-expressing CD11c and
mannose receptor did not appear to correlate with PC burden (Figure 5.25c).
Furthermore, these cells did not reflect treatment with rmGM-CSF by increasing
in number at day 12 post-infection.
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Figure 5.25 Groups receiving TMP/SMX had reduced numbers of LMs
expressing activation markers. Mice were infected with PC as neonates (24 to 72
h after birth). Beginning on day 7 post-infection, mice were treated with either 40
mg/kg TMP/SMX orally twice daily for 14 days + 10 µl NS daily for 7 days
(TMP/SMX), 5ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 40 mg/kg
TMP/SMX orally twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily for 7days
(Combo), or 10 µl NS daily for 7 days (Control). Lungs were lavaged on days 12,
19, 22, and 29 post-infection, and cells were stained with antibodies specific for
CD11c, CD11b (A), Dectin-1 (B), Mannose receptor (C), and MHC class II
molecules (D) and analyzed by flow cytometry. Cells were gated for large nonlymphoid cells by using forward and side light scatter and were gated on CD11c+
cells. Data represent the mean ± SD of four to five mice per group and are
representative of 3 separate experiments. *Total number of cells expressing the
marker indicated is significantly greater than the control group at the indicated
time point, p<0.05. +Total number of cells expressing the marker indicated is
significantly greater than all other groups at the indicated time point, p<0.05.
The same markers were analyzed in the lung digest in order to capture
both resident macrophages as well as cells that were actively translocating into
the alveolar spaces. In this case, a similar pattern was observed among all the
receptors, including mannose receptor (Figures 5.26 and 5.27). Early on, cell
activation

markers

were

driven

by

treatment

with

rmGM-CSF.

Upon

discontinuation of rmGM-CSF, these markers began to more closely correlate
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with PC burden with TMP/SMX groups having fewer cells expressing CD11c,
CD11b, dectin-1, MHC class II, or mannose receptor. By day 29 post-infection, a
significant rebound in cells expressing these markers occurs, likely due to the
discontinuation of TMP/SMX on day 21 post-infection. Together, these data
suggest that rmGM-CSF is capable of driving an increase in LM activation;
however it did not demonstrate an improvement in PC burden beyond that
produced by TMP/SMX alone. By looking at day 29 post-infection, one can see
that the PC burden in the combo group remained relatively low compared to the
TMP/SMX group; this is reflected in the lower number of cells expressing
activation markers in both the BALF and the lung digest (Figures 5.22-5.27).
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Figure 5.26 GM-CSF drove an increase and TMP/SMX drove a decrease in
infiltrating AMs in PC-infected pup mice. Mice were infected with PC as neonates
(24 to 72 h after birth). Beginning on day 7 post-infection, mice were treated with
either 40 mg/kg TMP/SMX orally twice daily for 14 days + 10 µl NS daily for 7
days (TMP/SMX), 5ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 40 mg/kg
TMP/SMX orally twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily for 7days
(Combo), or 10 µl NS daily for 7 days (Control). Whole lungs were collected on
days 12, 19, 22, and 29 post-infection and processed into a single-cell
suspension. Cells were stained with antibodies specific for CD11c and analyzed
by flow cytometry. Cells were gated for large non-lymphoid cells by using forward
and side light scatter. (A) Data represent the mean ± SD of four to five mice per
group and are representative of 3 separate experiments. +p<0.05 compared to
TMP/SMX and control groups; *p<0.05 compared to control group. (B) Timeline
depicts the start and discontinuation of treatments.
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Figure 5.27 GM-CSF drove an increase and TMP/SMX drove a decrease in
infiltrating and activated AMs in PC-infected pup mice. Mice were infected with
PC as neonates (24 to 72 h after birth). Beginning on day 7 post-infection, mice
were treated with either 40 mg/kg TMP/SMX orally twice daily for 14 days + 10 µl
NS daily for 7 days (TMP/SMX), 5ng/g i.n. rmGM-CSF daily for 7days (GM-CSF),
40 mg/kg TMP/SMX orally twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily
for 7 days (Combo), or 10 µl NS daily for 7 days (Control). Whole lungs were
collected on days 12, 19, 22, and 29 post-infection and processed into a singlecell suspension. Cells were stained with antibodies specific for CD11c, CD11b
(A), Dectin-1 (B), Mannose receptor (C), and MHC class II molecules (D) and
analyzed by flow cytometry. Cells were gated for large non-lymphoid cells by
using forward and side light scatter and were gated on CD11c+ cells. Data
represent the mean ± SD of four to five mice per group and are representative of
3 separate experiments. +p<0.05 compared to TMP/SMX and control groups;
*p<0.05 compared to control group.
4. rmGM-CSF increases cytokine production in mouse lungs
Another method by which the activation level of LMs can be assessed is
through their production of cytokines; therefore, levels within the BALF were
analyzed for each of the four groups at each timepoint tested. Treatment with
rmGM-CSF ± TMP/SMX appeared to stimulate the production of TNFα and IL-
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12p70 as well as MCP-1 early on but did not stimulate IL-6 production (Figure
5.28a-d). rmGM-CSF alone was important early in the experiment (days 12 and
19) for driving the production of TNFα and MCP-1. These two cytokines may
have contributed to the increase in activated resident macrophages in the lung
digest observed at day 22 post-infection and the subsequent decrease in PC
burden during this same time (Figures 5.22, 5.26-27).

Figure 5.28 GM-CSF drove early TNFα and MCP-1 production in PC-infected
pup mice. Mice were infected with PC as neonates (24 to 72 h after birth).
Beginning on day 7 post-infection, mice were treated with either 7µl/g TMP/SMX
orally twice daily for 14 days + 10 µl NS daily for 7 days (TMP/SMX), 5ng/g i.n.
rmGM-CSF daily for 7days (GM-CSF), 7 µl/g TMP/SMX orally twice daily for 14
days and 5ng/g i.n. rmGM-CSF daily for 7days (Combo), or 10 µl NS daily for 7
days (Control). Lungs were lavaged on days 12, 19, 22, and 29 post-infection
and analyzed for cytokine production using a BD CBA® kit specific for (A) TNFα,
(B) IL-12p70, (C) MCP-1, and IL-6 (D). Data represent the mean ± SD of four to
five mice per group and are representative of 3 separate experiments. (A)
*p<0.05 compared to TMP/SMX and control groups; (C-D) *p<0.05 compared to
all other groups at the indicated time points.
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5. Lymphocyte infiltration was driven by rmGM-CSF and Pneumocystis
burden
In addition to looking at the LM response secondary to rmGM-CSF ±
TMP/SMX, the infiltration and activation of T lymphocytes into the lungs and
lymph nodes was also analyzed. The influx of activated cells by day 12 postinfection likely reflects rmGM-CSF treatment, whereas the decrease in these
cells by day 19 most likely reflects the discontinuation of rmGM-CSF along with
the decrease in PC burden in the mice receiving TMP/SMX (Figure 5.22 and
5.29a and c).

Once again, at day 29 post-infection there is a considerable

rebound in the number of activated lymphocytes infiltrating into the lungs in the
TMP/SMX group alone compared to the combo group (Figure 5.29a and c). The
presence of activated T cells in the lymph node reflect the ability of TMP/SMX to
reduce PC burden as the groups receiving TMP/SMX required less overall T cell
activation (Figure 5.29b and d).
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Figure 5.29 GM-CSF drove an increase and TMP/SMX drove a decrease in
infiltrating AMs in PC-infected pup mice. Mice were infected with PC as neonates
(24 to 72 h after birth). Beginning on day 7 post-infection, mice were treated with
either 40 mg/kg TMP/SMX orally twice daily for 14 days + 10 µl NS daily for 7
days (TMP/SMX), 5ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 40 mg/kg
TMP/SMX orally twice daily for 14 days and 5ng/g i.n. rmGM-CSF daily for 7
days (Combo), or 10 µl NS daily for 7 days (Control). Whole lungs and TBLNs
were collected on days 12, 19, 22, and 29 post-infection and processed into
single-cell suspensions. Cells were stained with antibodies specific for CD4 (AB), CD8 (C-D), CD44, and CD62L and analyzed by flow cytometry. Cells were
gated for small non-granular cells by using forward and side light scatter. Data
represent of the mean ± SD of four to five mice per group and are representative
of 3 separate experiments. +p<0.05 compared to TMP/SMX and control groups;
*p<0.05 compared to control group.
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6. High dose rmGM-CSF reduced Pneumocystis burden in the combination
group
Based on the initial TMP/SMX + rmGM-CSF experiment, a final rmGMCSF experiment was designed to evaluate the role of rmGM-CSF at a higher
dose. The experimental design was the same as described above except that
the rmGM-CSF dose was 50ng/g body weight instead of 5ng/g. Two time points
were analyzed at days 17 and 22 post-infection. As in the previous experiment,
PC burden was reduced in the TMP/SMX and rmGM-CSF plus TMP/SMX
groups. The use of a higher dose of rmGM-CSF, however, reduced PC burden
significantly compared to the TMP/SMX group alone at day 22 post-infection
(Figure 5.30)

Figure 5.30 PC burden was significantly reduced in the combination group
compared to TMP/SMX alone. Mice were infected with PC as neonates (24 to 72
h after birth). Beginning on day 7 post-infection, mice were treated with either
7µl/g TMP/SMX orally twice daily for 14 days + 10 µl NS daily for 7 days
(TMP/SMX), 50ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 7 µl/g TMP/SMX
orally twice daily for 14 days and 50ng/g i.n. rmGM-CSF daily for 7days (Combo),
or 10 µl NS daily for 7 days (Control). Whole lungs were collected on days 17
and 22 post-infection and were processed into single-cell suspensions. Aliquots
were spun onto glass slides, stained with Diff-Quick®, and enumerated
microscopically. *p<0.05 compared to control groups at the indicated time points.
+p<0.05 compared to TMP/SMX and control groups at the indicated time point.
Data represent the mean ± SD of four to five mice per group.
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7. Lung macrophage activation markers with high dose rmGM-CSF
The same macrophage activation markers were evaluated as previously
described, except that instead of looking at mannose receptor, TLR2 and TLR4
were included instead. TLR2 has recently been shown to be a receptor for PC
antigens and TLR4 stimulation, although not previously shown to interact with
PC, is a known inducer of TNFα (Figure 5.31) (44, 246-249). The increased dose
of rmGM-CSF did not alter the number of cells expressing CD11c, CD11b,
dectin-1, or MHC class II compared to the lower treatment dose (data not
shown). The number of cells expressing TLR2 in the lung digest at day 22
resembles the pattern seen with LM activation markers during the initial rmGMCSF/TMP/SMX experiment in which the cells followed the burden of PC (Figure
5.31d). No additional trends in cells expressing TLR2 or TLR4 appeared to
correspond with mGM-CSF treatment or PC burden (Figure 5.31 a-c).
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Figure 5.31 TMP/SMX drove a reduction in the number of cells expressing
TLR2. Mice were infected with PC as neonates (24 to 72 h after birth). Beginning
on day 7 post-infection, mice were treated with either 7µl/g TMP/SMX orally twice
daily for 14 days + 10 µl NS daily for 7 days (TMP/SMX), 50ng/g i.n. rmGM-CSF
daily for 7days (GM-CSF), 7 µl/g TMP/SMX orally twice daily for 14 days and
50ng/g i.n. rmGM-CSF daily for 7days (Combo), or 10 µl NS daily for 7 days
(Control). Whole lungs and lung lavaged was collected on days 17 and 22 postinfection and were processed into single-cell suspensions. Cells were stained
with antibodies specific for CD11c, TLR4 (A-B), and TLR2 (C-D). Cells were
gated for large non-lymphocytes using forward and side scatter and were gated
on CD11c+ cells. Data represent the mean ± SD of four to five mice per group.
The infiltration of activated CD4+ and CD8+ T cells in the lung digest
appeared to be primarily driven by rmGM-CSF treatment with cell numbers being
greatest at day 17 post-infection in the groups receiving rmGM-CSF (Figure 5.32
a-b). The levels of TNFα, IL-12p70, MCP-1, and IL-6 produced in the lung
subsequent treatment with 50ng/g of rmGM-CSF were comparable to those
produced following the lower dose of rmGM-CSF (data not shown). Taken
together, these data suggest that the combination of TMP/SMX plus rmGM-CSF
is more efficient at reducing PC burden and keeping the burden low compared to
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TMP/SMX alone in pup PC-infected pup mice. The addition of rmGM-CSF to the
treatment of this opportunistic infection appears to cooperate with TMP/SMX by
recruiting and activating macrophages within the lung.

Figure 5.32 GM-CSF drove an early increase and late reduction in T cell
infiltration into PC-infected pup lungs. Mice were infected with PC as neonates
(24 to 72 h after birth). Beginning on day 7 post-infection, mice were treated with
either 7µl/g TMP/SMX orally twice daily for 14 days + 10 µl NS daily for 7 days
(TMP/SMX), 50ng/g i.n. rmGM-CSF daily for 7days (GM-CSF), 7 µl/g TMP/SMX
orally twice daily for 14 days and 50ng/g i.n. rmGM-CSF daily for 7days (Combo),
or 10 µl NS daily for 7 days (Control). Whole lungs were collected on days 17
and 22 post-infection and were processed into single-cell suspensions. Cells
were stained with antibodies specific for CD44, CD4 (A), and CD8 (B). Cells were
gated for small non-granulocytes using forward and side scatter. Data represent
the mean ± SD of four to five mice per group.

Copyright © Kerry McGarr Empey 2007
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CHAPTER 6: Human neonatal lung macrophages have a poor activation
profile compared to adults
Infants, predominantly those that are immunocompromised, appear to be
particularly susceptible to primary PC infection. It is believed that the higher
incidence of PC as well as other pulmonary infections among infants is likely due
to an immature immune system as the neonatal lung environment is deficient
immunologically in preterm as well as term infants (7, 8). Decreased phagocytic
capacity of monocytes and macrophages in newborns may contribute to this
increased risk of infection from inhaled pathogens (7, 8).

To evaluate the

response of human neonatal versus adult macrophages against exogenous
stimuli and extend the findings derived from our animal studies, a series of
experiments were performed using human-derived macrophages.
1. LPS stimulates less cytokine production in neonatal compared to adult
lung macrophages
Our studies in mouse models have taught us that pup LMs are less
efficient than adult LMs in mounting a response against PC, as well as other
stimuli such as LPS. To determine if human LMs respond similarly to exogenous
stimuli, in vitro experiments were performed to evaluate the ability of neonatal
LMs to produce cytokine compared to adult LMs. Peripheral blood was collected
from healthy adult volunteers. The monocytes were isolated, cultured, and
allowed to differentiate into macrophages. At the same time, suctioned sputum
samples from intubated neonates were collected and the macrophages were
isolated. The adult peripheral blood monocyte-derived macrophages and the
isolated neonatal LMs were aliquoted into 96-well tissue culture plates and
stimulated with LPS for 24 hours to determine if neonatal and adult cells would
produce similar levels of cytokine. Cytokine production among the adult
macrophages was significantly greater than that produced by neonatal LMs
(Figure 6.1). The production of TNFα, IL-10, IL-6, and IL-1 was significantly
greater among adult macrophages compared to neonatal LMs following 24 hours
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of LPS stimulation (Figure 6.1a-d). Interestingly, IL-8 production was equivalent
between adult and neonatal cells (Figure 6.1e). This data suggests that neonatal
cells do not produce cytokine as efficiently as adult cells despite exposure to a
strong stimulus such as LPS. The discordance between IL-8 production and the
other cytokines analyzed may indicate that alternate receptors are present which
recognizing LPS on neonatal LMs resulting in adequate IL-8 production while
other cytokines are reduced compared to adult cells. It is possible that the
neonatal LPS receptors which ultimately lead to the production of TNFα, IL-10,
IL-6, and IL-1 are deficient in either their expression or function, whereas the LPS
receptor responsible for IL-8 production is fully expressed and functional
compared to that of an adult.
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Figure 6.1 Human adult macrophages produced more cytokine than
neonatal LMs stimulated with LPS. Adult peripheral blood monocyte-derived
macrophages and neonatal LMs were isolated and cultured in a 96-well tissue
culture plate at 2 x105 cells per well in 200µl of human-specific culture media.
After 24 hours, media was replaced with fresh media containing 100ng/ml of LPS
(LPS) or media alone (Con). BD CBA® kit was used to determine cytokine
concentrations after 24 hours of stimulation. *p<0.05 compared to respective
neonate or adult control groups. +p<0.05 compared to neonatal LPS and adult
control groups. Data represent the mean ± SD of three to four wells per group
and are representative of 3 separate experiments.
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Figure 6.2 Human adult LMs produced more cytokine than neonatal LMs
stimulated with LPS. Adult and neonatal LMs were isolated and cultured in a 96well tissue culture plate at 2 x105 cells per well in 200µl of human-specific culture
media. After 24 hours, media was replaced with fresh media containing 100ng/ml
of LPS (LPS) or media alone (Con). BD CBA® kit was used to determine cytokine
concentrations after 24 hours of stimulation. *p<0.05 compared to respective
neonate or adult control groups. +p<0.05 compared to neonatal LPS and adult
control groups. Data represent the mean ± SD of three to four wells per group
and are representative of 3 separate experiments.
The expression of surface molecules found on macrophages can vary
depending on the tissues in which they reside. It is possible; therefore, that
cytokine production may also vary among tissue-specific macrophages. Thus,
this experiment was repeated using adult macrophages isolated from bronchiolar
lavage samples and neonatal suctioned sputum samples. As in the previous
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experiment, the production of TNFα and IL-6 were significantly greater among
the adult cells stimulated with LPS compared to the neonatal samples (Figure
6.2a and c). While IL-1 and IL-10 maintained similar patterns, there were no
significant differences between the two groups (Figure 6.2b and d). The
production of IL-8 was significantly greater in adult compared to the neonatal
LMs in both the stimulated and unstimulated cells, demonstrating that adult LMs
constitutively produce IL-8 in the absence of exogenous stimuli (Figure 6.2e).
Furthermore, this data suggests that PRRs on human adult LMs vary compared
to adult peripheral blood monocyte-derived macrophages. Overall, these data
show that human neonatal lung macrophages are less responsive to LPS than
adult lung macrophages. This finding may indicate a deficient expression of the
LPS receptor, TLR4, or either of its two co-molecules, CD14 or MD-2.
Alternatively, human neonatal LMs may be deficient in their intracellular signaling
pathway downstream from TLR4.
2.

Neonatal

lung

macrophages

respond

similarly

to

adult

lung

macrophages when stimulated with Zymosan
To determine if human neonatal LMs were capable of responding to an
antigenic stimuli that targeted PRRs different than those targeted by LPS,
zymosan was used. Zymosan is known to bind to dectin-1, mannose receptor,
and TLR2, receptors which are also thought to ligate PC antigenic components.
These experiments were performed using macrophages from both human
neonatal and adult sputum specimens. Culture supernatants were collected after
12 and 24 hours of stimulation with zymosan or media alone. At both 12 and 24
hours post-stimulation, TNFα, IL-6, and IL-10 production was significantly
increased among neonatal and adult LMs compared to their control cells (Figure
6.3a-f). The levels of cytokine produced by neonatal versus adult LMs varied
depending on the cytokine. TNFα and IL-8 production was greater among adult
LMs (Figure 6.3a-b, g-h), however IL-6 and IL-10 was greater among neonatal
LMs (Figure 6.3c-f). No differences in IL-1 production were observed between
groups (data not shown). The higher IL-10 levels seen in neonates compared to
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adults following zymosan stimulation coincide with what we saw in mice and may
be part of a protective mechanism specific for developing neonatal lung
macrophages. This zymosan data is in contrast to stimulation with LPS in which
adult LMs produced significantly greater levels of all cytokines tested (Figure
6.2). The variable response to zymosan suggests that neonatal LMs are more
responsive to stimuli that targets both dectin-1 and TLR2.
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Figure 6.3 Zymosan stimulated comparable levels of cytokine production in
neonatal LMs compared to adult LMs. Adult and neonatal LMs were isolated and
cultured in a 96-well tissue culture plate at 2 x105 cells per well in 200µl of
human-specific culture media. After 24 hours, media was replaced with fresh
media containing 250 µg/ml of zymosan (zym) or media alone (Con). BD CBA®
kit was used to determine cytokine concentrations after 12 and 24 hours of
stimulation. The first column represents data collected after 12 hours of
stimulation and the second column represents data collected after 24 hours of
stimulation. *p<0.05 compared to respective neonate or adult control groups.
+p<0.05 compared to neonatal LPS and adult control groups. Data represent the
mean ± SD of three to four wells per group and one to two neonate or adult
pooled samples per well and are representative of 3 separate experiments.
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Figure 6.4 PC did not stimulate cytokine production in neonatal LMs. Adult and
neonatal LMs were isolated and cultured in a 96-well tissue culture plate at 2
x105 cells per well in 200µl of human-specific culture media. After 24 hours,
media was replaced with fresh media containing PC at a concentration of 50 PC
organisms to every 1 macrophage (1:50) or media alone (Con). BD CBA® kit was
used to determine cytokine concentrations after 12 and 24 hours of stimulation.
The first column represents data collected after 12 hours of stimulation and the
second column represents data collected after 24 hours of stimulation. *p<0.05
compared to respective PC-stimulated adult LMs. Data represent the mean ± SD
of three to four wells per group and one to two neonate or adult pooled samples
per well and are representative of 3 separate experiments.
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3. Pneumocystis did not stimulate neonatal lung macrophage cytokine
production above background levels
We have demonstrated that human neonatal LMs respond poorly to LPS
compared to adult LMs, but respond similarly to zymosan. Since PC contains
some of the same antigen motifs as zymosan, namely beta-glucan and mannose,
we next stimulated with PC to determine if cytokine production was similar to that
seen with zymosan. Overall, cytokine production from neonatal LMs surpassed
that of adult LMs in both the PC-stimulated and control cells (Figure 6.4a-h).
However, PC did not provide a strong enough stimulus for the neonatal LMs to
overcome their own background levels of cytokine production. Adult cells
stimulated with exogenous PC responded with increases in TNFα, IL-6, IL-10,
and IL-8 (Figure 6.4a-h) production relative to their control cells; however these
differences did not reach statistical significance. The high background level of
cytokines produced by the neonatal LMs may be due to the mechanical
ventilation that these neonates were receiving at the time the lavage samples
were retrieved and make this data somewhat difficult to interpret. Overall,
however, thse data demonstrate that human adult cells are capable of stimulation
with PC, but neonatal cells are not.
4. rhGM-CSF did not increase cytokine production in Pneumocystisstimulated neontal lung macrophages
GM-CSF has been shown to enhance the clearance and improve
outcomes of many different pulmonary infections (24), (25), (26, 27), (28),
including PC (29), presumably though its ability to activate macrophages for
enhanced activity against invading pathogens (23) (24). Based on this premise,
we hypothesized that the addition of rhGM-CSF to PC-stimulated neonatal LMs
would enhance the cellular response and increase cytokine production. To test
this hypothesis, we repeated the experiments described above comparing human
neonatal and adult LMs with the addition of rhGM-CSF to PC-stimulated cells.
Overall, the addition of rhGM-CSF did not increase the level of cytokine
production among neonatal or adult LMs (Figure 6.5a-h). Interestingly, after 24
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hours of stimulation rhGM-CSF alone, neonatal cells appeared to produce more
TNFα than PC alone or the combination of rhGM-CSF plus PC suggesting that
PC may cause some cytokine inhibition in neonatal cells (Figure 6.5b).
Conversely, the combination of rhGM-CSF plus PC in adult cells induced slightly
more TNFα compared to PC alone. Overall, these data suggest that the addition
of rhGM-CSF to PC does not stimulate an increase in cytokine production among
human neonatal LMs compared to PC alone.
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Figure 6.5 rhGM-CSF increase TNFα production in neonatal LMs after 24 hours.
Adult and neonatal LMs were isolated and cultured in a 96-well tissue culture
plate at 2 x105 cells per well in 200µl of human-specific culture media. After 24
hours, media was replaced with fresh media containing 1:50 of PC (PC),
100ng/ml or rhGM-CSF (GM), 1:50 of PC plus 100ng/ml of rhGM-CSF (PC/GM)
or media alone (Con). BD CBA® kit was used to determine cytokine
concentrations after 12 and 24 hours of stimulation. The first column represents
data collected after 12 hours of stimulation and the second column represents
data collected after 24 hours of stimulation. *p<0.05 compared to respective adult
LM groups. + p<0.05 compared to neonatal PC and PC/GM and adult GM
groups. Data represent the mean ± SD of three to four wells per group and one
to two neonate or adult pooled samples per well and are representative of 3
separate experiments.
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5. rhGM-CSF improves neonatal lung macrophage phagocytosis of
Pneumocystis
We have previously shown that rmGM-CSF reduces PC burden in pup
lungs without an associated increase in LM cytokine production (Figure 5.18).
We hypothesized then, that human neonatal LMs were capable of improved
phagocytosis, despite the lack of cytokine production, through exogenous rhGMCSF stimulation. Adult and neonatal LMs were co-cultured with live PC
organisms at a ratio of 10 PC to every 1 LM (1:10) with or without rhGM-CSF for
25 minutes at 37ºC. Following several washes, an aliquot from each group was
spun onto glass slides and stained with Diff-Quick®. Phagocytosis was quantified
using oil-immersion microscopy (1000x) by examining at least 200 cells and
counting the number of internalized PC organisms in each one. A representative
slide can be seen in Figure 6.6. The amount of phagocytosis was calculated
according to the following formula: phagocytic index (PI) = (percent macrophages
containing at least 1 organism) x (mean number of PC per positive cell)(235237). Treatment of the neonatal LMs co-cultured with PC increased their PI to the
level of adult LMs (Figure 6.7). Only a minimal increase in the PI was observed
with the adult rhGM-CSF-treated LMs, likely due to the already high level of
phagocytosis occurring within these cells. Overall, these data suggest that
treatment of neonatal LMs with rhGM-CSF is capable of stimulating phagocytosis
without a concurrent increase in cytokine production.

134

A

B

Figure 6.6 Human LMs are capable of phagocytosing murine-specific PC.
Human LMs were co-cultured with Pneumocystis carinii f. sp. muris at a ratio of 1
macrophages:10 PC organisms for 25 minutes. Aliquots were spun onto glass
slides and PI was determined: PI = (percent macrophages containing at least 1
organism) x (mean number of PC per positive cell); 200 cells per slide were
counted. Figure is representative of one slide for each human neonate (A) and
adult (B) lavage sample collected; 1000x objective. Arrows indicate
phagocytosed PC organisms.

Figure 6.7 rhGM-CSF improves human neonatal LM phagocytosis of PC
organisms. Adult and neonatal LMs were co-cultured with live PC organisms
(1:10) with or without rhGM-CSF for 25 minutes at 37ºC. Aliquots from each
group were spun onto glass slides and stained with Diff-Quick®. Phagocytosis
was quantified using oil-immersion microscopy (1000x) by examining at least 200
cells and counting the number of internalized PC organisms in each one. The
phagocytic index (PI) was calculated according to the following formula: PI =
(percent macrophages containing at least 1 organism) x (mean number of PC per
positive cell). *p<0.05 compared to the Neon PC+/GM- group.
Copyright © Kerry McGarr Empey 2007
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CHAPTER 7: Discussion
A. Results Summary
The goal of this research was to determine if stimulation of LMs from
neonates with exogenous stimuli would improve activation of these cells and
expedite the clearance of PC. We began our investigations using a mouse model
and an in vitro culture system. The number of cells expressing many surface
molecules known to be upregulated during infection, including CD11c, CD11b,
MHC class II, CD40, CD80, CCR2, and CCR5 were all shown to be delayed in
pup compared to adult LMs infected with PC. The infiltration of T lymphocytes
into the lungs of PC-infected pups as well as cytokine production was also shown
to be delayed compared to adults.
We have demonstrated that IFNγ alone is not sufficient to expedite
clearance of PC organisms in pup mice. We proceeded to show that pup LMs are
capable of responding to the exogenous stimuli, LPS and are as efficient as adult
LMs at responding to zymosan. Furthermore, we demonstrated that pup mice
treated with aerosolized HKEC were able to clear PC infection faster than
untreated mice. This increased clearance correlated with CD4 and CD8 T cell
infiltration, LM activation and LM cytokine production. Using this HKEC model we
also reiterated the importance of the macrophage-T-cell interactions, but
demonstrated that in the absence of T cells, pup LMs can be stimulated
exogenously to improve phagocytosis.
We next explored the effect of GM-CSF on pup LMs and the clearance of
PC. We employed the use of GM-CSF specifically in these experiments due to its
commercial availability and because it has been proven safe and effective in the
immunocompromised patient population at improving macrophage function (23,
24) as well as improving outcomes in pulmonary infections (24-28), including PC
(29). In vitro stimulation of PC-exposed pup LMs with rmGM-CSF resulted in
increased cytokine production relative to their PC-exposed, untreated cells; for
TNFα, this increase was even greater than PC-exposed, rmGM-CSF-treated
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adult LMs. We transitioned our GM-CSF experiments in vivo first with i.p
administration of rmGM-CSF followed by i.n. administration at medium and high
doses. Overall, treatment with rmGM-CSF resulted in increased pup LM
activation and T cell infiltration as well as a slight reduction in PC burden.
Combining the increasing data supporting the use of combination therapy
with the rationale of using immunomodulatory agents in infectious diseases we
next explored the use of TMP/SMX together with GM-CSF for the treatment of
neonatal PC infection in mice. We discovered that co-treatment with rmGM-CSF
and TMP/SMX significantly reduced PC burden in pup lungs. We determined that
rmGM-CSF acted early to increase LM activation, cytokine production, and T cell
infiltration but that the subsequent reduction in PC burden led to a reduction in
LM activation, cytokine production, and T cell infiltration. We further
demonstrated that pup mice receiving combination therapy maintained a lower
PC burden after therapy was stopped unlike the mice receiving TMP/SMX alone
which had a rebound in PC burden following discontinuation of TMP/SMX.
Lastly, we extended our investigations to the human population by
collecting macrophages from human adult and neonatal lung aspirates. We
discovered that neonatal LMs were capable of exogenous stimulation with LPS
but their cytokine production was not to the extent that adult LMs achieved.
Stimulation with zymosan, however, a fungal cell wall preparation that binds to
different PRRs than LPS, resulted in cytokine production in neonatal LMs
equivalent to those in adult LMs and in some instances, even greater.
Alternatively, incubation with PC stimulated adult but not neonatal LM cytokine
production; this data was complicated by a high baseline cytokine production
among neonatal LMs. The addition of rhGM-CSF did nothing to improve the
cytokine profile in PC-infected neonatal LMs, but once again was complicated by
high baseline levels of cytokine production in the neonatal cells. Treatment of
neonatal LMs co-cultured with PC organisms led to an increase in the phagocytic
index reaching the level of adult LMs. Overall, we learned that treatment of
human neonatal LMs with rhGM-CSF improves the phagocytic capacity against
PC organisms without a concomitant increase in cytokine production.
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B. Lung Macropahge Activation is Delayed in Pneumocystis-infected Pup
Compared to Adult Mice
1. Activation markers
The finding that adult LMs express activation markers such as CD11b,
MHC class II, CD40, and CD80, approximately 2 weeks earlier than pup LMs
suggests that there is also at least a 2 week delay in the function that these
molecules provide. CD11b is the α-subunit of CD11b/CD18 (Mac-1) belonging to
the β2 subfamily of integrins. Functionally, Mac-1 promotes endothelium
adhesion,

phagocytosis,

and

oxidative

burst

(258).

Its

expression

on

macrophages is increased during states of activation making it a useful
monitoring tool for assessing activation status (258, 259). Throughout this
research we define alveolar and lung macrophages as being CD11c+. We further
describe the activated form of these cells in pups as being CD11c+/CD11b+.
CD11b is a β-glucan receptor that is capable of recognizing the β-glucan
component of fungal cell walls, including PC. Its upregulation during PC infection
may thus, contribute to clearance of the organism. We acknowledge that a small
population of these cells is likely dendritic cells, however, we are confident that
the vast majority are macrophages and the changes observed following
immunomodulatory therapy represents a change in macrophage rather than
dendritic cell phenotype. Tissue dendritic cells sample the alveolar spaces for
antigen by protruding their dendrites into these spaces; they generally do not
reside in the alveolar spaces. This is in contrast to AMs which reside in the
alveolar spaces and act as a first line of defense against inhaled pathogens.
Based on this information, we have assumed that CD11c+ cells derived from
lung lavaged fluid are almost entirely AMs. Although dendritic cells do reside in
the lung tissue, the concentration of lung macrophages far outways that of
dendritic cells (260). Subsequently, it is assumed that the majority of CD11c+
cells derived from the lung tissue are macrophages. Thus, phenotypic differences
observed in tissue-derived CD11c+ cells following immunomodulation represent
changes in macrophages rather than dendritic cells.
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FcγR is an important mediator of phagocytosis of IgG-coated antigens
(261). Its role in PC infection has not been previously described. We have shown
here that an increase in the number of LMs expressing FcγR is delayed
approximately 2 weeks compared to adult LMs. MHC class II, CD40, and CD80
are all involved with the macrophage:T cell interaction. The delay in the
expression of these molecules likely contributed to the delayed T cell activation
and may further lead to a delay in initiation of the adaptive immune response.
Wright and colleagues have demonstrated the importance if MCP-1 and MIP-1 in
the focal targeting of inflammatory cell recruitment to sites of PC infection (262).
Here we have demonstrated that there is a delay in the number of cells
expressing the receptors for these chemokines (CCR2 and CCR5). Taken
together, the delayed expression of these functional activation markers on LMs
likely all contribute to the delayed PC clearance observed in pup mice compared
to adults.
When comparing pup and adult markers of activation, it is important to
consider the total number of cells as this number is used to determine the total
number of cells expressing the marker of interest. In most experiments, percent
change from control was used to account for large differences in total cell
numbers; however, in some experiments total cell numbers were used. Figure
7.1 demonstrates the differences observed in total cell numbers derived from
lavaged fluid in pups versus adults over time.
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Figure 7.1 Total cells in pup versus adult Lungs. The total number of cells
enumerated in the lavaged fluid taken from pups and adults trends toward being
greater in PC-infected adults compared to pups early post-infection. No
statistically significant differences were observed overall. Pup and adult mice
were lavaged at the indicated time points and cells were counted using a
hemocytometer. Data represent the means ± SD for four to five mice per group.
2. T lymphocyte infiltration
The infiltration of CD4 and CD8 T cells into PC-infected pup lungs is
delayed at least 2 weeks compared to adults. This data supports what has
previously been shown in our lab (9, 10, 234). For both pups and adults, the
infiltration of T cells precedes the onset of PC clearance by about 1 week. One
reason for this delayed T cell infiltration could be due to a failure of neonatal lung
endothelial cells to up-regulate adhesion molecule pairs allowing for lymphocyte
extravasation into the lung. It has previously been shown in neonatal lungs that
ICAM-1 and VCAM-1 fail to up-regulate in response to PC infection (73). Without
this up-regulation, their integrin counterparts (LFA-1 and VLA-4, respectively)
expressed on lymphocytes fail to bind and no extravasation occurs. Alternatively,
we have also shown that there is a delay in the upregulation of pup LMs
expressing MHC class II molecules following PC infection (Figure 3.5). Without
the presentation of antigen in the context of these MHC class II molecules, T
cells fail to recognize antigen and thus their activation would be delayed.
Although macrophages are considered to be professional antigen presenting
cells, their primary function is phagocytic killing and cytokine production during
pathogen invasion. Dendritic cells (DCs) are the primary antigen presenting cells
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in the lungs therefore; we must consider that the delayed T cell infiltration may be
related to deficient antigen presentation function in neonatal DCs. Our lab has
previously demonstrated that there is a delay in DCs expressing MHC class II
molecules in PC-infected pup mice compared to adults (239). Thus deficient
antigen presentation in both LMs and DCs likely contributes to the delayed
infiltration of activated T cells into PC-infected pup lungs.
3. Cytokine production
The developing neonatal lung environment is a complex network of
immune stimulating and inhibiting mechanisms. They work to protect the lung
from pathogenic invasion while simultaneously trying to prevent damage caused
by host inflammation. Whenever a single cell is removed from this regulatory
environment, caution must be taken in interpreting the results, as they do not
account for the effects of the immune environment from which they came. This is
true for our in vitro culture stimulation experiments in which pup or adult LMs are
stimulated ex vivo. There are also benefits to this in vitro culture system. We
were able to identify cytokine production specific to the pup or adult LM being
stimulated and did not have to worry about possible unknown antigenic
stimulation as would have been the case in an in vivo system.
In evaluating cytokine production from pup and adult LMs, we varied time
and antigenic stimuli. We determined that in culture, pup LM TNFα and IL-6
production following PC stimulation is both delayed and lower than that of adult
LMs. The poor response seen in the pup cells may be multifactorial. It has been
proposed that TLR2 mediates the LM response to PC in mice (44) and that TLR2
co-localizes with dectin-1 to initiate macrophages’ pro-inflammatory response
(263). We have shown that the expression of both TLR2 and dectin-1 are present
in equal amounts on both pup and adult LMs, however it is possible that the colocalization of these molecules are impaired on pup cells following stimulation
with PC organisms. The timing and extent of release for individual cytokines is
guided by factors other than TLR2 and dectin-1 expression. Tachado and
colleagues demonstrated that co-expression of mannose receptor (MR) and
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TLR2 are required for PC-mediated IL-8 release (79). Although we have also
demonstrated that MR is equally expressed on both pup and adult LMs, it is
possible that other TLR signaling intermediates are involved with this delayed
cytokine response observed in pup compared to adult LMs stimulated with PC.
TLR2 ligand recognition involves cooperation with TLR1 or TLR6, which confer
discrimination among different microbial components, specifically, triacyl and
diacyl lipopeptides respectively (248, 264, 265). It is possible that there is a
delayed or impaired expression of either TLR1 or TLR6 on pup LMs. In addition
to potential differences in PRRs, there may also be differences in signaling
intermediates or transcriptions factors involved in TLR-mediated cytokine
activation. We have shown that NFkB nuclear translocation was minmal, but
similar in both pup and adult LMs stimulated with PC. It is possible however, that
pup LMs may generate cytokine production through activation of an alternate
transcription factor such as activation protein-1 (AP-1), NF-IL6, or a member of
the IRF family of transcription factors (248). Further research to determine if pup
LMs stimulated with PC initiate a MyD-88-independent pathway or transcription
factors other than NFkB may help explain the differential cytokine production
between pup and adult LMs.
MCP-1 production was produced very early following PC stimulation in
both pup and adult LMs with no difference in concentrations observed. Although
TNFα, IL-6, and MCP-1 are all known gene productions of the transcription factor
NFkB (266), it is unknown whether NFkB plays a significant role in the differential
production of NFkB-dependent cytokines or in coordinating the production of
these cytokines. Furthermore, it is thought that both the timing and the relative
amounts of NFkB-dependent cytokines produced following stimulation are likely
controlled by the interaction of NFkB with other transcription factors as well as
NFkB-independent factors (266). Thus, it appears that MCP-1 production is
controlled by factors other than those involved in TNFα and IL-6 production in
PC-stimulated mice.
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C. Exogenous Immunomodulation can Improve Lung Macrophage Function
and Pneumocystis Clearance in Pup Mice
1. Inteferon gamma
It has previously been demonstrated that IFNγ and TNFα are important for
the clearance of PC and that the delayed clearance of PC in pup mice
correspond with a delay in the up-regulation of these two cytokines (9, 10, 234).
Furthermore, it has been shown that SCID mice made to specifically overexpress
IFNγ in the lungs were able to stimulate clearance of the organism (243, 244). It
is curious, then, why treatment of neonatal mice with i.n. IFNγ demonstrated no
increased activation, cellular infiltration, or PC clearance. The most likely
explanation is that the addition of just one of the cytokines, IFNγ or TNFα alone,
does not increase susceptibility to PC infection, but rather both cytokines
together are important and necessary for clearance of the organism (267). IFNγ
acts on macrophages by sensitizing them to a second stimulatory signal. This
second signal is often TNFα, thus without also increasing the amount of TNFα
the microbicidal effect of IFNγ was likely lost. Other stimulatory signals, such as
certain pathogenic organisms, are also able to provide this second signal. We
have shown here that PC is unable to provide this second stimulatory signal and
that the combination of IFNγ plus PC is insufficient for macrophage activation.
This finding further demonstrates the inability of neonatal LMs to respond to PC
organisms despite the added stimulus of IFNγ.
2. LPS/Heat-killed E. coli
My initial in vitro cytokine data demonstrated that LPS significantly
increases cytokine production in pup macrophages compared to either control or
PC-stimulated cells, but overall, adult cells produced more cytokines than pup
cells following stimulation with LPS and PC. In general, PC appears to be a
relatively weak stimulus for both pup and adult LMs. There are many variables
involved in the type and level of cytokines produced following antigenic
stimulation in LMs, including the offending pathogen and the lung environment
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itself. By isolating AMs from pups and adults and stimulating them in culture in a
controlled environment we were able to eliminate the effects of the surrounding
lung environment. Differences in cytokine production between pup and adult
LMs, therefore, are most likely the result of differences in receptor expression or
intracellular signaling. There is growing evidence suggesting that dectin-1 (βglucan receptor) is an important receptor for the clearance of PC (61, 65, 268).
The β-glucans are important cell wall components of fungi and yeast cell walls
(269), including PC (65). A recent study done in dectin-1 knock-out mice
demonstrated that dectin-1 is critical for the production of reactive oxygen
species (ROS) in macrophages but is not necessary for normal T cell responses
(268). Furthermore, this study demonstrated that dectin-1 was required for PC
clearance in immunocompromised mice. Since β-glucans are found on PC
organisms (44, 65), we hypothesized that pup mice did not express dectin-1 as
well as adults. We discovered, however that dectin-1 was highly expressed on
both pup and adult mice, ruling out poor dectin-1 expression as the possible
cause of poor PC clearance in pup mice. It is possible that although dectin-1
expression is adequate, its function or downstream signaling may be deficient
resulting in a poor cytokine response following the recognition of β-glucan
particules.
The toll-like family of receptors is known to be important in mediating the
immune response to invading pathogens (248). Recently, TLR2 has been shown
to contribute to the innate immune response to PC (44, 61). Furthermore, TLR2
has been shown to collaborate with dectin-1 in mediating the macrophage
response to β-glucan (44, 61, 263), which is a major component of the PC cell
wall. This collaboration has been shown to stimulate macrophages to increase
the production of pro-inflammatory cytokines (60, 61). We demonstrated that pup
mice express TLR2 at the same level as adult mice, suggesting that the delayed
PC clearance in pup mice may be due to a delayed expression of TLR1 or TLR6
or a inefficient co-localization with TLR2. The decreased expression of TLR4 in
pup versus adult mice, however, may contribute to the reduced cytokine
production in pup mice stimulated with LPS. To initiate the intracellular signaling
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cascade, TLR4 must first form a complex with LPS-bound CD14 and MD-2 (66,
270, 271). Therefore, a deficiency in expression of CD14 or MD-2 or impaired colocalization could also cause a reduction in cytokine production following LPS
stimulation.
Recently, Sadeghi and colleagues demonstrated similar findings in human
newborns compared to adults (272). They showed that TLR4 expression and
cytokine secretion following LPS stimulation increases with gestational age, but
TLR2 levels did not differ between age groups. Alternatively, they found that
MyD88 levels were lower and p38 and ERK1/2 was impaired in newborns
compared to adults following stimulation with TLR-specific ligands. They also
showed that IL-1β, IL-6, and IL-8 cytokine production was significantly reduced
(P<0.001) compared to adults. MyD88 together with p38 and ERK represent 2
parallel intracellular signaling cascades that are initiated upon TLR ligation and
ultimately cytokine production (273, 274). Impairment in both of these signaling
systems would significantly contribute to the impaired cytokine production
observed in pups/neonates compared to adults.
One transcription factor ultimately stimulated to generate many proinflammatory cytokine genes is NFkB. In our mouse model we showed that NFkB
translocation in PC-stimulated adult mice was significantly greater than
unstimulated adult mice but that PC stimulation did not effect NFkB nuclear
translocation in pup mice. Alternatively, LPS-stimulation significantly increased
the nuclear translocation of NFkB in adult cells compared to both the adult
control cells as well as LPS-stimulated pup cells. Data previously generated in
our lab (unpublished; Brown and Qureshi) demonstrates that PC-stimulation
induces significantly more NFkB nuclear translocation compared to pup cells in
mice (Figure 7.1). Although my data demonstrated an increase in NFkB nuclear
translocation in PC-stimulated adult LMs, my data did not demonstrate a
significant increase over PC-stimulated pup LMs. The difference between these
two pieces of data can best be interpreted by understanding the differences
between how each of these studies was conducted. The experiment performed
by Brown and Qureshi use whole lungs compared to my experiments which use
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specifically LMs. It is possible then, that NFkB expression in the nucleus of PCstimulated adult LMs may be less pronounced than in other cells found in the
lung tissue such as bronchial epithelial cells. Additionally, the eariest time point
analyzed by Brown and Qureshi was at 24 hours in contrast to my experiment
which analyzed NFkB translocation after 1 hour of PC-stimulation. The longer
exposure time coupled with the inclusion of other lung cell types, such as lung
epithelial cells, may contribute to the discordant findings in my in vitro data
compared to Brown and Qureshi’s in vivo NFkB data. It is also possible that cells
removed from their lung environment respond to stimuli differently then they
would otherwise. It is possible that LM cytokine production occurs via an
alternative pathway (ex. MyD-88-independent) or via alternative transcription
factors (ex AP-1) when removed from its natural lung environment and thus
differences in NFkB were not detected in vitro.

Figure 7.2 PC-infected adults express significantly more NFkB compared to PCinfected pup mice. (Unpublished data; Brown and Qureshi) Pup mice were
infected with 1x106 PC at 24-72 hours old and adult mice were infected with
1x107 PC as adults. Whole lungs were collected at the indicated days postinfection and nuclear extracts were isolated. Electic mobility shift assays (EMSA)
were performed to identify NFkB in the nuclear extracts. Data represent the
mean ± SD for 3-5 mice per group per time point. * P < 0.05 compared to the pup
groups at the same time points.
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In vitro stimulation with zymosan, a ligand for TLR2 and dectin-1 (65, 248),
generated a high level of pro-inflammatory cytokine production in both pup and
adult LMs. This suggests that given the appropriate stimulation, pup LMs are
capable of producing cytokines at the level of adult cells and that PC specifically,
does not stimulate pup cells adequately. The finding that TLR2 and dectin-1
expression is similar on both pup and adult LMs supports this finding.
To evaluate the effects of LPS in vivo, we aerosolized pup mice with
HKEC, a method that has been shown to improve PC clearance in CD4 T celldepleted adult mice (238). We demonstrated that HKEC improves PC clearance
in pup mice. Moreover, we demonstrated that HKEC also influenced the PCinfected pup lung environment by increasing immune cell infiltration, LM
activation, and cytokine production. While TNFα, IFNγ, and MCP-1 were most
influenced by the combination of PC infection and HKEC treatment, IL-6 was
primarily driven by HKEC. The differences in cytokine production between this
HKEC in vivo data (Figure 5.10) and the cytokine data generated in vitro
following stimulation with LPS (Figure 5.3) underscores the influence of factors
other than NFkB in controlling the amount of cytokine produced, including the
lung environment and antigenic stimulus itself. The importance of T cells in
clearing PC infection has previously been established in the literature (241, 242).
Taking this a step further, we demonstrated that T cells are required for efficient
phagocytosis of PC organisms by LM. This interaction between T cells and LMs
is likely driven by IFNγ, a cytokine produced by T cells and required for LM
activation (50). Macrophages require two signals to become activated; the first is
IFNγ. The second signal varies, but can be provided by invading pathogens (ex.
LPS), TNFα (autocrine activity), but also by CD40L expressed on T cells (50).
Thus, both signals required for macrophage activation can be provided entirely
by T cells, reiterating the importance of the cognate interactions between LMs
and T cells during infection.
Overall, it is clear that pup LMs can be stimulated through exogenous
stimulation to expedite the clearance of PC organisms and that the best results
occur in the presence of functional CD4 T cells. The mechanism behind this
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appears to be primarily through LM activation, which is enhanced through the
cognate interactions with infiltrating T cells.
3. Granulocyte macrophage colony-stimulating factor
The gamut of infectious diseases has shifted over the past several years
to include those occurring predominantly in immunocompromised individuals.
Limited

efficacy

within

the

current

antimicrobial

armament

in

the

immunocompromised host combined with increasing resistance patterns has led
to an urgent need for new therapies against these infectious diseases. It is has
been well documented that this crisis in antimicrobial therapy stems
predominantly from antibiotic overuse, misuse, and a limited number of
antimicrobial agents in the pipeline (275). However, another important factor that
limits the utility of antimicrobial-based therapy is the decreased efficacy of these
agents in immunocompromised individuals versus to those with intact immune
systems (257). The era of HIV and chemotherapy has taught us a lot about the
relationship between host immunity and microbial pathogenesis. Pathogens that
are thought to be trivial in individuals with an intact immune system become lifethreatening in those that are immunocompromised. This underscores the crucial
bond between host immunity and pathogenesis and provides a powerful rationale
for fighting infectious diseases with immunomodulatory agents (257).
In the absence of GM-CSF, mice are more susceptible to PC organisms
(81), most likely due to impaired LM phagocytosis (81, 276) and reduced
cytokine production (81, 277, 278). In adults, treatment with GM-CSF has been
shown to enhance the clearance and improve outcomes in PC infection (29) as
well as many other pulmonary infections (24-28). Based on the rationale for
fighting

infectious

diseases

with

immunomodulatory

agents

and

the

aforementioned GM-CSF literature, we hypothesized that GM-CSF would
improve PC clearance and LM function in pup mice. By isolating pup and adult
AMs and culturing them in vitro with or without rmGM-CSF and PC we were able
to elucidate that alterations in cytokine production were secondary to AM
stimulation rather than other immune cells located within the lung environment.
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The increased production of TNFα, MCP-1, and IL-6, but not IL-10 following
treatment with rmGM-CSF suggests that it functions primarily to activate LMs
regardless of the presence or absence of PC; although cytokine production is
greater in the presence of the organism. We proceeded to administer rmGM-CSF
to pup mice in vivo to evaluate the response while considering the effect of the
lung environment. Varying doses using i.p. and i.n. administrations, we
determined that treatment of PC-infected pup mice with rmGM-CSF increases
LM activation and T cell infiltration. While PC burden was reduced in the groups
receiving rmGM-CSF, there were no statistically significant differences compared
to the control groups.
Similar to the previously described studies in which treatment with GMCSF demonstrated an increase in cytokine production (24, 29), our studies
demonstrated that rmGM-CSF is also able to stimulate cytokine production in
pup LMs. Unlike these same studies which describe an improvement in the
clearance of Group B streptococcus (24), Histoplasma capsulatum (26, 27), and
Pneumocystis carinii (29) in adult mice, our research demonstrates that PCinfected pup mice failed to achieve a significant reduction in PC burden. There
are several factors which must be considered, however, when interpreting these
findings. First, Mandujano et al. and Deepe and Gibbons demonstrated a
reduced microbial burden in CD4-depleted adult mice treated with rmGM-CSF.
Second, LeVine and colleagues demonstrated that rmGM-CSF did not improve
LM phagocytic uptake but did improve the production of ROS. Taken together
these previously published findings suggest that rmGM-CSF works primarily on
LMs to increase the amount of ROS, but not phagocytosis. There is conflicting
evidence in the literature regarding the phagocytic abilities of pup versus adult
macrophages (279-281). Nakano et al. observed that thioglycollate-elicited
macrophage from newborn mice phagocytose better than those from adult mice
(279, 280). Starobinas et al. was unable to reproduce the findings published by
Nakano and furthermore demonstrated that the phagocytic index of a 5 day-old
mouse is significantly less than that of an adult mouse (281). Previous research
performed in our lab demonstrated that pup mice are less efficient than adult
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mice at phagocytosing fluorescent beads and migrating with them to the draining
lymph nodes (234). If pup LMs are immature and innately deficient in their
phagocytic capacity, then rmGM-CSF may be unable to improve phagocytic
killing. The slight reduction in PC burden observed in rmGM-CSF-treated PCinfected pup mice may be generated from the stimulation of cytokine production
and the subsequent T cell infiltration, but without adequate phagocytic function,
the increased ROS production imparted by rmGM-CSF in adult LMs would be
rendered useless in pup LMs.
The functional activation of pup LMs may vary depending on the offending
organism. Using a rabbit model, Bellanti and colleagues demonstrated that the
phagocytic ability of the LM is well developed in the early post-natal period with
regard to Staphylococcus aureus and Escherichia coli but the microbicidal
activity does not fully develop until after the first postnatal month of life (282). The
postulated explanation for these conflicting observations is that while the
microbicidal mechanisms of the LM may be fully developed at birth, it may be
inhibited at this time by large quantities of phagocytosed surfactant-related
material (SRM) present in these cells during the early postnatal period (283).
This large phagocytic uptake has been found to correlate with a reduction in
observable lysosomes (283) and depletion of cellular energy reserves (284),
effects of which may interfere with normal microbicidal activity (282). Based on
this literature, two theories could possibly explain our data demonstrating a
failure of rmGM-CSF to significantly reduce PC burden but seemingly increase
LM activation. The first is that rmGM-CSF could not overcome the effects of SRM
present in the pup LMs and the subsequent reduction in lysosomes and depleted
energy reserves. The second theory is that pup LMs do not recognize or
efficiently bind PC organisms compared to other invading organisms resulting in
decreased phagocytosis that can not be overcome by rmGM-CSF.
The failure of rmGM-CSF to elicit a significant PC reduction could be
related to other immature functions associated with the neonatal lung, such as
poor T cell infiltration. This hypothesis is less likely, however, as we have shown
that treatment with rmGM-CSF improves T cell infiltration into the lungs of PC-
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infected pup mice. Thus, our rmGM-CSF data supports the literature which
demonstrates a phagocytic deficiency among infant mouse LMs to phagocytose
PC organisms or that these LMs are overwhelmed by SRM rendering them much
less responsive to rmGM-CSF. It is also possible that the use of a different
dosing strategy may generate a more functional activated LM in pup mice. We
used several different dosing strategies in our GM-CSF experiments. We began
with i.p. administration of 0.25µg per gram of body weight twice daily for 5 days.
This regimen was based on a work previously done in our lab in which rmGMCSF was used for the expansion of DCs (239). Other authors have shown
improved microbial clearance from the lungs of mice using doses ranging from
0.05µg – 0.25µg/g/day i.p. (26, 29). While these authors treated anywhere from 7
to 21 days, they saw reduction in microbial burdens within a week of starting GMCSF therapy. Based on the short half-life (2 hours) of GM-CSF, we initially chose
to administer the dose in 2 equally divided doses. While we demonstrated an
increase in LM activation and T cell infiltration, we did not see a reduction in PC
burden. In order to initiate a specific pulmonary immune response and potentially
improve PC clearance, we used the inhaled route of administration in subsequent
pup experiments (252-254, 256). Once again we demonstrated an increase in
LM activation and macrophage and T cell infiltration, but no reduction in PC
burden. For each experiment we waited 7 days following PC inoculation before
beginning GM-CSF treatment to allow time for the organisms to establish an
infection. Many of the other authors showing reductions in microbial burdens
began treatment on day 1 post-infection or even prior to infection (24, 26, 29). To
more closely mimic a clinical timeframe from infection to treatment, we chose to
wait seven days before initiating GM-CSF treatment. However, this may be one
reason why we were unable to demonstrate a reduction in PC burden.
Alternatively, it is possible that our pup mice were metabolizing the drug at a
much faster rate than adult mice. Thus despite using a higher dose/gram of body
weight compared to that used in adult mice, we were unable to demonstrate a
reduction in PC burden. It is possible that longer treatment duration or higher
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dose could improve PC clearance; this may be an area to explore in future
research.
4.

Granulocyte

macrophage

colony-stimulating

factor/Trimethoprim-

Sulfamethoxazole
Based on our findings in PC-infected pup mice treated with rmGM-CSF
along with recent reports supporting the use of combination therapy for infections
in immunocompromised individuals (257), we took our research forward by next
looking at the use of rmGM-CSF together with the standard of care treatment for
PC, TMP/SMX. While not always considered a part of the immunocompromised
population, neonates have been shown to be highly susceptible to pulmonary
infections due to the immaturity of the developing lungs (7, 8). Opportunistic
pathogens, including PC, which are often thought of as markers of
immunosuppresion, can cause infection in neonatal lungs (102, 115). While the
standard of care treatment for PC pneumonia is TMP/SMX, the use of
combination therapy for infectious diseases is a common, well-accepted practice
depending on the severity of infection, its location, and the virulence of the
infecting organism (257). Taking the use of combination therapy together with the
rationale of using immunomodulatory agents to fight infectious diseases, we
hypothesized that the use of GM-CSF and TMP/SMX together could improve PC
clearance in pup mice.
The results generated from the use of combination therapy with GM-CSF
and TMP/SMX appeared to volley between the stimulating effects of GM-CSF
and the control of PC burden by TMP/SMX. LM activation markers, cytokine
production and T cell infiltration all appeared to increase early on in the
experiments during active treatment with rmGM-CSF, although the addition of
TMP/SMX blunted these affects in the combination group. After rmGM-CSF was
discontinued, the reduction in LM stimulation appeared to be influenced by the
decrease in PC burden in the groups receiving TMP/SMX. Two important
findings were generated from these data. The first is that combination therapy
with TMP/SMX plus 50ng/g of i.n. rmGM-CSF reduces PC burden significantly
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more than TMP/SMX alone in PC-infected pup mice. The second is that control
of the PC infection is maintained better in the combination group compared to the
TMP/SMX group upon discontinuation of TMP/SMX. This second finding
suggests that the addition of rmGM-CSF boosts the immune system to help
TMP/SMX fight the infection and continues this enhanced effect even after
TMP/SMX is withdrawn.
Using an adult mouse model, Deepe and Gibbons demonstrated that i.p.
administration of GM-CSF together with a suboptimal dose of amphotericin B
reduced Histoplasma capsulatum CFU and improved survival compared to
optimal doses of amphotericin B alone (26). It is possible that the dose of
TMP/SMX could be reduced or the length of therapy shortened when given in
combination with GM-CSF. It is also possible that GM-CSF may be able to
improve the activity of alternative drugs for PC that are less effective than
TMP/SMX when administered alone, such as dapsone (221).
The need for more treatment options for PC infection is undeniable. While
the resistance patterns of PC organisms are difficult to define due to its inability
to be cultured, many studies have linked mutations in the DHPS gene with
chronic TMP/SMX prophylaxis (18, 210-215). A link between the DHPS
polymorphism and TMP/SMX treatment failures have also been identified (212,
217). This DHPS polymorphism is thought to be brought about by selective
evolutionary pressure from SMX (209); further overuse and misuse of TMP/SMX
will likely lead to increases in treatment failures against PC. Adverse reactions to
TMP/SMX are common, particularly in the immunocompromised population, the
population which most frequently uses this particular antibiotic. Fifteen percent of
children develop substantial adverse reactions to TMP/SMX (16), ranging from
rash to interstitial nephritis (13-15) and hyperbilirubinemia (199-201).
This is the first study to demonstrate an improved treatment option for
fighting PC infection in neonates since pentamidine was replaced with TMP/SMX
in 1974 (190-192) and was proven safe for children in 1977 (193, 194). The use
of GM-CSF has been proven safe in both immunocompetent as well as
immunocompromised children (285), making it an attractive option for

153

combination therapy in order to reduce the dose or treatment duration of
TMP/SMX or possibly even dapsone or caspofungin; further studies are needed
to assess these options.
D. Human Neonatal Lung Macrophage Activation is Delayed
Within the United States, PC infection remains primarily a disease of the
immunocompromised host, but in underdeveloped countries PC pneumonitis is
still a major cause of morbidity and mortality, particularly in young children (1).
Infants appear to be particularly susceptible to primary PC infection, likely due to
an immature immune system and a lung environment that protects against
damaging inflammation early after birth (5). Fortunately the United States has
remained somewhat sheltered from this ever-present infection. Despite this, PCP
is still one of the deadliest and most prominent infections among the immune
deficient population throughout the world. Research which furthers our
understanding of this organism and new drugs designed to target this organism
remains an extremely important task. Through our research using a mouse
model and murine cell lines, we have learned a lot about the neonatal immune
response to PC infection. We have also demonstrated that by combining GMCSF with TMP/SMX we can clear PC infection from neonatal lungs and maintain
this reduction after discontinuation of therapy. While some inferences can be
made in human infants based on the research we have done in mice, it is
important to determine if human LMs respond similarly to mouse LMs following
stimulation with PC, LPS, zymosan and GM-CSF. Considering that our research
has clinical implications the work we have done using human LMs will strengthen
our overall findings and perhaps lead to clinical trials implementing the use of
GM-CSF in populations vulnerable to PC infection as well as other opportunistic
infections.
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1. LPS
Our initial experiments were performed using adult peripheral blood
monocyte-derived macrophages compared to neonatal LMs isolated from
bronchiolar

suctioned

sputum.

Subsequently

we

performed

the

same

experiments using both adult and neonatal LMs isolated from bronchiolar
suctioned sputum. The differences in cytokine production observed in
macrophages derived from different areas, peripheral blood monocyte versus
lung, emphasizes the distinctive roles that macrophages play based on their
tissue specificity and the requirements for that particular organ. Adult
macrophages, regardless of source, produced more cytokines than neonatal LMs
following stimulation with LPS.

Lung derived adult macrophages produced

significantly less TNFα than peripheral blood monocyte-derived macrophages
(233 pg/ml vs. 3910 pg/ml; P< 0.05). This is likely because a large amount of
TNFα produced locally in the lung would initiate a huge inflammatory response.
Such a response would be detrimental in the lung environment where the
delicate balance between defending against invading pathogens and preventing
a damaging host response is crucial. Overall, the cytokine response of human
neonatal and adult LMs to LPS resembles that of pup and adult LMs in mice.
After 24 hours of LPS stimulation neonatal LMs produce significantly less TNFα
and IL-6 compared to adult LMs. This similarity between human and mouse data
would suggest that, as with mice, there may be a delayed or reduced expression
of TLR4, CD14, MD-2, or an impaired co-localization of these molecules.
2. Zymosan
As with LPS, stimulation of human LMs with zymosan produced similar
trends in cytokine production as those observed in mice with the exception of
TNFα. Pup mouse LMs produced more TNFα at both 12 and 24 hours poststimulation, although these differences were not statistically significant.
Conversely, human adult cells produced significantly more TNFα than neonatal
cells after 12 and 24 hours of zymosan stimulation and thus more closely
resemble the stimulation response seen with LPS. The production of IL-6 and IL155

10 more closely followed the patterns observed in mouse cells stimulated with
zymosan; human neonatal cells produced significantly more of these cytokines
compared to adults. In mice we demonstrated that TLR2 and dectin-1 expression
levels were similar on both pup and adults, which was supported by the finding
that TNFα and IL-6 production was also similar between pup and adults. The
discordance in TNFα and IL-6 production observed in human neonatal and adult
cells following zymosan stimulation is unlikely due to differences in TLR2
expression. We have shown in mice that TLR2 expression is similar for pup and
adult LMs. Furthermore, if TLR2 expression on neonatal LMs was low compared
to adult cells, it is likely that TNFα and IL-6 production in neonatal LMs would
also be low compared to adults. Since this is not the case, it is more likely that a
downstream signaling component is responsible for the difference observed in
these two cytokines between neonatal and adult LMs. As was observed in mouse
LMs, zymosan-stimulated cells produced significantly more cytokine than LPS in
both neonates and adults. This observation suggests that signaling through TLR2
produces a more pronounced cytokine response than TLR4-dependent signaling.
3. Pneumocystis
The failure of PC to stimulate cytokine production above baseline in
neonatal macrophages coincides with our pup mouse data. It is possible that if
we had incubated the neonatal cells with PC for 48 hours we may have detected
a difference, as we did with TNFα in our pup mouse data. Adult human and adult
mouse LMs both responded to PC with an increase in cytokine production above
that of their respective control cells, although these differences were not
statistically different in the human cells. The differential response of
neonatal/pups compared to adults to PC may be due to immature intracellular
signaling in the neonatal/pup cells. We have shown that there is no difference in
the expression of TLR2 or dectin-1 on mouse LMs. Additionally there are no
differences in the number of cells expressing these surface receptors. We have
also shown that there is no difference in the expression of mannose receptor on
pup versus adult mouse macrophages (data not shown). Mannose receptor is
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another receptor thought to bind pathogen-associated mannose structures found
on bacteria, yeast, and fungi (56). While some studies have suggested that MR is
important in the recognition and clearance of PC (51, 52), other studies found
that MR-/- mice were no more susceptible PC than their wild-type counterparts
(57) (58).
Another factor which must be considered pertains to the PC organism
itself. We have previously described that these organisms are species specific
and cannot be grown in culture. In our lab, our PC source is kept in a SCID
mouse colony and is therefore, mouse-specific (Pneumocystis carinii f. sp.
muris). Ideally, we would have liked to use human-specific PC (Pneumocystis
carinii f. sp. hominis); however, since this organism cannot be grown in culture,
the hominis strain of the organism is very difficult to acquire. There has been a lot
of debate over the classification and nomenclature of PC organisms since its
discovery in 1909. It is now clear that many different species make up the genus
Pneumocystis. Extensive research of this organism has taught us that almost
every mammalian species harbors at least one species of PC, which can thrive
only in its specific mammalian host and which are genetically distinct from one
another (286, 287). Within the rat, for example, there are at least five known PC
species (288). Comparisons of gene sequences among different PC species
using gene trees and bootstrap statistics have provided us with some idea of the
similarites between specific sequences responsible for proteins such as
superoxide dismutase (SOD), DHPS, and DHFR (289, 290). Unfortunately, it is
still unclear what makes a species specific to a mammalian host. Research
published by Gigliotti and Hughes has demonstrated that a single monoclonal
antibody (MAb) directed at the gp120 surface glycoprotein found on PC
organisms (Mab 5E12) was able to recognize PC from rat, rabbit, ferret, and
humans (291). This is an important finding considering that gp120 has been
implicated in binding of PC to type I pneumocytes and macrophages (292, 293)
as this would suggest that PC species specific to one mammalian host is capable
of binding to the pneumocytes of another. Overall, this published data together
with the increased cytokine production we observed within the human adult LMs
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suggests that human cells are capable of recognizing mouse-specific PC. As
such, this data demonstrates that human neonatal LMs, as with pup mouse LMs,
fail to respond to PC organisms compared to their adult counterparts.
Interestingly, the baseline level of cytokine production in neonatal cells
was much higher than the baseline production in adult cells. Since no
demographic or disease state information was collected on individual human
subjects it is difficult to provide an absolute explanation for this finding. It is
possible, however, that this observation can be attributed to the fact that each of
the neonatal subjects were receiving ventilation support, unlike the adult
subjects. This type of pulmonary stress may have stimulated the LMs leading to
an increase in cytokine production.
Unlike what was observed in mouse cells treated with rmGM-CSF, human
LMs co-cultured with PC did not demonstrate an increase in cytokine production
when stimulated with rhGM-CSF. Despite this, rhGM-CSF significantly improved
phagocytosis in neonatal LMs co-cultured with PC. There are a couple of
possibilities which could explain this discordance between cytokine production
and phagocytosis. The first is a possible timing issue. The phagocytosis index
was determined after 25 minutes of incubation with PC and GM-CSF.
Alternatively, aliquots for cytokine analysis were taken at 12 and 24 hours poststimulation. It is possible that GM-CSF produces an immediate early cytokine
response that was missed by collecting aliquots after 12 hours. The second
possible explanation for this discordance is that GM-CSF improved LM
phagocytosis without stimulating cytokine release. Deepe and Gibbons
demonstrated that there was no increase in cytokine production in mice infected
with Histoplasma capsulatum following GM-CSF treatment (26). An improvement
in phagocytosis without a concomitant increase in cytokine production may be
favorable depending on the type of organism and the extent of infection. As
described in the introduction, PC pathogenesis can be divided into two
categories; PC-mediated and immune-mediated lung injury. Although PC can
cause direct damage to the host lung by killing pneumocytes (147, 150) and
producing lung-damaging enzymes (151-157), it is possible that the majority of

158

damage comes from immune-mediated lung injury. In the clinical setting, the
presentation of PCP is highly dependent on the immune status of the patient,
suggesting that the host immune response to PCP is contributing to its
pathogenesis by initiating immune-mediated lung injury. The initial observation of
PCP in cancer patients often occurs once immunosuppressive steroid therapy is
being tapered (163) (164); in bone marrow transplant recipients it typically occurs
after engraftment and immune function restoration (165) (166); and in AIDS
patients it generally occurs following rapid recovery of CD4 T lymphocytes
secondary to initiating highly active antiretroviral therapy (HAART) (167, 168).
Additionally, it has been well documented that lung injury during moderate to
severe PCP is minimized with the administration of adjunctive steroid therapy,
reiterating the detrimental effects of the host immune response to PC in the
infected lung (169) (170). If the majority of lung damage is immune-mediated, it
would be favorable for LMs to ingest and kill the organisms without mounting a
more fulminate immune response.
Overall, the significant improvement in neonatal LM phagocytosis initiated
by GM-CSF is very promising. The failure of GM-CSF to increase adult LM
phagocytosis above baseline is likely because the baseline level of phagocytosis
among the adult LMs was already maximized. Based on these data, populations
vulnerable to pulmonary infection from PC and other pulmonary-specific
pathogens could benefit from the addition of GM-CSF to the standard
antimicrobial therapy.
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E. Conclusion
Neonatal lung research is difficult due to the size and delicate nature of
the still developing lung and homeostatic complexities. Balance between
protecting the neonatal lung from invading pathogens and an overwhelming
immune response is critical. When using immunomodulatory agents to treat
pulmonary infections, one must consider this delicate balance and make sure not
to tip the scale heavily in one direction over the other. The need for more
treatment options to accommodate the growing population of immune-deficient
adults and children is obviated by increasing antimicrobial resistance patterns
coupled with fewer new antimicrobials in the pipeline (294). GM-CSF has been
used clinically for many years in both immune-competent and incompetent
individuals. Its safety in children and efficacy in stimulating LMs have been
proven (23, 24, 285). Combination therapy has the benefit of often being able to
reduce doses or durations of therapy to minimize toxicity (257). It is known that
term and pre-term infants are more susceptible to pulmonary infection and often
have a more fulminate course of the disease (7, 8, 282). Since LMs are often the
first line of defense against inhaled pathogens we hypothesized that neonatal LM
function was impaired or delayed. We have shown, in pup mice that LMs are at
least partially responsible for this increased susceptibility due to a delay in
activation and cytokine production. We demonstrated in both mouse and humans
that functionally impaired neonatal LMs can be exogenously stimulated to
expedite activation and cytokine production and improve PC clearance. We have
demonstrated in human neonatal LMs that GM-CSF improves phagocytosis of
PC organisms without increasing cytokine production. GM-CSF was shown to
increase cytokine production in pup mouse LMs; however the failure to produce
cytokines in human neonatal LMs may be favorable for an organism which
imparts much of its lung damage through initiation of the innate and adaptive
immune systems. Taking together these mouse and human data, we believe that
combination therapy with GM-CSF and TMP/SMX is a viable treatment option for
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PC infections among immunocompromised populations, including the neonatal
population.
F. Future Directions
There are many avenues left to explore in this area of research; one such
area involves looking at surfactant proteins. Surfactant proteins A and D (SP-A
and SP-D) are large hydrophilic glycoproteins which participate in innate lung
immunity through interactions with a variety of organisms, including PC (295,
296). SP-A and SP-D have both been shown to bind PC (297-300) as well as
interact with and modulate the function of macrophages (301-303). Specifically,
SP-A has been shown to increase phagocytosis while SP-D increases the
production of ROS during PC infection (295, 296, 303, 304). The importance of
these surfactant proteins for clearance of PC infection has been demonstrated in
both animal models and in humans. Linke and colleagues demonstrated delayed
PC clearance in a SP-A-/- mouse model (298), while Hughes and colleagues
showed the efficacy of exogenous surfactant replacement using a PC-infected rat
model (305). In humans a limited number of publications have demonstrated that
surfactant treatment in PC-infected infants improves gas exchange and overall
oxygenation (306-309). However, none of these studies address the effect of
surfactant on LM function and PC clearance. Combining the fact that surfactant
treatment has already been used clinically to treat PC-infected infants with the
published evidence that surfactant improves LM function against PC organisms,
it would be reasonable to extend our research to determine if surfactant can
expedite PC clearance and improve outcomes in PC-infected infants.
Although there are several immunomodulatory agents commercially
available, including GM-CSF, they are not all optimized for delivery directly to the
lung. Historically, clinicians have used the available i.v. or s.c. formulations,
however these are designed to be delivered to the lung. The lungs are distinctly
different from the venous environment and thus a formulation and delivery
system that are specifically designed for the lung environment may help improve

161

the overall affect of GM-CSF. Furthermore, a delivery system that is designed to
instill the greatest amount of drug to the lung would also help optimized therapy
and waste as little drug as possible. Thus, efforts to optimize dose, delivery, and
formulation of GM-CSF as well as other immune modulating agents is an
important future objective with the overall goal of improving outcomes and
minimizing toxicity.

Copyright © Kerry McGarr Empey 2007
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